negative	In the present study, we tested whether the highly specific metabotropic glutamate receptor # antagonist, <e13> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e13> , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of <e23> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e23> .
negative	Weekly intramuscular <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> injections (## mg/kg body weight), in combination with daily administration of <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle).
negative	Weekly intramuscular <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> injections (## mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle).
negative	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (## mg/kg body weight), in combination with daily administration of <e13> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e13> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e23> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e23> / 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle).
negative	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (## mg/kg body weight), in combination with daily administration of <e13> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e13> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine versus <e23> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e23> /vehicle).
negative	After # weeks of <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> -treated monkeys were significantly affected.
negative	After # weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> -treated monkeys were significantly affected.
effect	After # weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> -treated monkeys were significantly affected.
effect	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> -treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated monkeys.
negative	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e13> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e13> -treated animals than in <e23> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e23> /vehicle-treated monkeys.
effect	The <e13> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e13> treatment also had a significant effect on the <e23> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e23> -induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.
negative	In <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> -treated monkeys.
effect	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in <e13> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e13> / <e23> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e23> -treated monkeys.
effect	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor # antagonist, <e13> 3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine </e13> , significantly reduces <e23> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e23> toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.
negative	Effect of <e10> ketoconazole </e10> -mediated CYP3A4 inhibition on clinical pharmacokinetics of <e20> panobinostat </e20> ( LBH589 ), an orally active histone_deacetylase_inhibitor .
negative	Effect of <e10> ketoconazole </e10> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e20> LBH589 </e20> ), an orally active histone_deacetylase_inhibitor .
negative	Effect of <e10> ketoconazole </e10> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( LBH589 ), an orally active <e22> histone_deacetylase_inhibitor </e22> .
negative	Effect of ketoconazole -mediated CYP3A4 inhibition on clinical pharmacokinetics of <e10> panobinostat </e10> ( LBH589 ), an orally active <e22> histone_deacetylase_inhibitor </e22> .
negative	Effect of ketoconazole -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e10> LBH589 </e10> ), an orally active <e22> histone_deacetylase_inhibitor </e22> .
negative	This study evaluated the effect of a potent CYP3A inhibitor, <e10> ketoconazole </e10> , on the pharmacokinetics and safety of <e20> panobinostat </e20> .
negative	On day 8, a single <e10> panobinostat </e10> dose was co-administered with <e20> ketoconazole </e20> .
mechanism	In the presence of <e10> ketoconazole </e10> , there was #- and #-fold increase in C (max) and AUC of <e20> panobinostat </e20> , respectively.
negative	Interaction study of <e10> moxifloxacin </e10> and <e20> lomefloxacin </e20> with co-administered drugs.
negative	<e10> Moxifloxacin </e10> and <e20> lomefloxacin </e20> are fluoroquinolone_antibiotics used in treating urinary and respiratory tract infections.
negative	<e10> Moxifloxacin </e10> and lomefloxacin are <e22> fluoroquinolone_antibiotics </e22> used in treating urinary and respiratory tract infections.
negative	Moxifloxacin and <e10> lomefloxacin </e10> are <e22> fluoroquinolone_antibiotics </e22> used in treating urinary and respiratory tract infections.
negative	Being <e10> moxifloxacin </e10> and lomefloxacin <e22> fluoroquinolones </e22> the interaction study of was carried out with sucralfate , gelusil , erythromycin and multi_minerals .
negative	Being <e10> moxifloxacin </e10> and lomefloxacin fluoroquinolones the interaction study of was carried out with <e20> sucralfate </e20> , gelusil , erythromycin and multi_minerals .
negative	Being <e10> moxifloxacin </e10> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , <e21> gelusil </e21> , erythromycin and multi_minerals .
negative	Being <e10> moxifloxacin </e10> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , <e20> erythromycin </e20> and multi_minerals .
negative	Being <e10> moxifloxacin </e10> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , erythromycin and <e22> multi_minerals </e22> .
negative	Being moxifloxacin and lomefloxacin <e12> fluoroquinolones </e12> the interaction study of was carried out with <e20> sucralfate </e20> , gelusil , erythromycin and multi_minerals .
negative	Being moxifloxacin and lomefloxacin <e12> fluoroquinolones </e12> the interaction study of was carried out with sucralfate , <e21> gelusil </e21> , erythromycin and multi_minerals .
negative	Being moxifloxacin and lomefloxacin <e12> fluoroquinolones </e12> the interaction study of was carried out with sucralfate , gelusil , <e20> erythromycin </e20> and multi_minerals .
negative	Being moxifloxacin and lomefloxacin <e12> fluoroquinolones </e12> the interaction study of was carried out with sucralfate , gelusil , erythromycin and <e22> multi_minerals </e22> .
negative	The response of <e10> moxifloxacin </e10> and <e20> lomefloxacin </e20> after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.
negative	<e10> Moxifloxacin </e10> and <e20> Lomefloxacin </e20> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with <e20> sucralfate </e20> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with sucralfate and <e21> gelusil </e21> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e20> erythromycin </e20> in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e22> multi-minerals </e22> in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with <e20> sucralfate </e20> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with sucralfate and <e21> gelusil </e21> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with sucralfate and gelusil in acidic media whereas with <e20> erythromycin </e20> in basic media and multi-minerals in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e22> multi-minerals </e22> in neutral media.
negative	Moxifloxacin and Lomefloxacin reacts faster with <e10> sucralfate </e10> and <e21> gelusil </e21> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
negative	Moxifloxacin and Lomefloxacin reacts faster with <e10> sucralfate </e10> and gelusil in acidic media whereas with <e20> erythromycin </e20> in basic media and multi-minerals in neutral media.
negative	Moxifloxacin and Lomefloxacin reacts faster with <e10> sucralfate </e10> and gelusil in acidic media whereas with erythromycin in basic media and <e22> multi-minerals </e22> in neutral media.
negative	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e11> gelusil </e11> in acidic media whereas with <e20> erythromycin </e20> in basic media and multi-minerals in neutral media.
negative	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e11> gelusil </e11> in acidic media whereas with erythromycin in basic media and <e22> multi-minerals </e22> in neutral media.
negative	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e10> erythromycin </e10> in basic media and <e22> multi-minerals </e22> in neutral media.
negative	Exposure to oral <e10> S-ketamine </e10> is unaffected by <e20> itraconazole </e20> but greatly increased by ticlopidine .
effect	Exposure to oral <e10> S-ketamine </e10> is unaffected by itraconazole but greatly increased by <e20> ticlopidine </e20> .
negative	Exposure to oral S-ketamine is unaffected by <e10> itraconazole </e10> but greatly increased by <e20> ticlopidine </e20> .
negative	This study examined drug-drug interactions of oral <e10> S-ketamine </e10> with the cytochrome P450 (CYP) 2B6 inhibitor <e20> ticlopidine </e20> and the CYP3A inhibitor itraconazole .
negative	This study examined drug-drug interactions of oral <e10> S-ketamine </e10> with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor <e20> itraconazole </e20> .
negative	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor <e10> ticlopidine </e10> and the CYP3A inhibitor <e20> itraconazole </e20> .
negative	In this randomized, blinded, crossover study, # healthy volunteers ingested # mg/kg <e10> S-ketamine </e10> after pretreatments with oral <e20> ticlopidine </e20> (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of # weeks.
negative	In this randomized, blinded, crossover study, # healthy volunteers ingested # mg/kg <e10> S-ketamine </e10> after pretreatments with oral ticlopidine (250 mg twice daily), <e20> itraconazole </e20> (200 mg once daily), or placebo in 6-day treatment periods at intervals of # weeks.
mechanism	<e10> Ticlopidine </e10> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral <e20> ketamine </e20> by #-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine .
negative	<e10> Ticlopidine </e10> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by #-fold, whereas <e20> itraconazole </e20> treatment did not increase the exposure to S-ketamine .
negative	<e10> Ticlopidine </e10> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by #-fold, whereas itraconazole treatment did not increase the exposure to <e20> S-ketamine </e20> .
negative	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral <e10> ketamine </e10> by #-fold, whereas <e20> itraconazole </e20> treatment did not increase the exposure to S-ketamine .
negative	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by #-fold, whereas <e10> itraconazole </e10> treatment did not increase the exposure to <e20> S-ketamine </e20> .
negative	The ratio of <e13> norketamine </e13> AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the <e20> ticlopidine </e20> (P &lt; #) and itraconazole phases (P = #) as compared to placebo.
negative	The ratio of <e13> norketamine </e13> AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the ticlopidine (P &lt; #) and <e20> itraconazole </e20> phases (P = #) as compared to placebo.
negative	The ratio of norketamine AUC(0- ) to <e10> ketamine </e10> AUC(0- ) was significantly decreased in the <e20> ticlopidine </e20> (P &lt; #) and itraconazole phases (P = #) as compared to placebo.
negative	The ratio of norketamine AUC(0- ) to <e10> ketamine </e10> AUC(0- ) was significantly decreased in the ticlopidine (P &lt; #) and <e20> itraconazole </e20> phases (P = #) as compared to placebo.
negative	The ratio of norketamine AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the <e10> ticlopidine </e10> (P &lt; #) and <e20> itraconazole </e20> phases (P = #) as compared to placebo.
negative	In the <e10> ticlopidine </e10> and <e20> itraconazole </e20> phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < #).
advise	The findings suggest that the dosage of <e10> S-ketamine </e10> should be reduced in patients receiving <e20> ticlopidine </e20> .
negative	We also found that Bcl-2 was overexpressed in <e13> DZNep </e13> insensitive cells, and cotreatment with DZNep and <e23> ABT-737 </e23> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
effect	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with <e13> DZNep </e13> and <e23> ABT-737 </e23> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
negative	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and <e13> ABT-737 </e13> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of <e23> DZNep </e23> insensitive MM cells.
negative	In addition, <e13> DZNep </e13> insensitivity might be associated with overexpression of Bcl-2, and the combination of <e23> ABT-737 </e23> and DZNep could synergistically induced apoptosis.
effect	In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of <e13> ABT-737 </e13> and <e23> DZNep </e23> could synergistically induced apoptosis.
effect	<e11> Implanon </e11> failure in an HIV-positive woman on <e22> antiretroviral </e22> therapy resulting in two ectopic pregnancies.
effect	We present an interesting case of an HIV-positive woman on <e12> antiretroviral </e12> therapy having tubal pregnancies on two separate occasions with <e21> Implanon </e21> in place.
negative	<e12> Antidepressant </e12> - <e20> warfarin </e20> interaction and associated gastrointestinal bleeding risk in a case-control study.
negative	We sought to evaluate whether initiation of an <e12> antidepressant </e12> increases the risk of hospitalization for gastrointestinal bleeding in <e20> warfarin </e20> users.
effect	<e10> Warfarin </e10> users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e20> citalopram </e20> (OR = # [95% CI, ##]), fluoxetine (OR = # [95% CI, ##]), paroxetine (OR = # [95% CI, ##]), amitriptyline (OR = # [95% CI, ##]).
effect	<e10> Warfarin </e10> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = # [95% CI, ##]), <e20> fluoxetine </e20> (OR = # [95% CI, ##]), paroxetine (OR = # [95% CI, ##]), amitriptyline (OR = # [95% CI, ##]).
effect	<e10> Warfarin </e10> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = # [95% CI, ##]), fluoxetine (OR = # [95% CI, ##]), <e20> paroxetine </e20> (OR = # [95% CI, ##]), amitriptyline (OR = # [95% CI, ##]).
effect	<e10> Warfarin </e10> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = # [95% CI, ##]), fluoxetine (OR = # [95% CI, ##]), paroxetine (OR = # [95% CI, ##]), <e20> amitriptyline </e20> (OR = # [95% CI, ##]).
effect	Also <e10> mirtazapine </e10> , which is not believed to interact with <e20> warfarin </e20> , increased the risk of GI bleeding (OR = # [95% CI, ##]).
effect	<e10> Warfarin </e10> users who initiated <e20> citalopram </e20> , fluoxetine , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
effect	<e10> Warfarin </e10> users who initiated citalopram , <e20> fluoxetine </e20> , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
effect	<e10> Warfarin </e10> users who initiated citalopram , fluoxetine , <e20> paroxetine </e20> , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
effect	<e10> Warfarin </e10> users who initiated citalopram , fluoxetine , paroxetine , <e20> amitriptyline </e20> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
effect	<e10> Warfarin </e10> users who initiated citalopram , fluoxetine , paroxetine , amitriptyline , or <e20> mirtazapine </e20> had an increased risk of hospitalization for gastrointestinal bleeding.
effect	<e13> ABT </e13> decreased the toxicity of <e23> precocene_I </e23> , increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.
negative	Of the isoform-specific CYP inhibitors tested for an effect on the <e13> precocene_I </e13> metabolite profile, only <e20> tranylcypromine </e20> was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.
negative	With respect to toxicity, the order of CYP inhibitor effectiveness was <e13> ABT </e13> > <e23> diethyldithiocarbamate </e23> ~ tranylcypromine > ketoconazole .
negative	With respect to toxicity, the order of CYP inhibitor effectiveness was <e13> ABT </e13> > diethyldithiocarbamate ~ <e20> tranylcypromine </e20> > ketoconazole .
negative	With respect to toxicity, the order of CYP inhibitor effectiveness was <e13> ABT </e13> > diethyldithiocarbamate ~ tranylcypromine > <e20> ketoconazole </e20> .
negative	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT > <e13> diethyldithiocarbamate </e13> ~ <e20> tranylcypromine </e20> > ketoconazole .
negative	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT > <e13> diethyldithiocarbamate </e13> ~ tranylcypromine > <e20> ketoconazole </e20> .
negative	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT > diethyldithiocarbamate ~ <e10> tranylcypromine </e10> > <e20> ketoconazole </e20> .
negative	<e13> Furafylline </e13> and <e23> sulfaphenazole </e23> had no effect, while quinidine appeared to augment precocene_I toxicity.
negative	<e13> Furafylline </e13> and sulfaphenazole had no effect, while <e20> quinidine </e20> appeared to augment precocene_I toxicity.
negative	<e13> Furafylline </e13> and sulfaphenazole had no effect, while quinidine appeared to augment <e23> precocene_I </e23> toxicity.
negative	Furafylline and <e13> sulfaphenazole </e13> had no effect, while <e20> quinidine </e20> appeared to augment precocene_I toxicity.
negative	Furafylline and <e13> sulfaphenazole </e13> had no effect, while quinidine appeared to augment <e23> precocene_I </e23> toxicity.
effect	Furafylline and sulfaphenazole had no effect, while <e10> quinidine </e10> appeared to augment <e23> precocene_I </e23> toxicity.
negative	<e13> AAV2 </e13> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e23> collagenase </e23> , hyaluronan_lyase , heparinase_III , or chondroitin_ABC_lyase .
negative	<e13> AAV2 </e13> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , <e23> hyaluronan_lyase </e23> , heparinase_III , or chondroitin_ABC_lyase .
negative	<e13> AAV2 </e13> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan_lyase , <e23> heparinase_III </e23> , or chondroitin_ABC_lyase .
negative	<e13> AAV2 </e13> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan_lyase , heparinase_III , or <e23> chondroitin_ABC_lyase </e23> .
negative	The addition of <e13> heparinase_III </e13> or <e23> chondroitin_ABC_lyase </e23> greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.
negative	<e13> Hyaluronan_lyase </e13> had a limited effect and <e23> collagenase </e23> was ineffective.
negative	Electroretinograms survived with higher concentrations of <e13> heparinase_III </e13> and <e23> chondroitin_ABC_lyase </e23> than were required for optimal retinal transduction.
effect	<e13> AAV2 </e13> -mediated retinal transduction is improved by co-injection of <e23> heparinase_III </e23> or chondroitin_ABC_lyase .
effect	<e13> AAV2 </e13> -mediated retinal transduction is improved by co-injection of heparinase_III or <e23> chondroitin_ABC_lyase </e23> .
negative	AAV2 -mediated retinal transduction is improved by co-injection of <e13> heparinase_III </e13> or <e23> chondroitin_ABC_lyase </e23> .
negative	Prevention of emergence agitation in seven children receiving low-dose <e10> ketamine </e10> and <e20> propofol </e20> total intravenous anesthesia.
negative	We retrospectively reviewed the records of # pediatric oncology patients who received low-dose <e10> ketamine </e10> in conjunction with <e20> propofol </e20> for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.
negative	EA signs were observed in all # patients in association with <e10> propofol </e10> TIVA but did not recur in any of # subsequent anesthetics sessions during which low-dose <e20> ketamine </e20> was added to propofol .
negative	EA signs were observed in all # patients in association with propofol TIVA but did not recur in any of # subsequent anesthetics sessions during which low-dose <e10> ketamine </e10> was added to <e20> propofol </e20> .
effect	Based on this experience, we suggest that low-dose <e10> ketamine </e10> added to <e20> propofol </e20> may be associated with prevention of EA in children with a history of EA with propofol TIVA.
negative	Based on this experience, we suggest that low-dose <e10> ketamine </e10> added to propofol may be associated with prevention of EA in children with a history of EA with <e20> propofol </e20> TIVA.
negative	<e10> Tamoxifen </e10> , an <e22> estrogen_antagonist </e22> , is the standard hormone treatment for breast cancer.
negative	<e10> Paroxetine </e10> and <e20> fluoxetine </e20> reduce the plasma concentration of endoxifen by about 50%.
mechanism	<e10> Paroxetine </e10> and fluoxetine reduce the plasma concentration of <e23> endoxifen </e23> by about 50%.
mechanism	Paroxetine and <e10> fluoxetine </e10> reduce the plasma concentration of <e23> endoxifen </e23> by about 50%.
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e10> tamoxifen </e10> for breast cancer, especially <e22> SSRI_antidepressants </e22> such as paroxetine and fluoxetine .
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e10> tamoxifen </e10> for breast cancer, especially SSRI_antidepressants such as <e20> paroxetine </e20> and fluoxetine .
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e10> tamoxifen </e10> for breast cancer, especially SSRI_antidepressants such as paroxetine and <e20> fluoxetine </e20> .
negative	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially <e12> SSRI_antidepressants </e12> such as <e20> paroxetine </e20> and fluoxetine .
negative	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially <e12> SSRI_antidepressants </e12> such as paroxetine and <e20> fluoxetine </e20> .
negative	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI_antidepressants such as <e10> paroxetine </e10> and <e20> fluoxetine </e20> .
negative	Depression does not always require <e12> antidepressant_drug </e12> therapy, and <e22> antidepressants </e22> have no proven preventive impact on hot flushes linked to the menopause.
advise	If in certain cases, an <e12> antidepressant </e12> is considered necessary, it may be advisable to replace <e20> tamoxifen </e20> with anastrozole .
negative	If in certain cases, an <e12> antidepressant </e12> is considered necessary, it may be advisable to replace tamoxifen with <e20> anastrozole </e20> .
negative	If in certain cases, an antidepressant is considered necessary, it may be advisable to replace <e10> tamoxifen </e10> with <e20> anastrozole </e20> .
negative	<e10> Amphetamine </e10> locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with <e23> quinpirole </e23> .
negative	The objective was to analyze the effects of neonatal <e13> quinpirole </e13> treatment on effects of <e20> amphetamine </e20> in adolescent rats using locomotor sensitization and conditioned place preference procedures.
effect	In female rats, neonatal <e13> quinpirole </e13> treatment enhanced <e20> amphetamine </e20> locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine .
negative	In female rats, neonatal <e13> quinpirole </e13> treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to <e20> amphetamine </e20> .
negative	In female rats, neonatal quinpirole treatment enhanced <e10> amphetamine </e10> locomotor sensitization compared with <e23> quinpirole </e23> -free controls sensitized to amphetamine .
negative	In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with <e13> quinpirole </e13> -free controls sensitized to <e20> amphetamine </e20> .
negative	Male rats demonstrated sensitization to <e10> amphetamine </e10> , although this was muted compared with female rats, and were unaffected by neonatal <e23> quinpirole </e23> .
negative	Rats treated with neonatal <e13> quinpirole </e13> enhanced time spent in the <e20> amphetamine </e20> -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
negative	Rats treated with neonatal <e13> quinpirole </e13> enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with <e20> amphetamine </e20> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
negative	Rats treated with neonatal <e13> quinpirole </e13> enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with <e20> amphetamine </e20> spent more time in the drug-paired context compared with saline-treated controls.
negative	Rats treated with neonatal quinpirole enhanced time spent in the <e10> amphetamine </e10> -paired context compared with <e23> quinpirole </e23> -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
negative	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with <e13> quinpirole </e13> -free controls conditioned with <e20> amphetamine </e20> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
negative	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with <e13> quinpirole </e13> -free controls conditioned with amphetamine , but only female controls conditioned with <e20> amphetamine </e20> spent more time in the drug-paired context compared with saline-treated controls.
negative	In vivo CYP3A activity is significantly lower in <e10> cyclosporine </e10> -treated as compared with <e20> tacrolimus </e20> -treated renal allograft recipients.
negative	In vitro studies have identified <e10> cyclosporine </e10> and <e20> tacrolimus </e20> as CYP3A inhibitors.
mechanism	Systemic and apparent oral <e10> midazolam </e10> clearance were 24% (269 # vs, # # ml/min, P = #) and 31% (479 # vs, # # ml/min, P = #), respectively, lower in <e20> cyclosporine </e20> -treated patients (n = 20) than in matched tacrolimus -treated patients (n = 20).
negative	Systemic and apparent oral <e10> midazolam </e10> clearance were 24% (269 # vs, # # ml/min, P = #) and 31% (479 # vs, # # ml/min, P = #), respectively, lower in cyclosporine -treated patients (n = 20) than in matched <e20> tacrolimus </e20> -treated patients (n = 20).
negative	Systemic and apparent oral midazolam clearance were 24% (269 # vs, # # ml/min, P = #) and 31% (479 # vs, # # ml/min, P = #), respectively, lower in <e10> cyclosporine </e10> -treated patients (n = 20) than in matched <e20> tacrolimus </e20> -treated patients (n = 20).
negative	The latter displayed <e10> midazolam </e10> clearances similar to those in two larger cohorts of nonmatched <e20> tacrolimus </e20> -treated patients (n = # and n = 80) and to those receiving a calcineurin_inhibitor -free regimen (n = 6).
negative	The latter displayed <e10> midazolam </e10> clearances similar to those in two larger cohorts of nonmatched tacrolimus -treated patients (n = # and n = 80) and to those receiving a <e22> calcineurin_inhibitor </e22> -free regimen (n = 6).
negative	The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched <e10> tacrolimus </e10> -treated patients (n = # and n = 80) and to those receiving a <e22> calcineurin_inhibitor </e22> -free regimen (n = 6).
negative	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving <e10> cyclosporine </e10> than in those receiving <e20> tacrolimus </e20> , indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.
negative	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving <e10> tacrolimus </e10> , indicating that, at the doses generally used in clinical practice, <e20> cyclosporine </e20> is the stronger of the two with respect to CYP3A inhibition.
negative	Improved parathyroid hormone control by <e10> cinacalcet </e10> is associated with reduction in <e20> darbepoetin </e20> requirement in patients with end-stage renal disease.
negative	Medical treatment with <e10> cinacalcet </e10> is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on <e20> darbepoetin </e20> dosing is unknown.
negative	The primary objective of the study was to ascertain the difference in <e10> darbepoetin </e10> responsiveness before and after # months of <e20> cinacalcet </e20> therapy.
effect	Reduction of PTH by <e10> cinacalcet </e10> is associated with a decrease in <e20> darbepoetin </e20> requirement.
effect	Interaction of <e10> celecoxib </e10> with different <e22> anti-cancer_drugs </e22> is antagonistic in breast but not in other cancer cells.
negative	This study investigates the ability of <e12> cyclooxygenase-2_inhibitors </e12> to sensitize cells from different origins to several <e22> chemotherapeutic_agents </e22> .
negative	We found antagonism between <e10> celecoxib </e10> and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and <e20> doxorubicin </e20> in all cell lines except for two combinations in HCT116 cells.
effect	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between <e10> celecoxib </e10> and <e20> doxorubicin </e20> in all cell lines except for two combinations in HCT116 cells.
negative	These results, if confirmed in-vivo, indicate that <e10> celecoxib </e10> is not a suitable chemosensitizer for breast cancer or with <e20> doxorubicin </e20> for other cancers.
negative	[Interaction between <e10> clopidogrel </e10> and <e22> proton_pump_inhibitors </e22> ].
negative	The drug interaction between <e12> proton_pump_inhibitors </e12> and <e20> clopidogrel </e20> has been the subject of much study in recent years.
negative	Contradictory results regarding the effect of <e12> proton_pump_inhibitors </e12> on platelet reactivity and on clinical outcome in <e20> clopidogrel </e20> -treated patients have been reported in literature.
mechanism	Concomitant use of <e10> omeprazole </e10> and <e20> clopidogrel </e20> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
negative	Concomitant use of omeprazole and <e10> clopidogrel </e10> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by <e20> omeprazole </e20> of CYP2C19, a cytochrome P450 (CYP) enzyme.
mechanism	<e10> Pantoprazole </e10> has a much weaker effect on <e20> clopidogrel </e20> 's pharmacokinetics and on platelet reactivity during concomitant use.
negative	The influence of the other <e12> proton_pump_inhibitors </e12> when used simultaneously with <e20> clopidogrel </e20> has not yet been investigated in adequately randomized studies.
advise	Regulatory agencies state that the combination of <e10> clopidogrel </e10> and the CYP2C19 inhibitors <e20> omeprazole </e20> and esomeprazole should be avoided.
advise	Regulatory agencies state that the combination of <e10> clopidogrel </e10> and the CYP2C19 inhibitors omeprazole and <e20> esomeprazole </e20> should be avoided.
negative	To date, there is no conclusive evidence of a clinically-relevant interaction between any of the <e12> proton_pump_inhibitors </e12> and <e20> clopidogrel </e20> .
negative	In vitro activity of <e10> minocycline </e10> combined with <e20> fosfomycin </e20> against clinical isolates of methicillin -resistant Staphylococcus aureus.
negative	In vitro activity of <e10> minocycline </e10> combined with fosfomycin against clinical isolates of <e20> methicillin </e20> -resistant Staphylococcus aureus.
negative	In vitro activity of minocycline combined with <e10> fosfomycin </e10> against clinical isolates of <e20> methicillin </e20> -resistant Staphylococcus aureus.
negative	This study aimed to evaluate the in vitro activity of <e10> minocycline </e10> combined with <e20> fosfomycin </e20> against isolates of methicillin -resistant Staphylococcus aureus (MRSA).
negative	This study aimed to evaluate the in vitro activity of <e10> minocycline </e10> combined with fosfomycin against isolates of <e20> methicillin </e20> -resistant Staphylococcus aureus (MRSA).
negative	This study aimed to evaluate the in vitro activity of minocycline combined with <e10> fosfomycin </e10> against isolates of <e20> methicillin </e20> -resistant Staphylococcus aureus (MRSA).
negative	The susceptibility results for <e10> minocycline </e10> and <e20> fosfomycin </e20> were interpreted according to the most relevant criteria.
effect	The combination of <e10> minocycline </e10> and <e20> fosfomycin </e20> can be synergistic against MRSA.
int	The authors report the case of an infant with confirmed congenital hypothyroidism on <e10> levothyroxine </e10> who experienced a possible drug interaction with <e20> simeticone </e20> .
negative	Questioning revealed the child was taking <e11> Infacol </e11> drops before feeds while on <e20> levothyroxine </e20> .
negative	Drug interaction of <e10> thyroxine </e10> with <e20> simeticone </e20> has not been reported previously and is not listed in the British National Formulary for Children.
negative	<e10> Calcium </e10> does not inhibit the absorption of # milligrams of <e20> nonheme_iron </e20> or heme_iron at doses less than # milligrams in nonpregnant women.
negative	<e10> Calcium </e10> does not inhibit the absorption of # milligrams of nonheme_iron or <e20> heme_iron </e20> at doses less than # milligrams in nonpregnant women.
mechanism	<e10> Calcium </e10> is the only known component in the diet that may affect absorption of both <e20> nonheme_iron </e20> and heme_iron .
mechanism	<e10> Calcium </e10> is the only known component in the diet that may affect absorption of both nonheme_iron and <e20> heme_iron </e20> .
mechanism	However, the evidence for a <e10> calcium </e10> effect on <e20> iron </e20> absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
negative	However, the evidence for a calcium effect on <e10> iron </e10> absorption mainly comes from studies that did not isolate the effect of <e20> calcium </e20> from that of other dietary components, because it was detected in single-meal studies.
negative	Our objective was to establish potential effects of <e10> calcium </e10> on absorption of <e20> nonheme_iron </e20> and heme_iron n and the dose response for this effect in the absence of a meal.
negative	Our objective was to establish potential effects of <e10> calcium </e10> on absorption of nonheme_iron and <e20> heme_iron </e20> n and the dose response for this effect in the absence of a meal.
negative	We evaluated the effects of <e10> calcium </e10> doses between # and # mg on absorption of # mg <e20> nonheme_iron </e20> (as ferrous_sulfate ).
negative	We evaluated the effects of <e10> calcium </e10> doses between # and # mg on absorption of # mg nonheme_iron (as <e20> ferrous_sulfate </e20> ).
negative	We also evaluated the effects of <e10> calcium </e10> doses between # and # mg on absorption of # mg <e20> heme_iron </e20> [as concentrated RBC (CRBC)].
negative	<e10> Calcium </e10> was administered as calcium_chloride in all studies and <e22> minerals </e22> were ingested on an empty stomach.
negative	Calcium was administered as <e10> calcium_chloride </e10> in all studies and <e22> minerals </e22> were ingested on an empty stomach.
mechanism	<e10> Calcium </e10> doses # mg diminished <e20> nonheme_iron </e20> absorption by an average of #%.
mechanism	A <e10> calcium </e10> dose of # mg diminished absorption of # mg <e20> heme_iron </e20> by #%.
mechanism	In conclusion, we demonstrated an isolated effect of <e10> calcium </e10> (as chloride) on absorption of # mg of iron provided as <e20> nonheme_iron </e20> (as sulfate) and heme_iron (as CRBC).
mechanism	In conclusion, we demonstrated an isolated effect of <e10> calcium </e10> (as chloride) on absorption of # mg of iron provided as nonheme_iron (as sulfate) and <e20> heme_iron </e20> (as CRBC).
int	Synergistic interaction between <e10> sunitinib </e10> and <e20> docetaxel </e20> is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
negative	This study was aimed to investigate the efficacy of single use of <e10> sunitinib </e10> and that of concurrent or sequential administration of sunitinib and <e20> docetaxel </e20> in NSCLC cell lines that are resistant to EGFR TKIs.
negative	This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of <e10> sunitinib </e10> and <e20> docetaxel </e20> in NSCLC cell lines that are resistant to EGFR TKIs.
negative	<e10> Sunitinib </e10> exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas <e20> docetaxel </e20> arrested at S phase.
effect	Although single or concurrent use of <e10> sunitinib </e10> and <e20> docetaxel </e20> has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.
effect	When cells were exposed to <e10> docetaxel </e10> followed by <e20> sunitinib </e20> , synergism was observed.
effect	The molecular basis of this synergism is that the signaling pathways that were initially activated by <e10> docetaxel </e10> exposure were efficiently suppressed by the subsequent exposure to <e20> sunitinib </e20> .
negative	<e10> Sunitinib </e10> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e20> docetaxel </e20> followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
negative	<e10> Sunitinib </e10> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by <e20> docetaxel </e20> and concurrent administration.
effect	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e10> docetaxel </e10> followed by <e20> sunitinib </e20> is superior to sunitinib followed by docetaxel and concurrent administration.
negative	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e10> docetaxel </e10> followed by sunitinib is superior to <e20> sunitinib </e20> followed by docetaxel and concurrent administration.
negative	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by <e10> sunitinib </e10> is superior to sunitinib followed by <e20> docetaxel </e20> and concurrent administration.
negative	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to <e10> sunitinib </e10> followed by <e20> docetaxel </e20> and concurrent administration.
negative	Distinct synergistic action of <e10> piperacillin </e10> and <e23> methylglyoxal </e23> against Pseudomonas aeruginosa.
effect	Distinct and statistically significant synergism was observed between <e13> methylglyoxal </e13> and <e20> piperacillin </e20> by disc diffusion tests when compared with their individual effects.
effect	Synergism was also noted when <e13> methylglyoxal </e13> was combined with <e20> carbenicillin </e20> and amikacin .
effect	Synergism was also noted when <e13> methylglyoxal </e13> was combined with carbenicillin and <e20> amikacin </e20> .
negative	Synergism was also noted when methylglyoxal was combined with <e10> carbenicillin </e10> and <e20> amikacin </e20> .
negative	Protective effect of <e10> acetyl-l-carnitine </e10> and <e23> alpha_lipoic_acid </e23> against the acute toxicity of diepoxybutane to human lymphocytes.
effect	(ii) <e10> acetyl-l-carnitine </e10> elicits a significant protective effect on DEB induced toxicity, which was potentiated by <e20> alpha-lipoic_acid </e20> .
negative	[Influence of <e13> hemantane </e13> and <e20> doxycycline </e20> on MPTP-evoked behavior violations in C57BL/6 mice].
negative	The effects of <e12> anti-parkinsonian_drug </e12> <e23> hemantane </e23> [ (2-adamantyl)hexamethylenimine ] (10 mg/kg, p, o.
negative	The effects of <e12> anti-parkinsonian_drug </e12> hemantane [ <e23> (2-adamantyl)hexamethylenimine </e23> ] (10 mg/kg, p, o.
negative	The effects of anti-parkinsonian_drug <e13> hemantane </e13> [ <e23> (2-adamantyl)hexamethylenimine </e23> ] (10 mg/kg, p, o.
negative	and/or <e12> antibiotic_drug </e12> <e20> doxycycline </e20> (100 mg/kg, p, o,), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( MPTP ) (4 x # mg/kg, i, p.
negative	and/or <e12> antibiotic_drug </e12> doxycycline (100 mg/kg, p, o,), as well as that of neurotoxin <e23> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e23> ( MPTP ) (4 x # mg/kg, i, p.
negative	and/or <e12> antibiotic_drug </e12> doxycycline (100 mg/kg, p, o,), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e23> MPTP </e23> ) (4 x # mg/kg, i, p.
negative	and/or antibiotic_drug <e10> doxycycline </e10> (100 mg/kg, p, o,), as well as that of neurotoxin <e23> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e23> ( MPTP ) (4 x # mg/kg, i, p.
negative	and/or antibiotic_drug <e10> doxycycline </e10> (100 mg/kg, p, o,), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e23> MPTP </e23> ) (4 x # mg/kg, i, p.
effect	Acute administration of <e13> hemantane </e13> or <e20> doxycycline </e20> failed to influence locomotion in mice, while their combination normalized motor activity.
effect	The role of p27(Kip1) in <e10> dasatinib </e10> -enhanced <e20> paclitaxel </e20> cytotoxicity in human ovarian cancer cells.
negative	The effect of <e10> dasatinib </e10> , an inhibitor of Src and Abl kinases, on <e20> paclitaxel </e20> sensitivity was measured in ovarian cancer cells and HEY xenografts.
negative	The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by <e10> dasatinib </e10> and <e20> paclitaxel </e20> were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.
effect	HEY cells treated with <e10> dasatinib </e10> plus <e20> paclitaxel </e20> formed fewer colonies than did cells treated with either agent alone.
effect	Treatment of HEY xenograft-bearing mice with <e10> dasatinib </e10> plus <e20> paclitaxel </e20> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel : # vs, # cm3, difference = # cm3, 95% confidence interval [CI] = # to # cm3, P = #);
negative	Treatment of HEY xenograft-bearing mice with <e10> dasatinib </e10> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + <e20> paclitaxel </e20> vs paclitaxel : # vs, # cm3, difference = # cm3, 95% confidence interval [CI] = # to # cm3, P = #);
negative	Treatment of HEY xenograft-bearing mice with <e10> dasatinib </e10> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs <e20> paclitaxel </e20> : # vs, # cm3, difference = # cm3, 95% confidence interval [CI] = # to # cm3, P = #);
negative	Treatment of HEY xenograft-bearing mice with dasatinib plus <e10> paclitaxel </e10> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e20> dasatinib </e20> + paclitaxel vs paclitaxel : # vs, # cm3, difference = # cm3, 95% confidence interval [CI] = # to # cm3, P = #);
negative	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e10> dasatinib </e10> + <e20> paclitaxel </e20> vs paclitaxel : # vs, # cm3, difference = # cm3, 95% confidence interval [CI] = # to # cm3, P = #);
negative	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e10> dasatinib </e10> + paclitaxel vs <e20> paclitaxel </e20> : # vs, # cm3, difference = # cm3, 95% confidence interval [CI] = # to # cm3, P = #);
negative	<e10> dasatinib </e10> + <e20> paclitaxel </e20> vs.
negative	The siRNA knockdown of p27(Kip1) decreased <e10> dasatinib </e10> - and <e20> paclitaxel </e20> -induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs, p27(Kip1) siRNA: #% vs, #%, difference = #%, 95% CI = #% to #%, P = #).
effect	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that <e10> dasatinib </e10> -mediated induction of p27(Kip1) enhanced <e20> paclitaxel </e20> -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.
effect	Inhibition of Src family and Abl kinases with either siRNAs or <e10> dasatinib </e10> enhances <e20> paclitaxel </e20> sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
negative	Phase I trial of <e10> lenalidomide </e10> and <e20> CCI-779 </e20> in patients with relapsed multiple myeloma: evidence for lenalidomide - CCI-779 interaction via P-glycoprotein.
negative	Phase I trial of <e10> lenalidomide </e10> and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide - <e20> CCI-779 </e20> interaction via P-glycoprotein.
negative	Phase I trial of lenalidomide and <e10> CCI-779 </e10> in patients with relapsed multiple myeloma: evidence for <e20> lenalidomide </e20> - CCI-779 interaction via P-glycoprotein.
negative	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for <e10> lenalidomide </e10> - <e20> CCI-779 </e20> interaction via P-glycoprotein.
effect	The preclinical combination of <e10> lenalidomide </e10> with the mTOR inhibitor <e20> CCI-779 </e20> has displayed synergy in vitro and represents a novel combination in MM.
negative	Enhancement of humoral immune responses to inactivated Newcastle disease and <e12> avian_influenza_vaccines </e12> by oral administration of <e23> ginseng_stem-and-leaf_saponins </e23> in chickens.
negative	The objective of this study was to evaluate the effect of oral administration of <e13> ginseng_stem-and-leaf_saponins </e13> ( GSLS ) on the humoral immune responses of chickens to <e20> inactivated_ND_vaccines </e20> and inactivated_AI_vaccines .
negative	The objective of this study was to evaluate the effect of oral administration of <e13> ginseng_stem-and-leaf_saponins </e13> ( GSLS ) on the humoral immune responses of chickens to inactivated_ND_vaccines and <e20> inactivated_AI_vaccines </e20> .
negative	The objective of this study was to evaluate the effect of oral administration of ginseng_stem-and-leaf_saponins ( <e13> GSLS </e13> ) on the humoral immune responses of chickens to <e20> inactivated_ND_vaccines </e20> and inactivated_AI_vaccines .
negative	The objective of this study was to evaluate the effect of oral administration of ginseng_stem-and-leaf_saponins ( <e13> GSLS </e13> ) on the humoral immune responses of chickens to inactivated_ND_vaccines and <e20> inactivated_AI_vaccines </e20> .
negative	In experiment 1, oral administration of <e13> GSLS </e13> at a dose of # mg/kg of BW for # d on the immune response in chickens intramuscularly injected with <e20> inactivated_ND_vaccine </e20> was evaluated.
effect	In experiment 2, the same regimen of <e13> GSLS </e13> was administered to chickens inoculated with <e20> inactivated_AI_vaccines </e20> , and an enhanced serum antibody response to AI vaccination was also observed.
negative	Interaction of <e10> dacarbazine </e10> and <e20> imexon </e20> , in vitro and in vivo, in human A375 melanoma cells.
negative	We evaluated mechanisms of interaction between the alkyating agent <e10> dacarbazine </e10> ( DTIC ) and the pro-oxidant, <e20> imexon </e20> , in the human A375 melanoma cell line.
negative	We evaluated mechanisms of interaction between the alkyating agent dacarbazine ( <e10> DTIC </e10> ) and the pro-oxidant, <e20> imexon </e20> , in the human A375 melanoma cell line.
negative	The effect of <e10> DTIC </e10> and <e20> imexon </e20> , alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).
negative	There was a >75% reduction in cellular glutathione and cysteine with <e10> imexon </e10> but not <e20> DTIC </e20> .
effect	<e10> Imexon </e10> and <e20> dacarbazine </e20> show additive effects in vitro but not in vivo in human A375 melanoma cells.
effect	<e10> Lapatinib </e10> enhances <e21> herceptin </e21> -mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
effect	Although it was previously reported that <e10> lapatinib </e10> combined with <e21> Herceptin </e21> improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
negative	Although it was previously reported that <e10> lapatinib </e10> combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with <e21> Herceptin </e21> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
negative	Although it was previously reported that lapatinib combined with <e11> Herceptin </e11> improved the progression-free survival rate compared with <e20> lapatinib </e20> alone for patients with Herceptin -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
negative	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with <e10> lapatinib </e10> alone for patients with <e21> Herceptin </e21> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
negative	We evaluated how <e10> lapatinib </e10> interacts with <e21> Herceptin </e21> in HER2-positive breast cancer, with a particular focus on Herceptin -mediated antibody-dependent cellular cytotoxicity (ADCC).
negative	We evaluated how <e10> lapatinib </e10> interacts with Herceptin in HER2-positive breast cancer, with a particular focus on <e21> Herceptin </e21> -mediated antibody-dependent cellular cytotoxicity (ADCC).
effect	In an in vitro assay, <e10> lapatinib </e10> induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of <e21> Herceptin </e21> -mediated ADCC.
effect	Furthermore, we present a case report in which a second <e11> Herceptin </e11> treatment following <e20> lapatinib </e20> resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.
negative	<e10> Lapatinib </e10> may have the potential to convert <e21> Herceptin </e21> -refractory to Herceptin -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
negative	<e10> Lapatinib </e10> may have the potential to convert Herceptin -refractory to <e21> Herceptin </e21> -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
negative	We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of <e13> CRM197 </e13> on these cells alone or in combination with <e22> anticancer_agent </e22> .
negative	<e13> CRM197 </e13> induced apoptosis, and furthermore, the combination of CRM197 plus <e20> doxorubicin </e20> enhanced cytotoxicity in a T-ALL cell line.
effect	CRM197 induced apoptosis, and furthermore, the combination of <e13> CRM197 </e13> plus <e20> doxorubicin </e20> enhanced cytotoxicity in a T-ALL cell line.
effect	<e10> Ephedrine </e10> enhances the antinociceptive effect of <e20> dexmedetomidine </e20> in mice.
negative	The purpose of this study was to evaluate whether the psychostimulant drug <e10> ephedrine </e10> has any effect on <e20> dexmedetomidine </e20> -induced antinociception and locomotor inhibitor activity in mice in acute application.
negative	saline + saline, <e10> ephedrine </e10> (10 mg/kg) + saline, saline + <e20> dexmedetomidine </e20> (15 g/kg) and ephedrine (10 mg/kg) + dexmedetomidine (15 g/kg), intraperitoneally, # min before hot plate or holed open field tests.
negative	saline + saline, <e10> ephedrine </e10> (10 mg/kg) + saline, saline + dexmedetomidine (15 g/kg) and ephedrine (10 mg/kg) + <e20> dexmedetomidine </e20> (15 g/kg), intraperitoneally, # min before hot plate or holed open field tests.
negative	saline + saline, ephedrine (10 mg/kg) + saline, saline + <e10> dexmedetomidine </e10> (15 g/kg) and <e20> ephedrine </e20> (10 mg/kg) + dexmedetomidine (15 g/kg), intraperitoneally, # min before hot plate or holed open field tests.
negative	saline + saline, ephedrine (10 mg/kg) + saline, saline + dexmedetomidine (15 g/kg) and <e10> ephedrine </e10> (10 mg/kg) + <e20> dexmedetomidine </e20> (15 g/kg), intraperitoneally, # min before hot plate or holed open field tests.
effect	In the hot plate test in mice, co-administration of # g/kg <e10> dexmedetomidine </e10> with # mg/kg <e20> ephedrine </e20> intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine .
negative	In the hot plate test in mice, co-administration of # g/kg dexmedetomidine with # mg/kg <e10> ephedrine </e10> intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by <e20> dexmedetomidine </e20> .
effect	At the same time, the locomotor inhibitory effect of <e10> dexmedetomidine </e10> was counteracted by <e20> ephedrine </e20> .
effect	We concluded that the combined administration of <e10> dexmedetomidine </e10> with <e20> ephedrine </e20> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
negative	We concluded that the combined administration of <e10> dexmedetomidine </e10> with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an <e22> analgesic </e22> in humans.
negative	We concluded that the combined administration of dexmedetomidine with <e10> ephedrine </e10> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e20> dexmedetomidine </e20> as an analgesic in humans.
negative	We concluded that the combined administration of dexmedetomidine with <e10> ephedrine </e10> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an <e22> analgesic </e22> in humans.
negative	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e10> dexmedetomidine </e10> as an <e22> analgesic </e22> in humans.
negative	But the use of fixed combination <e10> amlodipine </e10> / valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (#+/# and #+/# days, respectively, #), lesser number of <e22> antihypertensive_drugs </e22> (#+/# and #+/# days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, #).
negative	But the use of fixed combination amlodipine / <e10> valsartan </e10> compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (#+/# and #+/# days, respectively, #), lesser number of <e22> antihypertensive_drugs </e22> (#+/# and #+/# days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, #).
negative	We have demonstrated appropriateness of inhospital administration of fixed <e10> amlodipine </e10> / valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer <e22> antihypertensive_drugs </e22> , and diminishing concealed inefficacy of treatment.
negative	We have demonstrated appropriateness of inhospital administration of fixed amlodipine / <e10> valsartan </e10> combination as an approach allowing to achieve target BP in shorter time, with the use of fewer <e22> antihypertensive_drugs </e22> , and diminishing concealed inefficacy of treatment.
negative	<e10> Ticagrelor </e10> ( Brilinta )--better than <e20> clopidogrel </e20> ( Plavix )
negative	<e10> Ticagrelor </e10> ( Brilinta )--better than clopidogrel ( <e21> Plavix </e21> )
negative	Ticagrelor ( <e11> Brilinta </e11> )--better than <e20> clopidogrel </e20> ( Plavix )
negative	Ticagrelor ( <e11> Brilinta </e11> )--better than clopidogrel ( <e21> Plavix </e21> )
negative	The FDA has approved <e10> ticagrelor </e10> ( Brilinta -AstraZeneca), an oral <e22> antiplatelet_drug </e22> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
effect	The FDA has approved <e10> ticagrelor </e10> ( Brilinta -AstraZeneca), an oral antiplatelet_drug , for use with low-dose <e21> aspirin </e21> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
negative	The FDA has approved ticagrelor ( <e11> Brilinta </e11> -AstraZeneca), an oral <e22> antiplatelet_drug </e22> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
effect	The FDA has approved ticagrelor ( <e11> Brilinta </e11> -AstraZeneca), an oral antiplatelet_drug , for use with low-dose <e21> aspirin </e21> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
negative	The FDA has approved ticagrelor ( Brilinta -AstraZeneca), an oral <e12> antiplatelet_drug </e12> , for use with low-dose <e21> aspirin </e21> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
negative	It will compete with <e10> clopidogrel </e10> ( Plavix ) and <e20> prasugrel </e20> ( Effient ) for such use.
negative	It will compete with <e10> clopidogrel </e10> ( Plavix ) and prasugrel ( <e21> Effient </e21> ) for such use.
negative	It will compete with clopidogrel ( <e11> Plavix </e11> ) and <e20> prasugrel </e20> ( Effient ) for such use.
negative	It will compete with clopidogrel ( <e11> Plavix </e11> ) and prasugrel ( <e21> Effient </e21> ) for such use.
negative	Influence of <e13> piperine </e13> on <e20> ibuprofen </e20> induced antinociception and its pharmacokinetics.
effect	In the present study <e13> piperine </e13> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e20> ibuprofen </e20> evaluated by both acetic_acid writhing and formalin test, when it was administered with ibuprofen .
negative	In the present study <e13> piperine </e13> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e20> acetic_acid </e20> writhing and formalin test, when it was administered with ibuprofen .
negative	In the present study <e13> piperine </e13> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic_acid writhing and formalin test, when it was administered with <e20> ibuprofen </e20> .
negative	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e10> ibuprofen </e10> evaluated by both <e20> acetic_acid </e20> writhing and formalin test, when it was administered with ibuprofen .
negative	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e10> acetic_acid </e10> writhing and formalin test, when it was administered with <e20> ibuprofen </e20> .
mechanism	<e10> Ibuprofen </e10> plasma concentration was also increased when it was administered with <e23> piperine </e23> .
mechanism	The synergistic antinociception activity of <e10> ibuprofen </e10> when administered with <e23> piperine </e23> can be attributed to increased plasma concentration of ibuprofen .
negative	The synergistic antinociception activity of ibuprofen when administered with <e13> piperine </e13> can be attributed to increased plasma concentration of <e20> ibuprofen </e20> .
effect	From this study it can be concluded that <e13> piperine </e13> can be used as a bioenhancer along with <e20> ibuprofen </e20> .
negative	Pharmacokinetic properties of <e10> abacavir </e10> were not altered by the addition of either <e20> lamivudine </e20> or zidovudine or the combination of lamivudine and zidovudine .
negative	Pharmacokinetic properties of <e10> abacavir </e10> were not altered by the addition of either lamivudine or <e20> zidovudine </e20> or the combination of lamivudine and zidovudine .
negative	Pharmacokinetic properties of <e10> abacavir </e10> were not altered by the addition of either lamivudine or zidovudine or the combination of <e20> lamivudine </e20> and zidovudine .
negative	Pharmacokinetic properties of <e10> abacavir </e10> were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and <e20> zidovudine </e20> .
negative	Pharmacokinetic properties of abacavir were not altered by the addition of either <e10> lamivudine </e10> or <e20> zidovudine </e20> or the combination of lamivudine and zidovudine .
negative	Pharmacokinetic properties of abacavir were not altered by the addition of either <e10> lamivudine </e10> or zidovudine or the combination of lamivudine and <e20> zidovudine </e20> .
negative	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or <e10> zidovudine </e10> or the combination of <e20> lamivudine </e20> and zidovudine .
negative	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of <e10> lamivudine </e10> and <e20> zidovudine </e20> .
negative	No clinically significant changes to <e10> lamivudine </e10> or <e20> zidovudine </e20> pharmacokinetics were observed following concomitant administration of abacavir .
negative	No clinically significant changes to <e10> lamivudine </e10> or zidovudine pharmacokinetics were observed following concomitant administration of <e20> abacavir </e20> .
negative	No clinically significant changes to lamivudine or <e10> zidovudine </e10> pharmacokinetics were observed following concomitant administration of <e20> abacavir </e20> .
negative	<e10> Abacavir </e10> has no effect on the pharmacokinetic properties of <e20> ethanol </e20> .
mechanism	<e10> Ethanol </e10> decreases the elimination of <e20> abacavir </e20> causing an increase in overall exposure , The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir .
negative	Ethanol decreases the elimination of abacavir causing an increase in overall exposure , The addition of <e10> methadone </e10> has no clinically significant effect on the pharmacokinetic properties of <e20> abacavir </e20> .
mechanism	In a study of # HIV-infected patients receiving <e10> methadone </e10> -maintenance therapy (40 mg and # mg daily) with # mg of <e21> ZIAGEN </e21> twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
negative	In a study of # HIV-infected patients receiving methadone -maintenance therapy (40 mg and # mg daily) with # mg of <e11> ZIAGEN </e11> twice daily (twice the currently recommended dose), oral <e20> methadone </e20> clearance increased 22% (90% CI 6% to 42%).
negative	<e10> Cholestyramine </e10> : Concomitant cholestyramine administration decreased the mean AUC of total <e20> ezetimibe </e20> approximately 55%.
mechanism	Cholestyramine : Concomitant <e10> cholestyramine </e10> administration decreased the mean AUC of total <e20> ezetimibe </e20> approximately 55%.
effect	The incremental LDL-C reduction due to adding <e10> ezetimibe </e10> to <e20> cholestyramine </e20> may be reduced by this interaction.
negative	Fibrates : The safety and effectiveness of <e10> ezetimibe </e10> administered with <e22> fibrates </e22> have not been established.
advise	Co-administration of <e11> ZETIA </e11> with <e22> fibrates </e22> is not recommended until use in patients is studied.
negative	<e10> Fenofibrate </e10> : In a pharmacokinetic study, concomitant fenofibrate administration increased total <e20> ezetimibe </e20> concentrations approximately #-fold.
mechanism	Fenofibrate : In a pharmacokinetic study, concomitant <e10> fenofibrate </e10> administration increased total <e20> ezetimibe </e20> concentrations approximately #-fold.
negative	<e10> Gemfibrozil </e10> : In a pharmacokinetic study, concomitant gemfibrozil administration increased total <e20> ezetimibe </e20> concentrations approximately #-fold.
negative	Gemfibrozil : In a pharmacokinetic study, concomitant <e10> gemfibrozil </e10> administration increased total <e20> ezetimibe </e20> concentrations approximately #-fold.
negative	HMG-CoA_reductase_inhibitors : No clinically significant pharmacokinetic interactions were seen when <e10> ezetimibe </e10> was co-administered with <e20> atorvastatin </e20> , simvastatin , pravastatin , lovastatin , or fluvastatin .
negative	HMG-CoA_reductase_inhibitors : No clinically significant pharmacokinetic interactions were seen when <e10> ezetimibe </e10> was co-administered with atorvastatin , <e20> simvastatin </e20> , pravastatin , lovastatin , or fluvastatin .
negative	HMG-CoA_reductase_inhibitors : No clinically significant pharmacokinetic interactions were seen when <e10> ezetimibe </e10> was co-administered with atorvastatin , simvastatin , <e20> pravastatin </e20> , lovastatin , or fluvastatin .
negative	HMG-CoA_reductase_inhibitors : No clinically significant pharmacokinetic interactions were seen when <e10> ezetimibe </e10> was co-administered with atorvastatin , simvastatin , pravastatin , <e20> lovastatin </e20> , or fluvastatin .
negative	HMG-CoA_reductase_inhibitors : No clinically significant pharmacokinetic interactions were seen when <e10> ezetimibe </e10> was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or <e20> fluvastatin </e20> .
mechanism	Cyclosporine : The total <e10> ezetimibe </e10> level increased 12-fold in one renal transplant patient receiving multiple medications, including <e20> cyclosporine </e20> .
advise	Patients who take both <e10> ezetimibe </e10> and <e20> cyclosporine </e20> should be carefully monitored.
negative	Multiple dose studies of <e10> ezetimibe </e10> given in combination with <e22> HMG-CoA_reductase_inhibitors </e22> ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
negative	Multiple dose studies of <e10> ezetimibe </e10> given in combination with HMG-CoA_reductase_inhibitors ( <e22> statins </e22> ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
negative	Multiple dose studies of ezetimibe given in combination with <e12> HMG-CoA_reductase_inhibitors </e12> ( statins ) in rats and rabbits during organogenesis result in higher <e20> ezetimibe </e20> and statin exposures.
negative	Multiple dose studies of ezetimibe given in combination with HMG-CoA_reductase_inhibitors ( <e12> statins </e12> ) in rats and rabbits during organogenesis result in higher <e20> ezetimibe </e20> and statin exposures.
negative	When <e11> ZETIA </e11> is administered with an <e20> HMG-CoA_reductase_inhibitor </e20> in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA_reductase_inhibitor .
negative	When <e11> ZETIA </e11> is administered with an HMG-CoA_reductase_inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the <e20> HMG-CoA_reductase_inhibitor </e20> .
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , <e22> Coumarin-type_anticoagulants </e22> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , <e20> Phenytoin </e20> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , <e20> Cyclosporine </e20> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e20> Terfenadine </e20> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e20> Cisapride </e20> , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e20> Astemizole </e20> , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral <e12> hypoglycemics </e12> , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , <e20> Phenytoin </e20> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , <e20> Cyclosporine </e20> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , <e20> Rifampin </e20> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , <e20> Theophylline </e20> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e20> Terfenadine </e20> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e20> Cisapride </e20> , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e20> Astemizole </e20> , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , <e12> Coumarin-type_anticoagulants </e12> , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral <e22> hypoglycemics </e22> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , <e20> Cyclosporine </e20> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , <e20> Terfenadine </e20> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e20> Cisapride </e20> , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e20> Astemizole </e20> , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , <e10> Phenytoin </e10> , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral <e22> hypoglycemics </e22> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , <e20> Terfenadine </e20> , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , Terfenadine , <e20> Cisapride </e20> , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , Terfenadine , Cisapride , <e20> Astemizole </e20> , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , <e10> Cyclosporine </e10> , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral <e22> hypoglycemics </e22> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , <e10> Rifampin </e10> , Theophylline , Terfenadine , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , <e10> Rifampin </e10> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , <e10> Rifampin </e10> , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e10> Theophylline </e10> , Terfenadine , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e10> Theophylline </e10> , Terfenadine , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , <e10> Theophylline </e10> , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e10> Terfenadine </e10> , Cisapride , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e10> Terfenadine </e10> , Cisapride , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , <e10> Terfenadine </e10> , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e10> Cisapride </e10> , Astemizole , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e10> Cisapride </e10> , Astemizole , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , <e10> Cisapride </e10> , Astemizole , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e10> Astemizole </e10> , <e20> Rifabutin </e20> , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e10> Astemizole </e10> , Rifabutin , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , <e10> Astemizole </e10> , Rifabutin , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e10> Rifabutin </e10> , <e20> Tacrolimus </e20> , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e10> Rifabutin </e10> , Tacrolimus , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , <e10> Rifabutin </e10> , Tacrolimus , Short-acting_benzodiazepines , Oral <e22> hypoglycemics </e22> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e10> Tacrolimus </e10> , <e22> Short-acting_benzodiazepines </e22> , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , <e10> Tacrolimus </e10> , Short-acting_benzodiazepines , Oral <e22> hypoglycemics </e22> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
negative	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , <e12> Short-acting_benzodiazepines </e12> , Oral <e22> hypoglycemics </e22> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic_agents ;
effect	These are described in greater detail below: Oral hypoglycemics , Coumarin-type_anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting_benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of <e11> DIFLUCAN </e11> with oral <e22> hypoglycemic_agents </e22> ;
effect	one fatality has been reported from hypoglycemia in association with combined <e11> DIFLUCAN </e11> and <e20> glyburide </e20> use.
mechanism	<e11> DIFLUCAN </e11> reduces the metabolism of <e20> tolbutamide </e20> , glyburide , and glipizide and increases the plasma concentration of these agents.
mechanism	<e11> DIFLUCAN </e11> reduces the metabolism of tolbutamide , <e20> glyburide </e20> , and glipizide and increases the plasma concentration of these agents.
mechanism	<e11> DIFLUCAN </e11> reduces the metabolism of tolbutamide , glyburide , and <e20> glipizide </e20> and increases the plasma concentration of these agents.
advise	When <e11> DIFLUCAN </e11> is used concomitantly with these or other <e22> sulfonylurea_oral_hypoglycemic_agents </e22> , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
negative	When <e11> DIFLUCAN </e11> is used concomitantly with these or other sulfonylurea_oral_hypoglycemic_agents , blood glucose concentrations should be carefully monitored and the dose of the <e22> sulfonylurea </e22> should be adjusted as necessary.
effect	Coumarin-type_anticoagulants : Prothrombin time may be increased in patients receiving concomitant <e11> DIFLUCAN </e11> and <e22> coumarin-type_anticoagulants </e22> .
negative	In post-marketing experience, as with other <e12> azole_antifungals </e12> , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e20> fluconazole </e20> concurrently with warfarin .
negative	In post-marketing experience, as with other <e12> azole_antifungals </e12> , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with <e20> warfarin </e20> .
effect	In post-marketing experience, as with other azole_antifungals , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e10> fluconazole </e10> concurrently with <e20> warfarin </e20> .
advise	Careful monitoring of prothrombin time in patients receiving <e11> DIFLUCAN </e11> and <e22> coumarin-type_anticoagulants </e22> is recommended.
mechanism	Phenytoin : <e11> DIFLUCAN </e11> increases the plasma concentrations of <e20> phenytoin </e20> .
negative	Careful monitoring of <e10> phenytoin </e10> concentrations in patients receiving <e21> DIFLUCAN </e21> and phenytoin is recommended.
advise	Careful monitoring of phenytoin concentrations in patients receiving <e11> DIFLUCAN </e11> and <e20> phenytoin </e20> is recommended.
mechanism	Cyclosporine : <e11> DIFLUCAN </e11> may significantly increase <e20> cyclosporine </e20> levels in renal transplant patients with or without renal impairment.
negative	Careful monitoring of <e10> cyclosporine </e10> concentrations and serum creatinine is recommended in patients receiving <e21> DIFLUCAN </e21> and cyclosporine .
advise	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving <e11> DIFLUCAN </e11> and <e20> cyclosporine </e20> .
mechanism	Rifampin : <e10> Rifampin </e10> enhances the metabolism of concurrently administered <e21> DIFLUCAN </e21> .
advise	Depending on clinical circumstances, consideration should be given to increasing the dose of <e11> DIFLUCAN </e11> when it is administered with <e20> rifampin </e20> .
mechanism	Theophylline : <e11> DIFLUCAN </e11> increases the serum concentrations of <e20> theophylline </e20> .
negative	Careful monitoring of serum <e10> theophylline </e10> concentrations in patients receiving <e21> DIFLUCAN </e21> and theophylline is recommended.
advise	Careful monitoring of serum theophylline concentrations in patients receiving <e11> DIFLUCAN </e11> and <e20> theophylline </e20> is recommended.
effect	Terfenadine : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e12> azole_antifungals </e12> in conjunction with <e20> terfenadine </e20> , interaction studies have been performed.
negative	Another study at a 400-mg and 800-mg daily dose of <e10> fluconazole </e10> demonstrated that <e21> DIFLUCAN </e21> taken in doses of # mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.
negative	Another study at a 400-mg and 800-mg daily dose of <e10> fluconazole </e10> demonstrated that DIFLUCAN taken in doses of # mg per day or greater significantly increases plasma levels of <e20> terfenadine </e20> when taken concomitantly.
mechanism	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that <e11> DIFLUCAN </e11> taken in doses of # mg per day or greater significantly increases plasma levels of <e20> terfenadine </e20> when taken concomitantly.
advise	The combined use of <e10> fluconazole </e10> at doses of # mg or greater with <e20> terfenadine </e20> is contraindicated.
advise	The coadministration of <e10> fluconazole </e10> at doses lower than # mg/day with <e20> terfenadine </e20> should be carefully monitored.
effect	Cisapride : There have been reports of cardiac events, including torsade de pointes in patients to whom <e10> fluconazole </e10> and <e20> cisapride </e20> were coadministered.
mechanism	A controlled study found that concomitant <e10> fluconazole </e10> # mg once daily and <e20> cisapride </e20> # mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
negative	A controlled study found that concomitant <e10> fluconazole </e10> # mg once daily and cisapride # mg four times a day yielded a significant increase in <e20> cisapride </e20> plasma levels and prolongation of QTc interval.
advise	The combined use of <e10> fluconazole </e10> with <e20> cisapride </e20> is contraindicated.
mechanism	Astemizole : The use of <e10> fluconazole </e10> in patients concurrently taking <e20> astemizole </e20> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
effect	Rifabutin : There have been reports of uveitis in patients to whom <e10> fluconazole </e10> and <e20> rifabutin </e20> were coadministered.
advise	Patients receiving <e10> rifabutin </e10> and <e20> fluconazole </e20> concomitantly should be carefully monitored.
effect	Tacrolimus : There have been reports of nephrotoxicity in patients to whom <e10> fluconazole </e10> and <e20> tacrolimus </e20> were coadministered.
advise	Patients receiving <e10> tacrolimus </e10> and <e20> fluconazole </e20> concomitantly should be carefully monitored.
mechanism	Short-acting_Benzodiazepines : Following oral administration of <e10> midazolam </e10> , <e20> fluconazole </e20> resulted in substantial increases in midazolam concentrations and psychomotor effects.
negative	Short-acting_Benzodiazepines : Following oral administration of midazolam , <e10> fluconazole </e10> resulted in substantial increases in <e20> midazolam </e20> concentrations and psychomotor effects.
effect	This effect on <e10> midazolam </e10> appears to be more pronounced following oral administration of <e20> fluconazole </e20> than with fluconazole administered intravenously.
negative	This effect on <e10> midazolam </e10> appears to be more pronounced following oral administration of fluconazole than with <e20> fluconazole </e20> administered intravenously.
advise	If <e12> short-acting_benzodiazepines </e12> , which are metabolized by the cytochrome P450 system, are concomitantly administered with <e20> fluconazole </e20> , consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
negative	If short-acting_benzodiazepines , which are metabolized by the cytochrome P450 system, are concomitantly administered with <e10> fluconazole </e10> , consideration should be given to decreasing the <e22> benzodiazepine </e22> dosage, and the patients should be appropriately monitored.
mechanism	<e10> Fluconazole </e10> tablets coadministered with <e20> ethinyl_estradiol </e20> - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
mechanism	<e10> Fluconazole </e10> tablets coadministered with ethinyl_estradiol - and <e20> levonorgestrel </e20> -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
negative	<e10> Fluconazole </e10> tablets coadministered with ethinyl_estradiol - and levonorgestrel -containing oral <e22> contraceptives </e22> produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
negative	<e10> Fluconazole </e10> tablets coadministered with ethinyl_estradiol - and levonorgestrel -containing oral contraceptives produced an overall mean increase in <e20> ethinyl_estradiol </e20> and levonorgestrel levels;
negative	<e10> Fluconazole </e10> tablets coadministered with ethinyl_estradiol - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and <e20> levonorgestrel </e20> levels;
negative	Fluconazole tablets coadministered with <e10> ethinyl_estradiol </e10> - and <e20> levonorgestrel </e20> -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
negative	Fluconazole tablets coadministered with <e10> ethinyl_estradiol </e10> - and levonorgestrel -containing oral <e22> contraceptives </e22> produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
negative	Fluconazole tablets coadministered with <e10> ethinyl_estradiol </e10> - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and <e20> levonorgestrel </e20> levels;
negative	Fluconazole tablets coadministered with ethinyl_estradiol - and <e10> levonorgestrel </e10> -containing oral <e22> contraceptives </e22> produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
negative	Fluconazole tablets coadministered with ethinyl_estradiol - and <e10> levonorgestrel </e10> -containing oral contraceptives produced an overall mean increase in <e20> ethinyl_estradiol </e20> and levonorgestrel levels;
negative	Fluconazole tablets coadministered with ethinyl_estradiol - and levonorgestrel -containing oral <e12> contraceptives </e12> produced an overall mean increase in <e20> ethinyl_estradiol </e20> and levonorgestrel levels;
negative	Fluconazole tablets coadministered with ethinyl_estradiol - and levonorgestrel -containing oral <e12> contraceptives </e12> produced an overall mean increase in ethinyl_estradiol and <e20> levonorgestrel </e20> levels;
negative	Fluconazole tablets coadministered with ethinyl_estradiol - and levonorgestrel -containing oral contraceptives produced an overall mean increase in <e10> ethinyl_estradiol </e10> and <e20> levonorgestrel </e20> levels;
negative	however, in some patients there were decreases up to 47% and 33% of <e10> ethinyl_estradiol </e10> and <e20> levonorgestrel </e20> levels.
negative	The data presently available indicate that the decreases in some individual <e10> ethinyl_estradiol </e10> and <e20> levonorgestrel </e20> AUC values with fluconazole treatment are likely the result of random variation.
negative	The data presently available indicate that the decreases in some individual <e10> ethinyl_estradiol </e10> and levonorgestrel AUC values with <e20> fluconazole </e20> treatment are likely the result of random variation.
negative	The data presently available indicate that the decreases in some individual ethinyl_estradiol and <e10> levonorgestrel </e10> AUC values with <e20> fluconazole </e20> treatment are likely the result of random variation.
mechanism	While there is evidence that <e10> fluconazole </e10> can inhibit the metabolism of <e20> ethinyl_estradiol </e20> and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
mechanism	While there is evidence that <e10> fluconazole </e10> can inhibit the metabolism of ethinyl_estradiol and <e20> levonorgestrel </e20> , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
negative	While there is evidence that <e10> fluconazole </e10> can inhibit the metabolism of ethinyl_estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of <e20> ethinyl_estradiol </e20> or levonorgestrel metabolism.
negative	While there is evidence that <e10> fluconazole </e10> can inhibit the metabolism of ethinyl_estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or <e20> levonorgestrel </e20> metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of <e10> ethinyl_estradiol </e10> and <e20> levonorgestrel </e20> , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of <e10> ethinyl_estradiol </e10> and levonorgestrel , there is no evidence that <e20> fluconazole </e20> is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of <e10> ethinyl_estradiol </e10> and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or <e20> levonorgestrel </e20> metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of ethinyl_estradiol and <e10> levonorgestrel </e10> , there is no evidence that <e20> fluconazole </e20> is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of ethinyl_estradiol and <e10> levonorgestrel </e10> , there is no evidence that fluconazole is a net inducer of <e20> ethinyl_estradiol </e20> or levonorgestrel metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of ethinyl_estradiol and levonorgestrel , there is no evidence that <e10> fluconazole </e10> is a net inducer of <e20> ethinyl_estradiol </e20> or levonorgestrel metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of ethinyl_estradiol and levonorgestrel , there is no evidence that <e10> fluconazole </e10> is a net inducer of ethinyl_estradiol or <e20> levonorgestrel </e20> metabolism.
negative	While there is evidence that fluconazole can inhibit the metabolism of ethinyl_estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of <e10> ethinyl_estradiol </e10> or <e20> levonorgestrel </e20> metabolism.
advise	You cannot take <e10> mazindol </e10> if you have taken a <e22> monoamine_oxidase_inhibitor </e22> ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( <e22> MAOI </e22> ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as <e20> isocarboxazid </e20> ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( <e21> Marplan </e21> ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), <e20> tranylcypromine </e20> ( Parnate ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( <e21> Parnate </e21> ), or phenelzine ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or <e20> phenelzine </e20> ( Nardil ) in the last # days.
advise	You cannot take <e10> mazindol </e10> if you have taken a monoamine_oxidase_inhibitor ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( <e21> Nardil </e21> ) in the last # days.
negative	You cannot take mazindol if you have taken a <e12> monoamine_oxidase_inhibitor </e12> ( MAOI ) such as <e20> isocarboxazid </e20> ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a <e12> monoamine_oxidase_inhibitor </e12> ( MAOI ) such as isocarboxazid ( <e21> Marplan </e21> ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a <e12> monoamine_oxidase_inhibitor </e12> ( MAOI ) such as isocarboxazid ( Marplan ), <e20> tranylcypromine </e20> ( Parnate ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a <e12> monoamine_oxidase_inhibitor </e12> ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( <e21> Parnate </e21> ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a <e12> monoamine_oxidase_inhibitor </e12> ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or <e20> phenelzine </e20> ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a <e12> monoamine_oxidase_inhibitor </e12> ( MAOI ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( <e21> Nardil </e21> ) in the last # days.
negative	You cannot take mazindol if you have taken a monoamine_oxidase_inhibitor ( <e12> MAOI </e12> ) such as <e20> isocarboxazid </e20> ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a monoamine_oxidase_inhibitor ( <e12> MAOI </e12> ) such as isocarboxazid ( <e21> Marplan </e21> ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a monoamine_oxidase_inhibitor ( <e12> MAOI </e12> ) such as isocarboxazid ( Marplan ), <e20> tranylcypromine </e20> ( Parnate ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a monoamine_oxidase_inhibitor ( <e12> MAOI </e12> ) such as isocarboxazid ( Marplan ), tranylcypromine ( <e21> Parnate </e21> ), or phenelzine ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a monoamine_oxidase_inhibitor ( <e12> MAOI </e12> ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or <e20> phenelzine </e20> ( Nardil ) in the last # days.
negative	You cannot take mazindol if you have taken a monoamine_oxidase_inhibitor ( <e12> MAOI </e12> ) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( <e21> Nardil </e21> ) in the last # days.
advise	Changes in <e10> insulin </e10> and other diabetes drug therapies may be necessary during treatment with <e20> mazindol </e20> .
effect	<e10> Mazindol </e10> may reduce the effects of <e20> guanethidine </e20> ( Ismelin ).
effect	<e10> Mazindol </e10> may reduce the effects of guanethidine ( <e21> Ismelin </e21> ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as <e20> amitriptyline </e20> ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( <e21> Elavil </e21> ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), <e20> amoxapine </e20> ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( <e21> Asendin </e21> ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), <e20> doxepin </e20> ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( <e21> Sinequan </e21> ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), <e20> nortriptyline </e20> ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( <e21> Pamelor </e21> ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), <e20> imipramine </e20> ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( <e21> Tofranil </e21> ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), <e20> clomipramine </e20> ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( <e21> Anafranil </e21> ), protriptyline ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), <e20> protriptyline </e20> ( Vivactil ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( <e21> Vivactil </e21> ), or desipramine ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or <e20> desipramine </e20> ( Norpramin ).
negative	Before taking this medication, tell your doctor if you are taking a <e12> tricyclic_antidepressant </e12> such as amitriptyline ( Elavil ), amoxapine ( Asendin ), doxepin ( Sinequan ), nortriptyline ( Pamelor ), imipramine ( Tofranil ), clomipramine ( Anafranil ), protriptyline ( Vivactil ), or desipramine ( <e21> Norpramin </e21> ).
mechanism	Preliminary evidence suggests that <e10> cimetidine </e10> inhibits <e20> mebendazole </e20> metabolism and may result in an increase in plasma concentrations of mebendazole .
negative	Preliminary evidence suggests that <e10> cimetidine </e10> inhibits mebendazole metabolism and may result in an increase in plasma concentrations of <e20> mebendazole </e20> .
negative	Patients receiving <e12> antibiotics </e12> and <e22> sulfonamides </e22> generally should not be treated with ganglion_blockers .
advise	Patients receiving <e12> antibiotics </e12> and sulfonamides generally should not be treated with <e22> ganglion_blockers </e22> .
advise	Patients receiving antibiotics and <e12> sulfonamides </e12> generally should not be treated with <e22> ganglion_blockers </e22> .
effect	The action of <e10> Mecamylamine </e10> may be potentiated by anesthesia, other <e22> antihypertensive_drugs </e22> and alcohol .
effect	The action of <e10> Mecamylamine </e10> may be potentiated by anesthesia, other antihypertensive_drugs and <e20> alcohol </e20> .
mechanism	<e10> Aminoglutethimide </e10> administered concomitantly with <e21> depo-subQ_provera_104 </e21> may significantly decrease the serum concentrations of MPA .
negative	<e10> Aminoglutethimide </e10> administered concomitantly with depo-subQ_provera_104 may significantly decrease the serum concentrations of <e23> MPA </e23> .
negative	Aminoglutethimide administered concomitantly with <e11> depo-subQ_provera_104 </e11> may significantly decrease the serum concentrations of <e23> MPA </e23> .
negative	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e10> zidovudine </e10> or <e20> rifabutin </e20> to warrant dosage adjustment when megestrol_acetate is administered with these drugs.
negative	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e10> zidovudine </e10> or rifabutin to warrant dosage adjustment when <e20> megestrol_acetate </e20> is administered with these drugs.
negative	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or <e10> rifabutin </e10> to warrant dosage adjustment when <e20> megestrol_acetate </e20> is administered with these drugs.
mechanism	A pharmacokinetic study demonstrated that coadministration of <e10> megestrol_acetate </e10> and <e20> indinavir </e20> results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir .
negative	A pharmacokinetic study demonstrated that coadministration of <e10> megestrol_acetate </e10> and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of <e20> indinavir </e20> .
advise	Administration of a higher dose of <e10> indinavir </e10> should be considered when coadministering with <e20> megestrol_acetate </e20> .
negative	The effects of <e10> indinavir </e10> , zidovudine or rifabutin on the pharmacokinetics of <e20> megestrol_acetate </e20> were not studied.
negative	The effects of indinavir , <e10> zidovudine </e10> or rifabutin on the pharmacokinetics of <e20> megestrol_acetate </e20> were not studied.
negative	The effects of indinavir , zidovudine or <e10> rifabutin </e10> on the pharmacokinetics of <e20> megestrol_acetate </e20> were not studied.
int	<e10> Melatonin </e10> may interact with the following drugs: <e21> aspirin </e21> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other <e22> NSAIDs </e22> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e20> fluvoxamine </e20> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e22> beta_blockers </e22> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e20> fluoxetine </e20> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e22> progestin </e22> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
int	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	<e10> Melatonin </e10> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other <e22> NSAIDs </e22> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower <e20> melatonin </e20> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), <e20> fluvoxamine </e20> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e20> melatonin </e20> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e20> melatonin </e20> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e20> fluoxetine </e20> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e22> progestin </e22> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e20> melatonin </e20> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: <e11> aspirin </e11> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower <e20> melatonin </e20> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), <e20> fluvoxamine </e20> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral <e20> melatonin </e20> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e20> melatonin </e20> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e20> fluoxetine </e20> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e22> progestin </e22> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e20> melatonin </e20> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other <e12> NSAIDs </e12> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), <e20> fluvoxamine </e20> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e22> beta_blockers </e22> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e20> fluoxetine </e20> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e22> progestin </e22> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e10> melatonin </e10> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral <e20> melatonin </e20> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e20> melatonin </e20> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e20> melatonin </e20> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e10> fluvoxamine </e10> (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), <e22> beta_blockers </e22> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), <e20> fluoxetine </e20> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e22> progestin </e22> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e10> melatonin </e10> is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease <e20> melatonin </e20> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e20> melatonin </e20> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e12> beta_blockers </e12> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), <e20> fluoxetine </e20> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), fluoxetine (reports of psychotic episodes when coadministered), <e22> progestin </e22> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease <e10> melatonin </e10> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e10> fluoxetine </e10> (reports of psychotic episodes when coadministered), progestin (coadministration of <e20> melatonin </e20> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e10> fluoxetine </e10> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e10> fluoxetine </e10> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e10> fluoxetine </e10> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e10> fluoxetine </e10> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), <e10> fluoxetine </e10> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e12> progestin </e12> (coadministration of <e20> melatonin </e20> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e12> progestin </e12> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e12> progestin </e12> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e12> progestin </e12> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e12> progestin </e12> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
effect	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e10> melatonin </e10> with <e22> progestin </e22> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e10> melatonin </e10> with progestin can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e10> melatonin </e10> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e10> melatonin </e10> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e10> melatonin </e10> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e12> progestin </e12> can inhibit ovarian function in women), <e22> benzodiazepenes </e22> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e12> progestin </e12> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e12> progestin </e12> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e12> progestin </e12> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e12> progestin </e12> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e12> benzodiazepenes </e12> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e22> corticosteroids </e22> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e12> benzodiazepenes </e12> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e12> benzodiazepenes </e12> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e12> benzodiazepenes </e12> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e12> corticosteroids </e12> (coadministration of <e20> melatonin </e20> and corticosteroids may interfere with the efficacy of the corticosteroids ).
effect	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e10> melatonin </e10> and <e22> corticosteroids </e22> may interfere with the efficacy of the corticosteroids ).
negative	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta_blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e10> melatonin </e10> and corticosteroids may interfere with the efficacy of the <e22> corticosteroids </e22> ).
negative	<e12> ACE_inhibitors </e12> Reports suggest that <e22> NSAIDs </e22> may diminish the antihypertensive effect of angiotensin-converting_enzyme_(ACE)_inhibitors .
negative	<e12> ACE_inhibitors </e12> Reports suggest that NSAIDs may diminish the antihypertensive effect of <e22> angiotensin-converting_enzyme_(ACE)_inhibitors </e22> .
effect	ACE_inhibitors Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> angiotensin-converting_enzyme_(ACE)_inhibitors </e22> .
advise	This interaction should be given consideration in patients taking <e12> NSAIDs </e12> concomitantly with <e22> ACE_inhibitors </e22> .
negative	<e11> Aspirin </e11> : Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e20> meloxicam </e20> .
mechanism	Aspirin : Concomitant administration of <e11> aspirin </e11> (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e20> meloxicam </e20> .
negative	however, as with other <e12> NSAIDs </e12> , concomitant administration of <e20> meloxicam </e20> and aspirin is not generally recommended because of the potential for increased adverse effects.
advise	however, as with other <e12> NSAIDs </e12> , concomitant administration of meloxicam and <e21> aspirin </e21> is not generally recommended because of the potential for increased adverse effects.
advise	however, as with other NSAIDs , concomitant administration of <e10> meloxicam </e10> and <e21> aspirin </e21> is not generally recommended because of the potential for increased adverse effects.
effect	Concomitant administration of low-dose <e11> aspirin </e11> with <e21> MOBIC </e21> may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.
negative	Concomitant administration of low-dose <e11> aspirin </e11> with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of <e21> MOBIC </e21> alone.
negative	<e11> MOBIC </e11> is not a substitute for <e21> aspirin </e21> for cardiovascular prophylaxis.
mechanism	Cholestyramine : Pretreatment for four days with <e10> cholestyramine </e10> significantly increased the clearance of <e20> meloxicam </e20> by 50%.
negative	<e10> Cimetidine </e10> : Concomitant administration of # mg cimetidine QID did not alter the single-dose pharmacokinetics of # mg <e20> meloxicam </e20> .
negative	Cimetidine : Concomitant administration of # mg <e10> cimetidine </e10> QID did not alter the single-dose pharmacokinetics of # mg <e20> meloxicam </e20> .
negative	Digoxin : <e10> Meloxicam </e10> # mg once daily for # days did not alter the plasma concentration profile of <e20> digoxin </e20> after b-acetyldigoxin administration for # days at clinical doses.
negative	In vitro testing found no protein binding drug interaction between <e10> digoxin </e10> and <e20> meloxicam </e20> .
negative	<e10> Furosemide </e10> : Clinical studies, as well as post-marketing observations, have shown that <e22> NSAIDs </e22> can reduce the natriuretic effect of furosemide and thiazide_diuretics in some patients.
negative	<e10> Furosemide </e10> : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and <e22> thiazide_diuretics </e22> in some patients.
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazide_diuretics in some patients.
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of furosemide and <e22> thiazide_diuretics </e22> in some patients.
negative	Furosemide : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of <e10> furosemide </e10> and <e22> thiazide_diuretics </e22> in some patients.
negative	Studies with <e10> furosemide </e10> agents and <e20> meloxicam </e20> have not demonstrated a reduction in natriuretic effect.
negative	<e10> Furosemide </e10> : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of <e20> meloxicam </e20> .
advise	Nevertheless, during concomitant therapy with <e10> furosemide </e10> and <e21> MOBIC </e21> , patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
negative	<e10> Lithium </e10> : In clinical trials, <e22> NSAIDs </e22> have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
mechanism	Lithium : In clinical trials, <e12> NSAIDs </e12> have produced an elevation of plasma <e20> lithium </e20> levels and a reduction in renal lithium clearance.
negative	Lithium : In clinical trials, <e12> NSAIDs </e12> have produced an elevation of plasma lithium levels and a reduction in renal <e20> lithium </e20> clearance.
negative	In a study conducted in healthy subjects, mean pre-dose <e10> lithium </e10> concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from # to # mg BID with <e20> meloxicam </e20> # mg QD as compared to subjects receiving lithium alone.
mechanism	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving <e10> lithium </e10> doses ranging from # to # mg BID with <e20> meloxicam </e20> # mg QD as compared to subjects receiving lithium alone.
negative	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from # to # mg BID with <e10> meloxicam </e10> # mg QD as compared to subjects receiving <e20> lithium </e20> alone.
advise	Patients on <e10> lithium </e10> treatment should be closely monitored when <e21> MOBIC </e21> is introduced or withdrawn.
negative	Methotrexate : A study in # rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e10> meloxicam </e10> on the pharmacokinetics of <e20> methotrexate </e20> taken once weekly.
negative	<e10> Meloxicam </e10> did not have a significant effect on the pharmacokinetics of single doses of <e20> methotrexate </e20> .
negative	In vitro, <e10> methotrexate </e10> did not displace <e20> meloxicam </e20> from its human serum binding sites.
advise	Warfarin : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing <e11> MOBIC </e11> therapy in patients receiving <e20> warfarin </e20> or similar agents, since these patients are at an increased risk of bleeding.
negative	The effect of <e10> meloxicam </e10> on the anticoagulant effect of <e20> warfarin </e20> was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between # and #.
negative	The effect of <e10> meloxicam </e10> on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of <e20> warfarin </e20> that produced an INR (International Normalized Ratio) between # and #.
negative	In these subjects, <e10> meloxicam </e10> did not alter <e20> warfarin </e20> pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.
negative	In these subjects, <e10> meloxicam </e10> did not alter warfarin pharmacokinetics and the average anticoagulant effect of <e20> warfarin </e20> as determined by prothrombin time.
advise	Caution should be used when administering <e11> MOBIC </e11> with <e20> warfarin </e20> since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
negative	Caution should be used when administering <e11> MOBIC </e11> with warfarin since patients on <e20> warfarin </e20> may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
negative	DRUG INTERACTIONS There are no known drug/drug interactions with oral <e11> ALKERAN </e11> Vaccinations with <e22> live_organism_vaccines </e22> are not recommended in immunocompromised individuals Nalidixic_acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
negative	DRUG INTERACTIONS There are no known drug/drug interactions with oral <e11> ALKERAN </e11> Vaccinations with live_organism_vaccines are not recommended in immunocompromised individuals <e20> Nalidixic_acid </e20> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
negative	DRUG INTERACTIONS There are no known drug/drug interactions with oral <e11> ALKERAN </e11> Vaccinations with live_organism_vaccines are not recommended in immunocompromised individuals Nalidixic_acid together with high-dose intravenous <e20> melphalan </e20> has caused deaths in children due to haemorrhagic enterocolitis.
negative	DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with <e12> live_organism_vaccines </e12> are not recommended in immunocompromised individuals <e20> Nalidixic_acid </e20> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
negative	DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with <e12> live_organism_vaccines </e12> are not recommended in immunocompromised individuals Nalidixic_acid together with high-dose intravenous <e20> melphalan </e20> has caused deaths in children due to haemorrhagic enterocolitis.
effect	DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live_organism_vaccines are not recommended in immunocompromised individuals <e10> Nalidixic_acid </e10> together with high-dose intravenous <e20> melphalan </e20> has caused deaths in children due to haemorrhagic enterocolitis.
effect	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous <e10> melphalan </e10> and who subsequently received <e20> cyclosporin </e20> to prevent graft-versus-host disease
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : <e20> amantadine </e20> , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , <e22> antiarrhythmic_agents_of_class_I </e22> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, <e20> quinidine </e20> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), <e22> antihistamines </e22> , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , <e22> antipsychotic_agents </e22> (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, <e22> phenothiazines </e22> ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), <e22> benzodiazepines </e22> , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , <e22> MAO_inhibitors </e22> , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , <e22> narcotic_analgesics </e22> (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, <e20> meperidine </e20> ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), <e22> nitrates </e22> and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and <e22> nitrites </e22> , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , <e22> sympathomimetic_agents </e22> , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	The following agents may increase certain actions or side effects of <e12> anticholinergic_drugs </e12> : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , <e22> tricyclic_antidepressants </e22> , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , <e22> antiarrhythmic_agents_of_class_I </e22> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , antiarrhythmic_agents_of_class_I (e,g,, <e20> quinidine </e20> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , <e22> MAO_inhibitors </e22> , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), <e22> nitrates </e22> and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and <e22> nitrites </e22> , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , <e22> sympathomimetic_agents </e22> , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : <e10> amantadine </e10> , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , <e22> tricyclic_antidepressants </e22> , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , <e12> antiarrhythmic_agents_of_class_I </e12> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , <e22> MAO_inhibitors </e22> , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , <e12> antiarrhythmic_agents_of_class_I </e12> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), <e22> nitrates </e22> and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , <e12> antiarrhythmic_agents_of_class_I </e12> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and <e22> nitrites </e22> , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , <e12> antiarrhythmic_agents_of_class_I </e12> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , <e22> sympathomimetic_agents </e22> , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , <e12> antiarrhythmic_agents_of_class_I </e12> (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , <e22> tricyclic_antidepressants </e22> , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, <e10> quinidine </e10> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , <e22> MAO_inhibitors </e22> , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, <e10> quinidine </e10> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), <e22> nitrates </e22> and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, <e10> quinidine </e10> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and <e22> nitrites </e22> , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, <e10> quinidine </e10> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , <e22> sympathomimetic_agents </e22> , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, <e10> quinidine </e10> ), antihistamines , antipsychotic_agents (e,g,, phenothiazines ), benzodiazepines , MAO_inhibitors , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , <e22> tricyclic_antidepressants </e22> , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , <e12> antipsychotic_agents </e12> (e,g,, phenothiazines ), benzodiazepines , <e22> MAO_inhibitors </e22> , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
negative	The following agents may increase certain actions or side effects of anticholinergic_drugs : amantadine , antiarrhythmic_agents_of_class_I (e,g,, quinidine ), antihistamines , antipsychotic_agents (e,g,, <e12> phenothiazines </e12> ), benzodiazepines , <e22> MAO_inhibitors </e22> , narcotic_analgesics (e,g,, meperidine ), nitrates and nitrites , sympathomimetic_agents , tricyclic_antidepressants , and other drugs having anticholinergic activity.
effect	<e12> Anticholinergics </e12> antagonize the effects of <e22> antiglaucoma_agents </e22> .
effect	<e12> Anticholinergic_drugs </e12> in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as <e22> corticosteroids </e22> .
mechanism	<e12> Anticholinergic_agents </e12> may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of <e20> digoxin </e20> ;
effect	<e12> Anticholinergic_drugs </e12> may antagonize the effects of drugs that alter gastrointestinal motility, such as <e22> metoclopramide </e22> .
mechanism	Because <e10> antacids </e10> may interfere with the absorption of <e22> anticholinergic_agents </e22> , simultaneous use of these drugs should be avoided.
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e22> NARCOTIC_ANALGESICS </e22> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL <e22> ANESTHETICS </e22> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e22> PHENOTHIAZINES </e22> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e22> TRANQUILIZERS </e22> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e22> SEDATIVE-HYPNOTICS </e22> (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e22> BARBITURATES </e22> ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), <e22> TRICYCLIC_ANTIDEPRESSANTS </e22> AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
advise	Interaction with Other Central_Nervous_System_Depressants : <e10> MEPERIDINE </e10> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , <e22> PHENOTHIAZINES </e22> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e22> TRANQUILIZERS </e22> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e22> SEDATIVE-HYPNOTICS </e22> (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e22> BARBITURATES </e22> ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), <e22> TRICYCLIC_ANTIDEPRESSANTS </e22> AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e12> NARCOTIC_ANALGESICS </e12> , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL <e12> ANESTHETICS </e12> , <e22> PHENOTHIAZINES </e22> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL <e12> ANESTHETICS </e12> , PHENOTHIAZINES , OTHER <e22> TRANQUILIZERS </e22> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL <e12> ANESTHETICS </e12> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL <e12> ANESTHETICS </e12> , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e12> PHENOTHIAZINES </e12> , OTHER <e22> TRANQUILIZERS </e22> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e12> PHENOTHIAZINES </e12> , OTHER TRANQUILIZERS , <e22> SEDATIVE-HYPNOTICS </e22> (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e12> PHENOTHIAZINES </e12> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e22> BARBITURATES </e22> ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e12> PHENOTHIAZINES </e12> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), <e22> TRICYCLIC_ANTIDEPRESSANTS </e22> AND OTHER CNS_DEPRESSANTS (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e12> PHENOTHIAZINES </e12> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , <e12> PHENOTHIAZINES </e12> , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e12> TRANQUILIZERS </e12> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER <e12> TRANQUILIZERS </e12> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e12> SEDATIVE-HYPNOTICS </e12> (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , <e12> SEDATIVE-HYPNOTICS </e12> (INCLUDING BARBITURATES ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e12> BARBITURATES </e12> ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING <e12> BARBITURATES </e12> ), TRICYCLIC_ANTIDEPRESSANTS AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), <e12> TRICYCLIC_ANTIDEPRESSANTS </e12> AND OTHER <e22> CNS_DEPRESSANTS </e22> (INCLUDING ALCOHOL ).
negative	Interaction with Other Central_Nervous_System_Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC_ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES ), <e12> TRICYCLIC_ANTIDEPRESSANTS </e12> AND OTHER CNS_DEPRESSANTS (INCLUDING <e20> ALCOHOL </e20> ).
int	Some <e12> anticonvulsants </e12> may interact with <e20> Mephenytoin </e20> .
negative	Those <e12> anticonvulsants </e12> include <e20> divalproex_sodium </e20> , valproic_acid , and phenobarbital .
negative	Those <e12> anticonvulsants </e12> include divalproex_sodium , <e20> valproic_acid </e20> , and phenobarbital .
negative	Those <e12> anticonvulsants </e12> include divalproex_sodium , valproic_acid , and <e20> phenobarbital </e20> .
effect	<e10> Mephenytoin </e10> may also affect the effects of other drugs, which include some <e22> steroid_medications </e22> , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
effect	<e10> Mephenytoin </e10> may also affect the effects of other drugs, which include some steroid_medications , <e20> warfarin </e20> , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
effect	<e10> Mephenytoin </e10> may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, <e22> anti-infective_medicines </e22> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
effect	<e10> Mephenytoin </e10> may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , <e20> furosemide </e20> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
effect	<e10> Mephenytoin </e10> may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and <e20> theophylline </e20> Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some <e12> steroid_medications </e12> , <e20> warfarin </e20> , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some <e12> steroid_medications </e12> , warfarin , certain heart medicines, birth control pills, <e22> anti-infective_medicines </e22> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some <e12> steroid_medications </e12> , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , <e20> furosemide </e20> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some <e12> steroid_medications </e12> , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and <e20> theophylline </e20> Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some <e12> steroid_medications </e12> , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and theophylline Please note that <e20> Mephenytoin </e20> may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , <e10> warfarin </e10> , certain heart medicines, birth control pills, <e22> anti-infective_medicines </e22> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , <e10> warfarin </e10> , certain heart medicines, birth control pills, anti-infective_medicines , <e20> furosemide </e20> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , <e10> warfarin </e10> , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and <e20> theophylline </e20> Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , <e10> warfarin </e10> , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and theophylline Please note that <e20> Mephenytoin </e20> may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, <e12> anti-infective_medicines </e12> , <e20> furosemide </e20> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, <e12> anti-infective_medicines </e12> , furosemide and <e20> theophylline </e20> Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, <e12> anti-infective_medicines </e12> , furosemide and theophylline Please note that <e20> Mephenytoin </e20> may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , <e10> furosemide </e10> and <e20> theophylline </e20> Please note that Mephenytoin may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , <e10> furosemide </e10> and theophylline Please note that <e20> Mephenytoin </e20> may interact with other drugs that are not listed here.
negative	Mephenytoin may also affect the effects of other drugs, which include some steroid_medications , warfarin , certain heart medicines, birth control pills, anti-infective_medicines , furosemide and <e10> theophylline </e10> Please note that <e20> Mephenytoin </e20> may interact with other drugs that are not listed here.
int	<e10> Mequitazine </e10> can interact with <e22> CNS_depressant </e22> , antichlolinergic , TCA , MAOIs , and alcohol .
int	<e10> Mequitazine </e10> can interact with CNS_depressant , <e22> antichlolinergic </e22> , TCA , MAOIs , and alcohol .
int	<e10> Mequitazine </e10> can interact with CNS_depressant , antichlolinergic , <e22> TCA </e22> , MAOIs , and alcohol .
int	<e10> Mequitazine </e10> can interact with CNS_depressant , antichlolinergic , TCA , <e22> MAOIs </e22> , and alcohol .
int	<e10> Mequitazine </e10> can interact with CNS_depressant , antichlolinergic , TCA , MAOIs , and <e20> alcohol </e20> .
mechanism	<e10> Probenecid </e10> competes with <e20> meropenem </e20> for active tubular secretion and thus inhibits the renal excretion of meropenem .
negative	<e10> Probenecid </e10> competes with meropenem for active tubular secretion and thus inhibits the renal excretion of <e20> meropenem </e20> .
advise	Therefore, the coadministration of <e10> probenecid </e10> with <e20> meropenem </e20> is not recommended.
mechanism	There is evidence that <e10> meropenem </e10> may reduce serum levels of <e20> valproic_acid </e20> to subtherapeutic levels (therapeutic range considered to be # to # g/mL total valproate ).
negative	There is evidence that <e10> meropenem </e10> may reduce serum levels of valproic_acid to subtherapeutic levels (therapeutic range considered to be # to # g/mL total <e20> valproate </e20> ).
negative	There is evidence that meropenem may reduce serum levels of <e10> valproic_acid </e10> to subtherapeutic levels (therapeutic range considered to be # to # g/mL total <e20> valproate </e20> ).
negative	<e11> ARAMINE </e11> should be used with caution in digitalized patients, since the combination of <e22> digitalis </e22> and sympathomimetic_amines may cause ectopic arrhythmias.
negative	<e11> ARAMINE </e11> should be used with caution in digitalized patients, since the combination of digitalis and <e22> sympathomimetic_amines </e22> may cause ectopic arrhythmias.
effect	ARAMINE should be used with caution in digitalized patients, since the combination of <e12> digitalis </e12> and <e22> sympathomimetic_amines </e22> may cause ectopic arrhythmias.
negative	<e12> Monoamine_oxidase_inhibitors </e12> or <e22> tricyclic_antidepressants </e22> may potentiate the action of sympathomimetic_amines .
effect	<e12> Monoamine_oxidase_inhibitors </e12> or tricyclic_antidepressants may potentiate the action of <e22> sympathomimetic_amines </e22> .
effect	Monoamine_oxidase_inhibitors or <e12> tricyclic_antidepressants </e12> may potentiate the action of <e22> sympathomimetic_amines </e22> .
effect	<e11> SKELAXIN </e11> may enhance the effects of <e20> alcohol </e20> , barbiturates and other CNS_depressants .
effect	<e11> SKELAXIN </e11> may enhance the effects of alcohol , <e22> barbiturates </e22> and other CNS_depressants .
effect	<e11> SKELAXIN </e11> may enhance the effects of alcohol , barbiturates and other <e22> CNS_depressants </e22> .
advise	Caution is advised for patients receiving high-dose <e11> aspirin </e11> and <e20> methazolamide </e20> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic_anhydrase_inhibitors .
negative	Caution is advised for patients receiving high-dose <e11> aspirin </e11> and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and <e22> carbonic_anhydrase_inhibitors </e22> .
negative	Caution is advised for patients receiving high-dose aspirin and <e10> methazolamide </e10> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e21> aspirin </e21> and carbonic_anhydrase_inhibitors .
negative	Caution is advised for patients receiving high-dose aspirin and <e10> methazolamide </e10> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and <e22> carbonic_anhydrase_inhibitors </e22> .
effect	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e11> aspirin </e11> and <e22> carbonic_anhydrase_inhibitors </e22> .
effect	Anticoagulants (oral): The activity of oral <e12> anticoagulants </e12> may be potentiated by anti-vitamin-K activity attributed to <e20> methimazole </e20> .
effect	Dosages of concomitantly administered <e12> opioids </e12> should be reduced by approximately half, because <e20> levomepromazine </e20> amplifies the therapeutic actions and side-effects of opioids .
effect	Dosages of concomitantly administered opioids should be reduced by approximately half, because <e10> levomepromazine </e10> amplifies the therapeutic actions and side-effects of <e22> opioids </e22> .
effect	Additive sedative effects and confusional states may emerge if <e10> levomepromazine </e10> is given with <e22> benzodiazepines </e22> or barbiturates .
effect	Additive sedative effects and confusional states may emerge if <e10> levomepromazine </e10> is given with benzodiazepines or <e22> barbiturates </e22> .
negative	Additive sedative effects and confusional states may emerge if levomepromazine is given with <e12> benzodiazepines </e12> or <e22> barbiturates </e22> .
advise	Exert particular caution in combining <e10> levomepromazine </e10> with other <e22> anticholinergic_drugs </e22> ( tricyclic_antidepressants and antiparkinsonian-agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
advise	Exert particular caution in combining <e10> levomepromazine </e10> with other anticholinergic_drugs ( <e22> tricyclic_antidepressants </e22> and antiparkinsonian-agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
advise	Exert particular caution in combining <e10> levomepromazine </e10> with other anticholinergic_drugs ( tricyclic_antidepressants and <e22> antiparkinsonian-agents </e22> ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
negative	<e10> Caffeine </e10> and/or stimulantes of the <e20> ephedrine </e20> / amphetamine type may counteract the specific actions of levomepromazine .
negative	<e10> Caffeine </e10> and/or stimulantes of the ephedrine / <e20> amphetamine </e20> type may counteract the specific actions of levomepromazine .
effect	<e10> Caffeine </e10> and/or stimulantes of the ephedrine / amphetamine type may counteract the specific actions of <e20> levomepromazine </e20> .
effect	Caffeine and/or stimulantes of the <e10> ephedrine </e10> / amphetamine type may counteract the specific actions of <e20> levomepromazine </e20> .
effect	Caffeine and/or stimulantes of the ephedrine / <e10> amphetamine </e10> type may counteract the specific actions of <e20> levomepromazine </e20> .
advise	Since <e11> Celontin </e11> ( methsuximide ) may interact with concurrently administered <e22> antiepileptic_drugs </e22> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ).
negative	Since <e11> Celontin </e11> ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg <e20> methsuximide </e20> may increase the plasma concentrations of phenytoin and phenobarbital ).
negative	Since <e11> Celontin </e11> ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e20> phenytoin </e20> and phenobarbital ).
negative	Since <e11> Celontin </e11> ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e20> phenobarbital </e20> ).
advise	Since Celontin ( <e10> methsuximide </e10> ) may interact with concurrently administered <e22> antiepileptic_drugs </e22> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ).
negative	Since Celontin ( <e10> methsuximide </e10> ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e20> phenytoin </e20> and phenobarbital ).
negative	Since Celontin ( <e10> methsuximide </e10> ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e20> phenobarbital </e20> ).
negative	Since Celontin ( methsuximide ) may interact with concurrently administered <e12> antiepileptic_drugs </e12> , periodic serum level determinations of these drugs may be necessary (eg <e20> methsuximide </e20> may increase the plasma concentrations of phenytoin and phenobarbital ).
negative	Since Celontin ( methsuximide ) may interact with concurrently administered <e12> antiepileptic_drugs </e12> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e20> phenytoin </e20> and phenobarbital ).
negative	Since Celontin ( methsuximide ) may interact with concurrently administered <e12> antiepileptic_drugs </e12> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e20> phenobarbital </e20> ).
mechanism	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg <e10> methsuximide </e10> may increase the plasma concentrations of <e20> phenytoin </e20> and phenobarbital ).
mechanism	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg <e10> methsuximide </e10> may increase the plasma concentrations of phenytoin and <e20> phenobarbital </e20> ).
negative	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e10> phenytoin </e10> and <e20> phenobarbital </e20> ).
negative	Hypokalemia may develop during concomitant use of <e12> steroids </e12> or <e20> ACTH </e20> .
effect	<e12> Thiazides </e12> may decrease arterial responsiveness to <e20> norepinephrine </e20> .
effect	<e12> Thiazide_drugs </e12> may increase the responsiveness of <e20> tubocurarine </e20> .
mechanism	<e10> Lithium </e10> renal clearance is reduced by <e22> thiazides </e22> , increasing the risk of lithium toxicity.
negative	Lithium renal clearance is reduced by <e12> thiazides </e12> , increasing the risk of <e20> lithium </e20> toxicity.
effect	<e12> Thiazides </e12> may add to or potentiate the action of other <e22> antihypertensive_drugs </e22> .
negative	Potentiation occurs with <e12> ganglionic_adrenergic_blocking_drugs </e12> or <e22> peripheral_adrenergic_blocking_drugs </e22> .
effect	When <e10> methyldopa </e10> is used with other <e22> antihypertensive_drugs </e22> , potentiation of antihypertensive effect may occur.
advise	Patients may require reduced doses of <e12> anesthetics </e12> when on <e20> methyldopa </e20> .
advise	When <e10> methyldopa </e10> and <e20> lithium </e20> are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
negative	When <e10> methyldopa </e10> and lithium are given concomitantly the patient should be carefully monitored for symptoms of <e20> lithium </e20> toxicity.
mechanism	Several studies demonstrate a decrease in the bioavailability of <e10> methyldopa </e10> when it is ingested with <e20> ferrous_sulfate </e20> or ferrous_gluconate .
mechanism	Several studies demonstrate a decrease in the bioavailability of <e10> methyldopa </e10> when it is ingested with ferrous_sulfate or <e20> ferrous_gluconate </e20> .
negative	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with <e10> ferrous_sulfate </e10> or <e20> ferrous_gluconate </e20> .
advise	Coadministration of <e10> methyldopa </e10> with <e20> ferrous_sulfate </e20> or ferrous_gluconate is not recommended.
advise	Coadministration of <e10> methyldopa </e10> with ferrous_sulfate or <e20> ferrous_gluconate </e20> is not recommended.
negative	Coadministration of methyldopa with <e10> ferrous_sulfate </e10> or <e20> ferrous_gluconate </e20> is not recommended.
negative	<e10> Methyldopa </e10> does not interfere with measurement of <e23> VMA </e23> ( vanillylmandelic_acid ), a test for pheochromocytoma, by those methods which convert VMA to vanillin .
negative	<e10> Methyldopa </e10> does not interfere with measurement of VMA ( <e23> vanillylmandelic_acid </e23> ), a test for pheochromocytoma, by those methods which convert VMA to vanillin .
negative	<e10> Methyldopa </e10> does not interfere with measurement of VMA ( vanillylmandelic_acid ), a test for pheochromocytoma, by those methods which convert <e23> VMA </e23> to vanillin .
negative	<e10> Methyldopa </e10> does not interfere with measurement of VMA ( vanillylmandelic_acid ), a test for pheochromocytoma, by those methods which convert VMA to <e23> vanillin </e23> .
negative	Methyldopa does not interfere with measurement of <e13> VMA </e13> ( vanillylmandelic_acid ), a test for pheochromocytoma, by those methods which convert VMA to <e23> vanillin </e23> .
negative	Methyldopa does not interfere with measurement of VMA ( <e13> vanillylmandelic_acid </e13> ), a test for pheochromocytoma, by those methods which convert <e23> VMA </e23> to vanillin .
negative	Methyldopa does not interfere with measurement of VMA ( <e13> vanillylmandelic_acid </e13> ), a test for pheochromocytoma, by those methods which convert VMA to <e23> vanillin </e23> .
negative	Methyldopa does not interfere with measurement of VMA ( vanillylmandelic_acid ), a test for pheochromocytoma, by those methods which convert <e13> VMA </e13> to <e23> vanillin </e23> .
negative	CYP 3A4 Inhibitors (e,g, <e12> Macrolide_Antibiotics </e12> and Protease_Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain <e22> ergot_alkaloid_drugs </e22> (e,g, dihydroergotamine and ergotamine ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
negative	CYP 3A4 Inhibitors (e,g, <e12> Macrolide_Antibiotics </e12> and Protease_Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot_alkaloid_drugs (e,g, <e20> dihydroergotamine </e20> and ergotamine ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
negative	CYP 3A4 Inhibitors (e,g, <e12> Macrolide_Antibiotics </e12> and Protease_Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot_alkaloid_drugs (e,g, dihydroergotamine and <e20> ergotamine </e20> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
negative	CYP 3A4 Inhibitors (e,g, Macrolide_Antibiotics and <e12> Protease_Inhibitors </e12> ) There have been rare reports of serious adverse events in connection with the coadministration of certain <e22> ergot_alkaloid_drugs </e22> (e,g, dihydroergotamine and ergotamine ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
negative	CYP 3A4 Inhibitors (e,g, Macrolide_Antibiotics and <e12> Protease_Inhibitors </e12> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot_alkaloid_drugs (e,g, <e20> dihydroergotamine </e20> and ergotamine ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
negative	CYP 3A4 Inhibitors (e,g, Macrolide_Antibiotics and <e12> Protease_Inhibitors </e12> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot_alkaloid_drugs (e,g, dihydroergotamine and <e20> ergotamine </e20> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
negative	Examples of some of the more potent CYP 3A4 inhibitors include macrolide_antibiotics (e,g,, erythromycin , troleandomycin , clarithromycin ), <e12> HIV_protease_inhibitors </e12> or <e22> reverse_transcriptase_inhibitors </e22> (e,g,, ritonavir , indinavir , nelfinavir , delavirdine ) or azole_antifungals (e,g,, ketoconazole , itraconazole , voriconazole ).
negative	Examples of some of the more potent CYP 3A4 inhibitors include macrolide_antibiotics (e,g,, erythromycin , troleandomycin , clarithromycin ), <e12> HIV_protease_inhibitors </e12> or reverse_transcriptase_inhibitors (e,g,, ritonavir , indinavir , nelfinavir , delavirdine ) or <e22> azole_antifungals </e22> (e,g,, ketoconazole , itraconazole , voriconazole ).
negative	Examples of some of the more potent CYP 3A4 inhibitors include macrolide_antibiotics (e,g,, erythromycin , troleandomycin , clarithromycin ), <e12> HIV_protease_inhibitors </e12> or reverse_transcriptase_inhibitors (e,g,, ritonavir , indinavir , nelfinavir , delavirdine ) or azole_antifungals (e,g,, <e20> ketoconazole </e20> , itraconazole , voriconazole ).
negative	Examples of some of the more potent CYP 3A4 inhibitors include macrolide_antibiotics (e,g,, erythromycin , troleandomycin , clarithromycin ), <e12> HIV_protease_inhibitors </e12> or reverse_transcriptase_inhibitors (e,g,, ritonavir , indinavir , nelfinavir , delavirdine ) or azole_antifungals (e,g,, ketoconazole , <e20> itraconazole </e20> , voriconazole ).
negative	Examples of some of the more potent CYP 3A4 inhibitors include macrolide_antibiotics (e,g,, erythromycin , troleandomycin , clarithromycin ), <e12> HIV_protease_inhibitors </e12> or reverse_transcriptase_inhibitors (e,g,, ritonavir , indinavir , nelfinavir , delavirdine ) or azole_antifungals (e,g,, ketoconazole , itraconazole , <e20> voriconazole </e20> ).
advise	Caution should be exercised when <e11> Methergine </e11> ( methylergonovine_maleate ) is used concurrently with other <e22> vasoconstrictors </e22> or ergot_alkaloids .
advise	Caution should be exercised when <e11> Methergine </e11> ( methylergonovine_maleate ) is used concurrently with other vasoconstrictors or <e22> ergot_alkaloids </e22> .
advise	Caution should be exercised when Methergine ( <e10> methylergonovine_maleate </e10> ) is used concurrently with other <e22> vasoconstrictors </e22> or ergot_alkaloids .
negative	Caution should be exercised when Methergine ( <e10> methylergonovine_maleate </e10> ) is used concurrently with other vasoconstrictors or <e22> ergot_alkaloids </e22> .
negative	Caution should be exercised when Methergine ( methylergonovine_maleate ) is used concurrently with other <e12> vasoconstrictors </e12> or <e22> ergot_alkaloids </e22> .
effect	<e11> Ritalin </e11> may decrease the hypotensive effect of <e20> guanethidine </e20> .
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of <e22> coumarin_anticoagulants </e22> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , <e22> anticonvulsants </e22> ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( <e20> phenobarbital </e20> , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , <e20> diphenylhydantoin </e20> , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e20> primidone </e20> ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), <e20> phenylbutazone </e20> , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and <e22> tricyclic_drugs </e22> ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( <e20> imipramine </e20> , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , <e20> clomipramine </e20> , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , <e20> desipramine </e20> ).
negative	The safety of using <e10> methylphenidate </e10> in combination with <e20> clonidine </e20> or other centrally acting alpha-2_agonists has not been systemically evaluated.
negative	The safety of using <e10> methylphenidate </e10> in combination with clonidine or other centrally acting <e22> alpha-2_agonists </e22> has not been systemically evaluated.
negative	The safety of using methylphenidate in combination with <e10> clonidine </e10> or other centrally acting <e22> alpha-2_agonists </e22> has not been systemically evaluated.
mechanism	Mutual inhibition of metabolism occurs with concurrent use of <e10> cyclosporin </e10> and <e20> methylprednisolone </e20> ;
effect	convulsions have been reported with concurrent use of <e10> methylprednisolone </e10> and <e20> cyclosporin </e20> .
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin , and rifampin may increase the clearance of <e20> methylprednisolone </e20> and may require increased in methylprednisolone dose to achieve the desired response.
advise	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in <e20> methylprednisolone </e20> dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> , and rifampin may increase the clearance of <e20> methylprednisolone </e20> and may require increased in methylprednisolone dose to achieve the desired response.
advise	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> , and rifampin may increase the clearance of methylprednisolone and may require increased in <e20> methylprednisolone </e20> dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and <e10> rifampin </e10> may increase the clearance of <e20> methylprednisolone </e20> and may require increased in methylprednisolone dose to achieve the desired response.
advise	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and <e10> rifampin </e10> may increase the clearance of methylprednisolone and may require increased in <e20> methylprednisolone </e20> dose to achieve the desired response.
negative	Drugs such as <e10> troleandomycin </e10> and <e20> ketoconazole </e20> may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
mechanism	Drugs such as <e10> troleandomycin </e10> and ketoconazole may inhibit the metabolism of <e20> methylprednisolone </e20> and thus decrease its clearance.
mechanism	Drugs such as troleandomycin and <e10> ketoconazole </e10> may inhibit the metabolism of <e20> methylprednisolone </e20> and thus decrease its clearance.
mechanism	<e10> Methylprednisolone </e10> may increase the clearance of chronic high dose <e21> aspirin </e21> .
negative	This could lead to decreased <e12> salicylate </e12> serum levels or increase the risk of salicylate toxicity when <e20> methylprednisolone </e20> is withdrawn.
effect	This could lead to decreased salicylate serum levels or increase the risk of <e12> salicylate </e12> toxicity when <e20> methylprednisolone </e20> is withdrawn.
advise	<e11> Aspirin </e11> should be used cautiously in conjunction with <e22> corticosteroids </e22> in patients suffering from hypoprothrombinemia.
negative	The effect of <e10> methylprednisolone </e10> on oral <e22> anticoagulants </e22> is variable.
effect	There are reports of enhanced as well as diminished effects of <e12> anticoagulant </e12> when given concurrently with <e22> corticosteroids </e22> .
negative	<e10> Methscopolamine </e10> may interact with <e22> antidepressants </e22> ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( <e22> tricyclic </e22> type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), <e22> MAO_inhibitors </e22> (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, <e20> phenelzine </e20> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , <e20> linezolid </e20> , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , <e20> tranylcypromine </e20> , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , <e20> isocarboxazid </e20> , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , <e20> selegiline </e20> , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e20> furazolidone </e20> ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), <e20> quinidine </e20> , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , <e20> amantadine </e20> , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , <e22> antihistamines </e22> (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, <e20> diphenhydramine </e20> ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other <e22> anticholinergics </e22> , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , <e20> potassium_chloride </e20> supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, <e20> antacids </e20> , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , <e22> absorbent-type_anti-diarrhea_medicines </e22> (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, <e20> kaolin </e20> - pectin ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - <e20> pectin </e20> ), phenothiazines (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
int	<e10> Methscopolamine </e10> may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with <e12> antidepressants </e12> ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with <e12> antidepressants </e12> ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with <e12> antidepressants </e12> ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( <e12> tricyclic </e12> type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( <e12> tricyclic </e12> type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( <e12> tricyclic </e12> type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), <e12> MAO_inhibitors </e12> (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), <e12> MAO_inhibitors </e12> (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), <e12> MAO_inhibitors </e12> (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, <e10> phenelzine </e10> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, <e10> phenelzine </e10> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, <e10> phenelzine </e10> , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , <e10> linezolid </e10> , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , <e10> linezolid </e10> , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , <e10> linezolid </e10> , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , <e10> tranylcypromine </e10> , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , <e10> tranylcypromine </e10> , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , <e10> tranylcypromine </e10> , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , <e10> isocarboxazid </e10> , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , <e10> isocarboxazid </e10> , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , <e10> isocarboxazid </e10> , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , <e10> selegiline </e10> , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , <e10> selegiline </e10> , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , <e10> selegiline </e10> , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e10> furazolidone </e10> ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e10> furazolidone </e10> ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , <e10> furazolidone </e10> ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), <e10> quinidine </e10> , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), <e10> quinidine </e10> , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), <e10> quinidine </e10> , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , <e10> amantadine </e10> , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , <e10> amantadine </e10> , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , <e10> amantadine </e10> , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , <e12> antihistamines </e12> (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , <e12> antihistamines </e12> (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , <e12> antihistamines </e12> (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, <e10> diphenhydramine </e10> ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, <e10> diphenhydramine </e10> ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, <e10> diphenhydramine </e10> ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other <e12> anticholinergics </e12> , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other <e12> anticholinergics </e12> , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other <e12> anticholinergics </e12> , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , <e10> potassium_chloride </e10> supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , <e10> potassium_chloride </e10> supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , <e10> potassium_chloride </e10> supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, <e10> antacids </e10> , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, <e10> antacids </e10> , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, <e10> antacids </e10> , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , <e12> absorbent-type_anti-diarrhea_medicines </e12> (e,g,, kaolin - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , <e12> absorbent-type_anti-diarrhea_medicines </e12> (e,g,, kaolin - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , <e12> absorbent-type_anti-diarrhea_medicines </e12> (e,g,, kaolin - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, <e10> kaolin </e10> - pectin ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, <e10> kaolin </e10> - pectin ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, <e10> kaolin </e10> - pectin ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - <e10> pectin </e10> ), <e22> phenothiazines </e22> (e,g,, chlorpromazine , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - <e10> pectin </e10> ), phenothiazines (e,g,, <e20> chlorpromazine </e20> , promethazine ).
negative	Methscopolamine may interact with antidepressants ( tricyclic type), MAO_inhibitors (e,g,, phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ), quinidine , amantadine , antihistamines (e,g,, diphenhydramine ), other anticholinergics , potassium_chloride supplements, antacids , absorbent-type_anti-diarrhea_medicines (e,g,, kaolin - <e10> pectin </e10> ), phenothiazines (e,g,, chlorpromazine , <e20> promethazine </e20> ).
negative	Concurrent use of <e10> alcohol </e10> and other <e22> CNS_depression-producing_drugs </e22> may increase the CNS depressant effects of methyprylon or these other medications.
effect	Concurrent use of <e10> alcohol </e10> and other CNS_depression-producing_drugs may increase the CNS depressant effects of <e20> methyprylon </e20> or these other medications.
effect	Concurrent use of alcohol and other <e12> CNS_depression-producing_drugs </e12> may increase the CNS depressant effects of <e20> methyprylon </e20> or these other medications.
effect	<e10> Methysergide </e10> may reverse the analgesic activity of <e22> narcotic_analgesics </e22> .
negative	Concurrent use with <e12> vasoconstrictor_agents </e12> including <e22> ergot_alkaloids </e22> , sumatriptan , and nicotine (e,g, smoking) may result in enhanced vasoconstriction.
negative	Concurrent use with <e12> vasoconstrictor_agents </e12> including ergot_alkaloids , <e20> sumatriptan </e20> , and nicotine (e,g, smoking) may result in enhanced vasoconstriction.
negative	Concurrent use with <e12> vasoconstrictor_agents </e12> including ergot_alkaloids , sumatriptan , and <e20> nicotine </e20> (e,g, smoking) may result in enhanced vasoconstriction.
effect	The effects of <e12> metoclopramide </e12> on gastrointestinal motility are antagonized by <e22> anticholinergic_drugs </e22> and narcotic_analgesics .
effect	The effects of <e12> metoclopramide </e12> on gastrointestinal motility are antagonized by anticholinergic_drugs and <e22> narcotic_analgesics </e22> .
negative	The effects of metoclopramide on gastrointestinal motility are antagonized by <e12> anticholinergic_drugs </e12> and <e22> narcotic_analgesics </e22> .
effect	Additive sedative effects can occur when <e12> metoclopramide </e12> is given with <e20> alcohol </e20> , sedatives , hypnotics , narcotics , or tranquilizers .
effect	Additive sedative effects can occur when <e12> metoclopramide </e12> is given with alcohol , <e22> sedatives </e22> , hypnotics , narcotics , or tranquilizers .
effect	Additive sedative effects can occur when <e12> metoclopramide </e12> is given with alcohol , sedatives , <e22> hypnotics </e22> , narcotics , or tranquilizers .
effect	Additive sedative effects can occur when <e12> metoclopramide </e12> is given with alcohol , sedatives , hypnotics , <e22> narcotics </e22> , or tranquilizers .
effect	Additive sedative effects can occur when <e12> metoclopramide </e12> is given with alcohol , sedatives , hypnotics , narcotics , or <e22> tranquilizers </e22> .
advise	The finding that <e12> metoclopramide </e12> releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving <e22> monoamine_oxi-dase_inhibitors </e22> .
mechanism	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by <e22> metoclopramide </e22> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, <e20> acetaminophen </e20> , tetracycline , levodopa , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , <e20> tetracycline </e20> , levodopa , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , <e20> levodopa </e20> , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , levodopa , <e20> ethanol </e20> , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , levodopa , ethanol , <e20> cyclosporine </e20> ).
mechanism	Absorption of drugs from the stomach may be diminished (e,g,, digoxin ) by <e12> metoclopramide </e12> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, <e20> acetaminophen </e20> , tetracycline , levodopa , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, digoxin ) by <e12> metoclopramide </e12> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , <e20> tetracycline </e20> , levodopa , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, digoxin ) by <e12> metoclopramide </e12> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , <e20> levodopa </e20> , ethanol , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, digoxin ) by <e12> metoclopramide </e12> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , levodopa , <e20> ethanol </e20> , cyclosporine ).
negative	Absorption of drugs from the stomach may be diminished (e,g,, digoxin ) by <e12> metoclopramide </e12> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , levodopa , ethanol , <e20> cyclosporine </e20> ).
advise	Because the action of <e12> metoclopramide </e12> will influence the delivery of food to the intestines and thus the rate of absorption, <e20> insulin </e20> dosage or timing of dosage may require adjustment.
negative	Diuretics : <e10> Furosemide </e10> and probably other <e22> loop_diuretics </e22> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
effect	Diuretics : <e10> Furosemide </e10> and probably other loop_diuretics given concomitantly with <e20> metolazone </e20> can cause unusually large or prolonged losses of fluid and electrolytes.
effect	Diuretics : Furosemide and probably other <e12> loop_diuretics </e12> given concomitantly with <e20> metolazone </e20> can cause unusually large or prolonged losses of fluid and electrolytes.
advise	Other Antihypertensives : When <e11> MYKROX </e11> Tablets are used with other <e22> antihypertensive_drugs </e22> , care must be taken, especially during initial therapy.
effect	Digitalis_Glycosides : <e12> Diuretic </e12> -induced hypokalemia can increase the sensitivity of the myocardium to <e22> digitalis </e22> .
negative	<e12> Corticosteroids </e12> or <e20> ACTH </e20> : May increase the risk of hypokalemia and increase salt and water retention.
effect	Curariform_Drugs : <e12> Diuretic </e12> -induced hypokalemia may enhance neuromuscular blocking effects of <e22> curariform_drugs </e22> (such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea.
effect	Curariform_Drugs : <e12> Diuretic </e12> -induced hypokalemia may enhance neuromuscular blocking effects of curariform_drugs (such as <e20> tubocurarine </e20> ) the most serious effect would be respiratory depression which could proceed to apnea.
negative	<e12> Salicylates </e12> and Other <e22> Non-Steroidal_Anti-Inflammatory_Drugs </e22> : May decrease the antihypertensive effects of MYKROX Tablets.
effect	<e12> Salicylates </e12> and Other Non-Steroidal_Anti-Inflammatory_Drugs : May decrease the antihypertensive effects of <e21> MYKROX </e21> Tablets.
effect	Salicylates and Other <e12> Non-Steroidal_Anti-Inflammatory_Drugs </e12> : May decrease the antihypertensive effects of <e21> MYKROX </e21> Tablets.
effect	Sympathomimetics : <e10> Metolazone </e10> may decrease arterial responsiveness to <e20> norepinephrine </e20> , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
effect	<e10> Methenamine </e10> : Efficacy may be decreased due to urinary alkalizing effect of <e20> metolazone </e20> .
negative	<e12> Anticoagulants </e12> : <e20> Metolazone </e20> , as well as other thiazide-like_diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
negative	<e12> Anticoagulants </e12> : Metolazone , as well as other <e22> thiazide-like_diuretics </e22> , may affect the hypoprothrombinemic response to anticoagulants ;
negative	Anticoagulants : <e10> Metolazone </e10> , as well as other <e22> thiazide-like_diuretics </e22> , may affect the hypoprothrombinemic response to anticoagulants ;
effect	Anticoagulants : <e10> Metolazone </e10> , as well as other thiazide-like_diuretics , may affect the hypoprothrombinemic response to <e22> anticoagulants </e22> ;
negative	Anticoagulants : Metolazone , as well as other <e12> thiazide-like_diuretics </e12> , may affect the hypoprothrombinemic response to <e22> anticoagulants </e22> ;
effect	Catecholamine-depleting drugs (e,g,, <e10> reserpine </e10> ) may have an additive effect when given with <e22> beta-blocking_agents </e22> .
effect	Oral <e10> metronidazole </e10> has been reported to potentiate the anticoagulant effect of <e22> coumarin </e22> and warfarin , resulting in a prolongation of prothrombin time.
effect	Oral <e10> metronidazole </e10> has been reported to potentiate the anticoagulant effect of coumarin and <e20> warfarin </e20> , resulting in a prolongation of prothrombin time.
negative	Oral metronidazole has been reported to potentiate the anticoagulant effect of <e12> coumarin </e12> and <e20> warfarin </e20> , resulting in a prolongation of prothrombin time.
negative	Drug interactions should be kept in mind when <e11> METROGEL </e11> ( metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical <e20> metronidazole </e20> administration because of low absorption.
mechanism	The metabolism of <e11> Metopirone </e11> is accelerated by <e20> phenytoin </e20> ;
mechanism	<e11> Metopirone </e11> inhibits the glucuronidation of <e20> acetaminophen </e20> and could possibly potentiate acetaminophen toxicity.
effect	<e11> Metopirone </e11> inhibits the glucuronidation of acetaminophen and could possibly potentiate <e20> acetaminophen </e20> toxicity.
advise	Caution should be observed in administering <e11> DEMSER </e11> to patients receiving <e22> phenothiazines </e22> or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
advise	Caution should be observed in administering <e11> DEMSER </e11> to patients receiving phenothiazines or <e20> haloperidol </e20> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
negative	Caution should be observed in administering DEMSER to patients receiving <e12> phenothiazines </e12> or <e20> haloperidol </e20> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
effect	Concurrent use of <e11> DEMSER </e11> with <e20> alcohol </e20> or other CNS_depressants can increase their sedative effects.
effect	Concurrent use of <e11> DEMSER </e11> with alcohol or other <e22> CNS_depressants </e22> can increase their sedative effects.
negative	Concurrent use of DEMSER with <e10> alcohol </e10> or other <e22> CNS_depressants </e22> can increase their sedative effects.
negative	Since <e11> MEXITIL </e11> is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter <e20> mexiletine </e20> plasma concentrations.
mechanism	In a formal, single-dose interaction study (n = # males) the clearance of <e10> mexiletine </e10> was decreased by 38% following the coadministration of <e20> fluvoxamine </e20> , an inhibitor of CYP1A2.
negative	In another formal study (n = # extensive and n = # poor metabolizers of CYP2D6), coadministration of <e10> propafenone </e10> did not alter the kinetics of <e20> mexiletine </e20> in the poor CYP2D6 metabolizer group.
negative	In this crossover steady state study, the pharmacokinetics of <e10> propafenone </e10> were unaffected in either phenotype by the coadministration of <e20> mexiletine </e20> .
negative	Addition of <e10> mexiletine </e10> to <e20> propafenone </e20> did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.
negative	Addition of <e10> mexiletine </e10> to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than <e20> propafenone </e20> alone.
negative	In a large compassionate use program <e11> Mexitil </e11> has been used concurrently with commonly employed antianginal, <e22> antihypertensive </e22> , and anticoagulant_drugs without observed interactions.
negative	In a large compassionate use program <e11> Mexitil </e11> has been used concurrently with commonly employed antianginal, antihypertensive , and <e22> anticoagulant_drugs </e22> without observed interactions.
negative	In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal, <e12> antihypertensive </e12> , and <e22> anticoagulant_drugs </e22> without observed interactions.
negative	A variety of <e12> antiarrhythmics </e12> such as <e20> quinidine </e20> or propranolol were also added, sometimes with improved control of ventricular ectopy.
negative	A variety of <e12> antiarrhythmics </e12> such as quinidine or <e20> propranolol </e20> were also added, sometimes with improved control of ventricular ectopy.
negative	A variety of antiarrhythmics such as <e10> quinidine </e10> or <e20> propranolol </e20> were also added, sometimes with improved control of ventricular ectopy.
negative	When <e10> phenytoin </e10> or other hepatic enzyme inducers such as <e20> rifampin </e20> and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported.
negative	When <e10> phenytoin </e10> or other hepatic enzyme inducers such as rifampin and <e20> phenobarbital </e20> have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported.
mechanism	When <e10> phenytoin </e10> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with <e21> Mexitil </e21> , lowered Mexitil plasma levels have been reported.
negative	When <e10> phenytoin </e10> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered <e21> Mexitil </e21> plasma levels have been reported.
negative	When phenytoin or other hepatic enzyme inducers such as <e10> rifampin </e10> and <e20> phenobarbital </e20> have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported.
mechanism	When phenytoin or other hepatic enzyme inducers such as <e10> rifampin </e10> and phenobarbital have been taken concurrently with <e21> Mexitil </e21> , lowered Mexitil plasma levels have been reported.
negative	When phenytoin or other hepatic enzyme inducers such as <e10> rifampin </e10> and phenobarbital have been taken concurrently with Mexitil , lowered <e21> Mexitil </e21> plasma levels have been reported.
mechanism	When phenytoin or other hepatic enzyme inducers such as rifampin and <e10> phenobarbital </e10> have been taken concurrently with <e21> Mexitil </e21> , lowered Mexitil plasma levels have been reported.
negative	When phenytoin or other hepatic enzyme inducers such as rifampin and <e10> phenobarbital </e10> have been taken concurrently with Mexitil , lowered <e21> Mexitil </e21> plasma levels have been reported.
negative	In a formal study, <e12> benzodiazepines </e12> were shown not to affect <e21> Mexitil </e21> plasma concentrations.
mechanism	Concurrent administration of <e10> cimetidine </e10> and <e21> Mexitil </e21> has been reported to increase, decrease, or leave unchanged Mexitil plasma levels;
negative	Concurrent administration of <e10> cimetidine </e10> and Mexitil has been reported to increase, decrease, or leave unchanged <e21> Mexitil </e21> plasma levels;
negative	<e11> Mexitil </e11> does not alter serum <e20> digoxin </e20> levels but magnesium-aluminum_hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels.
negative	<e11> Mexitil </e11> does not alter serum digoxin levels but <e20> magnesium-aluminum_hydroxide </e20> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels.
negative	<e11> Mexitil </e11> does not alter serum digoxin levels but magnesium-aluminum_hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e20> digoxin </e20> levels.
negative	Mexitil does not alter serum <e10> digoxin </e10> levels but <e20> magnesium-aluminum_hydroxide </e20> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels.
negative	Mexitil does not alter serum <e10> digoxin </e10> levels but magnesium-aluminum_hydroxide , when used to treat gastrointestinal symptoms due to <e21> Mexitil </e21> , has been reported to lower serum digoxin levels.
negative	Mexitil does not alter serum digoxin levels but <e10> magnesium-aluminum_hydroxide </e10> , when used to treat gastrointestinal symptoms due to <e21> Mexitil </e21> , has been reported to lower serum digoxin levels.
mechanism	Mexitil does not alter serum digoxin levels but <e10> magnesium-aluminum_hydroxide </e10> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e20> digoxin </e20> levels.
negative	Mexitil does not alter serum digoxin levels but magnesium-aluminum_hydroxide , when used to treat gastrointestinal symptoms due to <e11> Mexitil </e11> , has been reported to lower serum <e20> digoxin </e20> levels.
mechanism	Concurrent use of <e11> Mexitil </e11> and <e20> theophylline </e20> may lead to increased plasma theophylline levels.
negative	Concurrent use of <e11> Mexitil </e11> and theophylline may lead to increased plasma <e20> theophylline </e20> levels.
negative	This increase was observed at the first test point which was the second day after starting Mexitil , <e10> Theophylline </e10> plasma levels returned to pre- <e21> Mexitil </e21> values within # hours after discontinuing Mexitil , If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.
mechanism	This increase was observed at the first test point which was the second day after starting Mexitil , <e10> Theophylline </e10> plasma levels returned to pre- Mexitil values within # hours after discontinuing <e21> Mexitil </e21> , If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.
advise	This increase was observed at the first test point which was the second day after starting Mexitil , Theophylline plasma levels returned to pre- Mexitil values within # hours after discontinuing Mexitil , If <e11> Mexitil </e11> and <e20> theophylline </e20> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.
negative	This increase was observed at the first test point which was the second day after starting Mexitil , Theophylline plasma levels returned to pre- Mexitil values within # hours after discontinuing Mexitil , If <e11> Mexitil </e11> and theophylline are to be used concurrently, <e20> theophylline </e20> blood levels should be monitored, particularly when the Mexitil dose is changed.
negative	This increase was observed at the first test point which was the second day after starting Mexitil , Theophylline plasma levels returned to pre- Mexitil values within # hours after discontinuing Mexitil , If Mexitil and <e10> theophylline </e10> are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e21> Mexitil </e21> dose is changed.
negative	This increase was observed at the first test point which was the second day after starting Mexitil , Theophylline plasma levels returned to pre- Mexitil values within # hours after discontinuing Mexitil , If Mexitil and theophylline are to be used concurrently, <e10> theophylline </e10> blood levels should be monitored, particularly when the <e21> Mexitil </e21> dose is changed.
mechanism	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of <e10> caffeine </e10> was decreased 50% following the administration of <e21> Mexitil </e21> .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - <e20> terfenadine </e20> , astemizole , cisapride , cyclosporine , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , <e20> astemizole </e20> , cisapride , cyclosporine , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , <e20> cisapride </e20> , cyclosporine , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , <e20> cyclosporine </e20> , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and <e22> tricyclic_antidepressants </e22> .
negative	There was no effect of a single dose or multiple doses of <e11> MYCAMINE </e11> on <e20> mycophenolate_mofetil </e20> , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics.
negative	There was no effect of a single dose or multiple doses of <e11> MYCAMINE </e11> on mycophenolate_mofetil , <e20> cyclosporine </e20> , tacrolimus , prednisolone , and fluconazole pharmacokinetics.
negative	There was no effect of a single dose or multiple doses of <e11> MYCAMINE </e11> on mycophenolate_mofetil , cyclosporine , <e20> tacrolimus </e20> , prednisolone , and fluconazole pharmacokinetics.
negative	There was no effect of a single dose or multiple doses of <e11> MYCAMINE </e11> on mycophenolate_mofetil , cyclosporine , tacrolimus , <e20> prednisolone </e20> , and fluconazole pharmacokinetics.
negative	There was no effect of a single dose or multiple doses of <e11> MYCAMINE </e11> on mycophenolate_mofetil , cyclosporine , tacrolimus , prednisolone , and <e20> fluconazole </e20> pharmacokinetics.
negative	There was no effect of a single dose or multiple doses of MYCAMINE on <e10> mycophenolate_mofetil </e10> , cyclosporine , tacrolimus , prednisolone , and <e20> fluconazole </e20> pharmacokinetics.
negative	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate_mofetil , cyclosporine , <e10> tacrolimus </e10> , prednisolone , and <e20> fluconazole </e20> pharmacokinetics.
mechanism	<e10> Sirolimus </e10> AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e21> MYCAMINE </e21> compared with sirolimus alone.
negative	Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e11> MYCAMINE </e11> compared with <e20> sirolimus </e20> alone.
mechanism	<e10> Nifedipine </e10> AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e21> MYCAMINE </e21> compared with nifedipine alone.
negative	Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e11> MYCAMINE </e11> compared with <e20> nifedipine </e20> alone.
negative	Patients receiving <e10> sirolimus </e10> or <e20> nifedipine </e20> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
advise	Patients receiving <e10> sirolimus </e10> or nifedipine in combination with <e21> MYCAMINE </e21> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving <e10> sirolimus </e10> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e20> nifedipine </e20> toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving <e10> sirolimus </e10> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e20> nifedipine </e20> dosage should be reduced if necessary.
advise	Patients receiving sirolimus or <e10> nifedipine </e10> in combination with <e21> MYCAMINE </e21> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or <e10> nifedipine </e10> in combination with MYCAMINE should be monitored for <e20> sirolimus </e20> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or <e10> nifedipine </e10> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e20> sirolimus </e20> or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with <e11> MYCAMINE </e11> should be monitored for <e20> sirolimus </e20> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with <e11> MYCAMINE </e11> should be monitored for sirolimus or <e20> nifedipine </e20> toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with <e11> MYCAMINE </e11> should be monitored for sirolimus or nifedipine toxicity and <e20> sirolimus </e20> or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with <e11> MYCAMINE </e11> should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e20> nifedipine </e20> dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e10> sirolimus </e10> or <e20> nifedipine </e20> toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e10> sirolimus </e10> or nifedipine toxicity and sirolimus or <e20> nifedipine </e20> dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e10> nifedipine </e10> toxicity and <e20> sirolimus </e20> or nifedipine dosage should be reduced if necessary.
negative	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e10> sirolimus </e10> or <e20> nifedipine </e20> dosage should be reduced if necessary.
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e22> azole_antimycotics </e22> , protease_inhibitors , calcium_channel_antagonists , and macrolide_antibiotics ).
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole_antimycotics , <e22> protease_inhibitors </e22> , calcium_channel_antagonists , and macrolide_antibiotics ).
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole_antimycotics , protease_inhibitors , <e22> calcium_channel_antagonists </e22> , and macrolide_antibiotics ).
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e10> midazolam </e10> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole_antimycotics , protease_inhibitors , calcium_channel_antagonists , and <e22> macrolide_antibiotics </e22> ).
mechanism	Drugs such as <e10> erythromycin </e10> , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , <e10> diltiazem </e10> , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , <e10> verapamil </e10> , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , verapamil , <e10> ketoconazole </e10> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , <e10> fluconazole </e10> and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and <e10> itraconazole </e10> were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
negative	Although not studied, the potent cytochrome P450 3A4 inhibitors <e10> ritonavir </e10> and <e20> nelfinavir </e20> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam .
mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors <e10> ritonavir </e10> and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e20> midazolam </e20> .
mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and <e10> nelfinavir </e10> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e20> midazolam </e20> .
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e10> rifampin </e10> , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral <e20> midazolam </e20> in adult studies.
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin , <e10> carbamazepine </e10> , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral <e20> midazolam </e20> in adult studies.
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin , carbamazepine , and <e10> phenytoin </e10> , induce metabolism and caused a markedly decreased C max and AUC of oral <e20> midazolam </e20> in adult studies.
negative	The difficulty in achieving adequate sedation may have been the result of decreased absorption of the <e12> sedatives </e12> due to both the gastrointestinal effects and stimulant effects of <e20> methylphenidate </e20> .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e22> narcotics </e22> (eg, morphine , meperidine and fentanyl ), propofol , ketamine , nitrous_oxide , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e20> morphine </e20> , meperidine and fentanyl ), propofol , ketamine , nitrous_oxide , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , <e20> meperidine </e20> and fentanyl ), propofol , ketamine , nitrous_oxide , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and <e20> fentanyl </e20> ), propofol , ketamine , nitrous_oxide , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), <e20> propofol </e20> , ketamine , nitrous_oxide , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), propofol , <e20> ketamine </e20> , nitrous_oxide , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), propofol , ketamine , <e20> nitrous_oxide </e20> , secobarbital and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), propofol , ketamine , nitrous_oxide , <e20> secobarbital </e20> and droperidol .
effect	The sedative effect of <e11> VERSED_Syrup </e11> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), propofol , ketamine , nitrous_oxide , secobarbital and <e20> droperidol </e20> .
negative	The sedative effect of VERSED_Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), <e10> propofol </e10> , <e20> ketamine </e20> , nitrous_oxide , secobarbital and droperidol .
negative	The sedative effect of VERSED_Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), <e10> propofol </e10> , ketamine , <e20> nitrous_oxide </e20> , secobarbital and droperidol .
negative	The sedative effect of VERSED_Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), <e10> propofol </e10> , ketamine , nitrous_oxide , <e20> secobarbital </e20> and droperidol .
negative	The sedative effect of VERSED_Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine , meperidine and fentanyl ), <e10> propofol </e10> , ketamine , nitrous_oxide , secobarbital and <e20> droperidol </e20> .
negative	No significant adverse interactions with common premedications (such as <e10> atropine </e10> , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle_relaxants ) or local <e22> anesthetics </e22> have been observed.
negative	No significant adverse interactions with common premedications (such as atropine , <e10> scopolamine </e10> , glycopyrrolate , diazepam , hydroxyzine , and other muscle_relaxants ) or local <e22> anesthetics </e22> have been observed.
negative	No significant adverse interactions with common premedications (such as atropine , scopolamine , <e10> glycopyrrolate </e10> , diazepam , hydroxyzine , and other muscle_relaxants ) or local <e22> anesthetics </e22> have been observed.
negative	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , <e10> diazepam </e10> , hydroxyzine , and other muscle_relaxants ) or local <e22> anesthetics </e22> have been observed.
negative	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , diazepam , <e10> hydroxyzine </e10> , and other muscle_relaxants ) or local <e22> anesthetics </e22> have been observed.
negative	No significant adverse interactions with common premedications (such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other <e12> muscle_relaxants </e12> ) or local <e22> anesthetics </e22> have been observed.
effect	When administered concomitantly with <e11> ProAmatine </e11> , <e22> cardiac_glycosides </e22> may enhance or precipitate bradycardia, A,V.
effect	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, <e10> phenylephrine </e10> , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of <e21> ProAmatine </e21> , Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.
negative	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, <e10> phenylephrine </e10> , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine , Therefore, caution should be used when <e21> ProAmatine </e21> is administered concomitantly with agents that cause vasoconstriction.
effect	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , <e10> pseudoephedrine </e10> , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of <e21> ProAmatine </e21> , Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.
negative	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , <e10> pseudoephedrine </e10> , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine , Therefore, caution should be used when <e21> ProAmatine </e21> is administered concomitantly with agents that cause vasoconstriction.
effect	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , pseudoephedrine , <e10> ephedrine </e10> , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of <e21> ProAmatine </e21> , Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.
negative	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , pseudoephedrine , <e10> ephedrine </e10> , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine , Therefore, caution should be used when <e21> ProAmatine </e21> is administered concomitantly with agents that cause vasoconstriction.
effect	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , pseudoephedrine , ephedrine , <e10> phenylpropanolamine </e10> or dihydroergotamine ) may enhance or potentiate the pressor effects of <e21> ProAmatine </e21> , Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.
negative	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , pseudoephedrine , ephedrine , <e10> phenylpropanolamine </e10> or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine , Therefore, caution should be used when <e21> ProAmatine </e21> is administered concomitantly with agents that cause vasoconstriction.
effect	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or <e10> dihydroergotamine </e10> ) may enhance or potentiate the pressor effects of <e21> ProAmatine </e21> , Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.
negative	The use of drugs that stimulate alpha-adrenergic receptors (e,g,, phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or <e10> dihydroergotamine </e10> ) may enhance or potentiate the pressor effects of ProAmatine , Therefore, caution should be used when <e21> ProAmatine </e21> is administered concomitantly with agents that cause vasoconstriction.
negative	<e11> ProAmatine </e11> has been used in patients concomitantly treated with salt-retaining steroid therapy (i,e,, <e20> fludrocortisone_acetate </e20> ), with or without salt supplementation.
negative	<e11> ProAmatine </e11> , <e22> Alpha-adrenergic_blocking_agents </e22> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as <e20> prazosin </e20> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , <e20> terazosin </e20> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e20> doxazosin </e20> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e23> desglymidodrine </e23> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
negative	<e11> ProAmatine </e11> , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as <e20> prazosin </e20> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , <e20> terazosin </e20> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and <e20> doxazosin </e20> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
effect	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e21> ProAmatine </e21> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e23> desglymidodrine </e23> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
negative	ProAmatine , <e12> Alpha-adrenergic_blocking_agents </e12> , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
effect	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of <e21> ProAmatine </e21> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e23> desglymidodrine </e23> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as <e10> prazosin </e10> , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
effect	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of <e21> ProAmatine </e21> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e23> desglymidodrine </e23> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , <e10> terazosin </e10> , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
effect	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of <e21> ProAmatine </e21> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e23> desglymidodrine </e23> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and <e10> doxazosin </e10> , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e23> desglymidodrine </e23> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
negative	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of <e11> ProAmatine </e11> , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
negative	Although specific drug or food interactions with <e10> mifepristone </e10> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e20> ketoconazole </e20> , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ).
negative	Although specific drug or food interactions with <e10> mifepristone </e10> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole , <e20> itraconazole </e20> , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ).
negative	Although specific drug or food interactions with <e10> mifepristone </e10> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole , itraconazole , <e20> erythromycin </e20> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone ).
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e10> ketoconazole </e10> , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e20> mifepristone </e20> ).
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole , <e10> itraconazole </e10> , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e20> mifepristone </e20> ).
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole , itraconazole , <e10> erythromycin </e10> , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e20> mifepristone </e20> ).
negative	Furthermore, <e10> rifampin </e10> , <e20> dexamethasone </e20> , St.
mechanism	John s Wort, and certain <e12> anticonvulsants </e12> ( phenytoin , phenobarbital , carbamazepine ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
negative	John s Wort, and certain <e12> anticonvulsants </e12> ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of <e20> mifepristone </e20> ).
mechanism	John s Wort, and certain anticonvulsants ( <e10> phenytoin </e10> , phenobarbital , carbamazepine ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
negative	John s Wort, and certain anticonvulsants ( <e10> phenytoin </e10> , phenobarbital , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of <e20> mifepristone </e20> ).
mechanism	John s Wort, and certain anticonvulsants ( phenytoin , <e10> phenobarbital </e10> , carbamazepine ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
negative	John s Wort, and certain anticonvulsants ( phenytoin , <e10> phenobarbital </e10> , carbamazepine ) may induce mifepristone metabolism (lowering serum levels of <e20> mifepristone </e20> ).
mechanism	John s Wort, and certain anticonvulsants ( phenytoin , phenobarbital , <e10> carbamazepine </e10> ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
negative	John s Wort, and certain anticonvulsants ( phenytoin , phenobarbital , <e10> carbamazepine </e10> ) may induce mifepristone metabolism (lowering serum levels of <e20> mifepristone </e20> ).
mechanism	While co-administration of <e11> ZAVESCA </e11> appeared to increase the clearance of <e21> Cerezyme </e21> by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme .
negative	While co-administration of <e11> ZAVESCA </e11> appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of <e21> Cerezyme </e21> .
advise	Combination therapy with <e11> Cerezyme </e11> ( imiglucerase ) and <e21> ZAVESCA </e21> is not indicated.
advise	Combination therapy with Cerezyme ( <e10> imiglucerase </e10> ) and <e21> ZAVESCA </e21> is not indicated.
advise	Because <e12> tetracyclines </e12> have been shown to depress plasma prothrombin activity, patients who are on <e22> anticoagulant </e22> therapy may require downward adjustment of their anticoagulant dosage.
negative	Because <e12> tetracyclines </e12> have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their <e22> anticoagulant </e22> dosage.
negative	Since bacteriostatic drugs may interfere with the bactericidal action of <e10> penicillin </e10> , it is advisable to avoid giving <e22> tetracycline_class_drugs </e22> in conjunction with penicillin .
advise	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving <e12> tetracycline_class_drugs </e12> in conjunction with <e20> penicillin </e20> .
negative	Absorption of <e12> tetracyclines </e12> is impaired by <e20> antacids </e20> containing aluminum , calcium or magnesium , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing <e20> aluminum </e20> , calcium or magnesium , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing aluminum , <e20> calcium </e20> or magnesium , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing aluminum , calcium or <e20> magnesium </e20> , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing aluminum , calcium or magnesium , and <e20> iron </e20> -containing preparations.
negative	Absorption of tetracyclines is impaired by <e10> antacids </e10> containing <e20> aluminum </e20> , calcium or magnesium , and iron -containing preparations.
negative	Absorption of tetracyclines is impaired by <e10> antacids </e10> containing aluminum , <e20> calcium </e20> or magnesium , and iron -containing preparations.
negative	Absorption of tetracyclines is impaired by <e10> antacids </e10> containing aluminum , calcium or <e20> magnesium </e20> , and iron -containing preparations.
negative	Absorption of tetracyclines is impaired by <e10> antacids </e10> containing aluminum , calcium or magnesium , and <e20> iron </e20> -containing preparations.
negative	Absorption of tetracyclines is impaired by antacids containing <e10> aluminum </e10> , calcium or magnesium , and <e20> iron </e20> -containing preparations.
negative	Absorption of tetracyclines is impaired by antacids containing aluminum , <e10> calcium </e10> or magnesium , and <e20> iron </e20> -containing preparations.
negative	Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or <e10> magnesium </e10> , and <e20> iron </e20> -containing preparations.
effect	The concurrent use of <e10> tetracycline </e10> and <e20> methoxyflurane </e20> has been reported to result in fatal renal toxicity.
effect	Concurrent use of <e12> tetracyclines </e12> with oral <e22> contraceptives </e22> may render oral contraceptives less effective.
negative	Concurrent use of <e12> tetracyclines </e12> with oral contraceptives may render oral <e22> contraceptives </e22> less effective.
effect	Interaction with Guanethidine : Although <e10> minoxidil </e10> does not itself cause orthostatic hypotension, its administration to patients already receiving <e20> guanethidine </e20> can result in profound orthostatic effects.
advise	If at all possible <e10> guanethidine </e10> should be discontinued well before <e20> minoxidil </e20> is begun.
negative	While in vitro studies have shown that <e10> mirtazapine </e10> is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of <e21> REMERON_SolTab </e21> with most other drugs metabolized by these enzymes has not been formally studied.
negative	While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that <e10> mirtazapine </e10> is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of <e21> REMERON_SolTab </e21> with most other drugs metabolized by these enzymes has not been formally studied.
negative	<e10> Alcohol </e10> : Concomitant administration of alcohol (equivalent to # g) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy male subjects.
mechanism	Alcohol : Concomitant administration of <e10> alcohol </e10> (equivalent to # g) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy male subjects.
effect	However, the impairment of cognitive and motor skills produced by <e11> REMERON </e11> were shown to be additive with those produced by <e20> alcohol </e20> .
advise	Accordingly, patients should be advised to avoid <e10> alcohol </e10> while taking <e21> REMERON_SolTab </e21> , Diazepam : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid <e10> alcohol </e10> while taking REMERON_SolTab , <e20> Diazepam </e20> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid <e10> alcohol </e10> while taking REMERON_SolTab , Diazepam : Concomitant administration of <e20> diazepam </e20> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid <e10> alcohol </e10> while taking REMERON_SolTab , Diazepam : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid alcohol while taking <e11> REMERON_SolTab </e11> , <e20> Diazepam </e20> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid alcohol while taking <e11> REMERON_SolTab </e11> , Diazepam : Concomitant administration of <e20> diazepam </e20> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid alcohol while taking <e11> REMERON_SolTab </e11> , Diazepam : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy subjects.
negative	Accordingly, patients should be advised to avoid alcohol while taking REMERON_SolTab , <e10> Diazepam </e10> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy subjects.
mechanism	Accordingly, patients should be advised to avoid alcohol while taking REMERON_SolTab , Diazepam : Concomitant administration of <e10> diazepam </e10> (15 mg) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy subjects.
effect	However, the impairment of motor skills produced by <e11> REMERON </e11> has been shown to be additive with those caused by <e20> diazepam </e20> .
advise	Accordingly, patients should be advised to avoid <e10> diazepam </e10> and other similar drugs while taking <e21> REMERON_SolTab </e21> .
mechanism	<e10> Mitotane </e10> has been reported to accelerate the metabolism of <e20> warfarin </e20> by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin .
negative	<e10> Mitotane </e10> has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for <e20> warfarin </e20> .
negative	Therefore, physicians should closely monitor patients for a change in <e12> anticoagulant </e12> dosage requirements when administering <e20> Mitotane </e20> to patients on coumarin-type_anticoagulants .
advise	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering <e10> Mitotane </e10> to patients on <e22> coumarin-type_anticoagulants </e22> .
negative	Although <e11> MIVACRON </e11> (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and <e20> succinylcholine </e20> has not been systematically studied.
negative	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between <e11> MIVACRON </e11> and <e20> succinylcholine </e20> has not been systematically studied.
effect	Prior administration of <e10> succinylcholine </e10> can potentiate the neuromuscular blocking effects of <e20> nondepolarizing_agents </e20> .
advise	Evidence of spontaneous recovery from <e10> succinylcholine </e10> should be observed before the administration of <e21> MIVACRON </e21> .
negative	The use of <e11> MIVACRON </e11> before <e20> succinylcholine </e20> to attenuate some of the side effects of succinylcholine has not been studied.
negative	The use of <e11> MIVACRON </e11> before succinylcholine to attenuate some of the side effects of <e20> succinylcholine </e20> has not been studied.
negative	There are no clinical data on the use of <e11> MIVACRON </e11> with other <e22> nondepolarizing_neuromuscular_blocking_agents </e22> .
negative	<e10> Isoflurane </e10> and <e20> enflurane </e20> (administered with nitrous_oxide / oxygen to achieve # M,C.
negative	<e10> Isoflurane </e10> and enflurane (administered with <e20> nitrous_oxide </e20> / oxygen to achieve # M,C.
negative	<e10> Isoflurane </e10> and enflurane (administered with nitrous_oxide / <e20> oxygen </e20> to achieve # M,C.
negative	Isoflurane and <e10> enflurane </e10> (administered with <e20> nitrous_oxide </e20> / oxygen to achieve # M,C.
negative	Isoflurane and <e10> enflurane </e10> (administered with nitrous_oxide / <e20> oxygen </e20> to achieve # M,C.
negative	A greater potentiation of the neuromuscular blocking effects of <e11> MIVACRON </e11> may be expected with higher concentrations of <e20> enflurane </e20> or isoflurane .
negative	A greater potentiation of the neuromuscular blocking effects of <e11> MIVACRON </e11> may be expected with higher concentrations of enflurane or <e20> isoflurane </e20> .
negative	A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of <e10> enflurane </e10> or <e20> isoflurane </e20> .
negative	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as <e21> MIVACRON </e21> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain <e22> antibiotics </e22> (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, <e22> aminoglycosides </e22> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , <e22> tetracyclines </e22> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , <e20> bacitracin </e20> , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , <e22> polymyxins </e22> , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , <e20> lincomycin </e20> , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> clindamycin </e20> , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e20> colistin </e20> , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e20> sodium_colistimethate </e20> ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e20> magnesium </e20> salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, <e20> lithium </e20> , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local <e22> anesthetics </e22> , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , <e20> procainamide </e20> , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of <e10> nondepolarizing_agents </e10> such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and <e20> quinidine </e20> .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain <e22> antibiotics </e22> (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, <e22> aminoglycosides </e22> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , <e22> tetracyclines </e22> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , <e20> bacitracin </e20> , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , <e22> polymyxins </e22> , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , <e20> lincomycin </e20> , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> clindamycin </e20> , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e20> colistin </e20> , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e20> sodium_colistimethate </e20> ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e20> magnesium </e20> salts, lithium , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, <e20> lithium </e20> , local anesthetics , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local <e22> anesthetics </e22> , procainamide , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , <e20> procainamide </e20> , and quinidine .
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> MIVACRON </e11> include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and <e20> quinidine </e20> .
negative	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e10> magnesium </e10> salts, <e20> lithium </e20> , local anesthetics , procainamide , and quinidine .
negative	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e10> magnesium </e10> salts, lithium , local <e22> anesthetics </e22> , procainamide , and quinidine .
negative	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e10> magnesium </e10> salts, lithium , local anesthetics , <e20> procainamide </e20> , and quinidine .
negative	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as MIVACRON include certain antibiotics (e,g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e10> magnesium </e10> salts, lithium , local anesthetics , procainamide , and <e20> quinidine </e20> .
effect	The neuromuscular blocking effect of <e11> MIVACRON </e11> may be enhanced by drugs that reduce plasma cholinesterase activity (e,g,, chronically administered oral <e22> contraceptives </e22> , glucocorticoids , or certain monoamine_oxidase_inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase , Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular_blocking_agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
effect	The neuromuscular blocking effect of <e11> MIVACRON </e11> may be enhanced by drugs that reduce plasma cholinesterase activity (e,g,, chronically administered oral contraceptives , <e22> glucocorticoids </e22> , or certain monoamine_oxidase_inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase , Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular_blocking_agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
effect	The neuromuscular blocking effect of <e11> MIVACRON </e11> may be enhanced by drugs that reduce plasma cholinesterase activity (e,g,, chronically administered oral contraceptives , glucocorticoids , or certain <e22> monoamine_oxidase_inhibitors </e22> ) or by drugs that irreversibly inhibit plasma cholinesterase , Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular_blocking_agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e,g,, chronically administered oral contraceptives , glucocorticoids , or certain monoamine_oxidase_inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase , Resistance to the neuromuscular blocking action of nondepolarizing <e12> neuromuscular_blocking_agents </e12> has been demonstrated in patients chronically administered <e20> phenytoin </e20> or carbamazepine .
effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e,g,, chronically administered oral contraceptives , glucocorticoids , or certain monoamine_oxidase_inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase , Resistance to the neuromuscular blocking action of nondepolarizing <e12> neuromuscular_blocking_agents </e12> has been demonstrated in patients chronically administered phenytoin or <e20> carbamazepine </e20> .
negative	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e,g,, chronically administered oral contraceptives , glucocorticoids , or certain monoamine_oxidase_inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase , Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular_blocking_agents has been demonstrated in patients chronically administered <e10> phenytoin </e10> or <e20> carbamazepine </e20> .
negative	While the effects of chronic <e10> phenytoin </e10> or <e20> carbamazepine </e20> therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
effect	While the effects of chronic <e10> phenytoin </e10> or carbamazepine therapy on the action of <e21> MIVACRON </e21> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
effect	While the effects of chronic phenytoin or <e10> carbamazepine </e10> therapy on the action of <e21> MIVACRON </e21> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e20> phenytoin </e20> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e20> carbamazepine </e20> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e22> antibiotics </e22> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e20> cisplatin </e20> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e20> edrophonium </e20> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e20> neostigmine </e20> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - <e12> corticosteroids </e12> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or <e20> carbamazepine </e20> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain <e22> antibiotics </e22> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - <e20> cisplatin </e20> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - <e20> edrophonium </e20> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e20> neostigmine </e20> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e10> phenytoin </e10> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain <e22> antibiotics </e22> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - <e20> cisplatin </e20> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - <e20> edrophonium </e20> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - <e20> neostigmine </e20> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e10> carbamazepine </e10> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - <e20> cisplatin </e20> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - <e20> edrophonium </e20> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - <e20> neostigmine </e20> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e12> antibiotics </e12> given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - <e20> edrophonium </e20> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - <e20> neostigmine </e20> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e10> cisplatin </e10> - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - <e20> neostigmine </e20> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e10> edrophonium </e10> - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - <e20> polymyxin_B </e20> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - polymyxin_B or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - polymyxin_B or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - polymyxin_B or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e10> neostigmine </e10> - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e10> polymyxin_B </e10> or <e20> bacitracin </e20> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e10> polymyxin_B </e10> or bacitracin - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e10> polymyxin_B </e10> or bacitracin - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e10> polymyxin_B </e10> or bacitracin - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e10> polymyxin_B </e10> or bacitracin - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e10> polymyxin_B </e10> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e10> bacitracin </e10> - local <e22> anesthetics </e22> such as procaine - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e10> bacitracin </e10> - local anesthetics such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e10> bacitracin </e10> - local anesthetics such as procaine - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e10> bacitracin </e10> - local anesthetics such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or <e10> bacitracin </e10> - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e12> anesthetics </e12> such as <e20> procaine </e20> - general anesthetics - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e12> anesthetics </e12> such as procaine - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local <e12> anesthetics </e12> such as procaine - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e10> procaine </e10> - general <e22> anesthetics </e22> - succinylcholine or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e10> procaine </e10> - general anesthetics - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as <e10> procaine </e10> - general anesthetics - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e12> anesthetics </e12> - <e20> succinylcholine </e20> or other muscle_relaxants
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general <e12> anesthetics </e12> - succinylcholine or other <e22> muscle_relaxants </e22>
negative	Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin_B or bacitracin - local anesthetics such as procaine - general anesthetics - <e10> succinylcholine </e10> or other <e22> muscle_relaxants </e22>
negative	<e12> Diuretics </e12> : Excessive reductions in blood pressure may occur in patients on diuretic therapy when <e22> ACE_inhibitors </e22> are started.
negative	<e10> Potassium </e10> Supplements and Potassium-Sparing_Diuretics : <e21> UNIVASC </e21> can increase serum potassium because it decreases aldosterone secretion.
negative	Potassium Supplements and <e12> Potassium-Sparing_Diuretics </e12> : <e21> UNIVASC </e21> can increase serum potassium because it decreases aldosterone secretion.
effect	Use of <e12> potassium-sparing_diuretics </e12> ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with <e22> ACE_inhibitors </e22> can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( <e10> spironolactone </e10> , triamterene , amiloride ) or <e20> potassium </e20> supplements concomitantly with ACE_inhibitors can increase the risk of hyperkalemia.
effect	Use of potassium-sparing_diuretics ( <e10> spironolactone </e10> , triamterene , amiloride ) or potassium supplements concomitantly with <e22> ACE_inhibitors </e22> can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , <e10> triamterene </e10> , amiloride ) or <e20> potassium </e20> supplements concomitantly with ACE_inhibitors can increase the risk of hyperkalemia.
effect	Use of potassium-sparing_diuretics ( spironolactone , <e10> triamterene </e10> , amiloride ) or potassium supplements concomitantly with <e22> ACE_inhibitors </e22> can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , triamterene , <e10> amiloride </e10> ) or <e20> potassium </e20> supplements concomitantly with ACE_inhibitors can increase the risk of hyperkalemia.
effect	Use of potassium-sparing_diuretics ( spironolactone , triamterene , <e10> amiloride </e10> ) or potassium supplements concomitantly with <e22> ACE_inhibitors </e22> can increase the risk of hyperkalemia.
effect	Use of potassium-sparing_diuretics ( spironolactone , triamterene , amiloride ) or <e10> potassium </e10> supplements concomitantly with <e22> ACE_inhibitors </e22> can increase the risk of hyperkalemia.
negative	Oral <e12> Anticoagulants </e12> : Interaction studies with <e20> warfarin </e20> failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.
negative	Oral Anticoagulants : Interaction studies with <e10> warfarin </e10> failed to identify any clinically important effect on the serum concentrations of the <e22> anticoagulant </e22> or on its anticoagulant effect.
negative	<e10> Lithium </e10> : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e22> ACE_inhibitors </e22> during therapy with lithium .
negative	Lithium : Increased serum <e10> lithium </e10> levels and symptoms of lithium toxicity have been reported in patients receiving <e22> ACE_inhibitors </e22> during therapy with lithium .
negative	Lithium : Increased serum lithium levels and symptoms of <e10> lithium </e10> toxicity have been reported in patients receiving <e22> ACE_inhibitors </e22> during therapy with lithium .
effect	Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e12> ACE_inhibitors </e12> during therapy with <e20> lithium </e20> .
effect	If a <e12> diuretic </e12> is also used, the risk of <e20> lithium </e20> toxicity may be increased.
negative	Other Agents: No clinically important pharmacokinetic interactions occurred when <e11> UNIVASC </e11> was administered concomitantly with <e20> hydrochlorothiazide </e20> , digoxin , or cimetidine .
negative	Other Agents: No clinically important pharmacokinetic interactions occurred when <e11> UNIVASC </e11> was administered concomitantly with hydrochlorothiazide , <e20> digoxin </e20> , or cimetidine .
negative	Other Agents: No clinically important pharmacokinetic interactions occurred when <e11> UNIVASC </e11> was administered concomitantly with hydrochlorothiazide , digoxin , or <e20> cimetidine </e20> .
negative	<e11> UNIVASC </e11> has been used in clinical trials concomitantly with <e22> calcium-channel-blocking_agents </e22> , diuretics , H2_blockers , digoxin , oral hypoglycemic_agents , and cholesterol-lowering agents.
negative	<e11> UNIVASC </e11> has been used in clinical trials concomitantly with calcium-channel-blocking_agents , <e22> diuretics </e22> , H2_blockers , digoxin , oral hypoglycemic_agents , and cholesterol-lowering agents.
negative	<e11> UNIVASC </e11> has been used in clinical trials concomitantly with calcium-channel-blocking_agents , diuretics , <e22> H2_blockers </e22> , digoxin , oral hypoglycemic_agents , and cholesterol-lowering agents.
negative	<e11> UNIVASC </e11> has been used in clinical trials concomitantly with calcium-channel-blocking_agents , diuretics , H2_blockers , <e20> digoxin </e20> , oral hypoglycemic_agents , and cholesterol-lowering agents.
negative	<e11> UNIVASC </e11> has been used in clinical trials concomitantly with calcium-channel-blocking_agents , diuretics , H2_blockers , digoxin , oral <e22> hypoglycemic_agents </e22> , and cholesterol-lowering agents.
mechanism	However, <e10> ketoconazole </e10> , a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of <e20> mometasone_furoate </e20> during concomitant dosing.
negative	<e10> Montelukast </e10> at a Dose of # mg Once Daily Dosed to Pharmacokinetic Steady State - did not cause clinically significant changes in the kinetics of a single intravenous dose of <e20> theophylline </e20> (predominantly a cytochrome P450 1A2 substrate).
negative	- did not change the plasma concentration profile of <e10> terfenadine </e10> (a substrate of cytochrome P450 3A4) or <e20> fexofenadine </e20> , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine # mg twice daily.
negative	- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or <e10> fexofenadine </e10> , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with <e20> terfenadine </e20> # mg twice daily.
negative	<e10> Montelukast </e10> at Doses of # mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral <e22> contraceptive </e22> containing norethindrone # mg/ethinyl estradiol # mcg.
negative	<e10> Montelukast </e10> at Doses of # mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e20> norethindrone </e20> # mg/ethinyl estradiol # mcg.
negative	<e10> Montelukast </e10> at Doses of # mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone # mg/ethinyl <e20> estradiol </e20> # mcg.
negative	Montelukast at Doses of # mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral <e12> contraceptive </e12> containing <e20> norethindrone </e20> # mg/ethinyl estradiol # mcg.
negative	Montelukast at Doses of # mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral <e12> contraceptive </e12> containing norethindrone # mg/ethinyl <e20> estradiol </e20> # mcg.
negative	Montelukast at Doses of # mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e10> norethindrone </e10> # mg/ethinyl <e20> estradiol </e20> # mcg.
negative	- did not cause any clinically significant change in plasma profiles of <e10> prednisone </e10> or <e20> prednisolone </e20> following administration of either oral prednisone or intravenous prednisolone .
negative	- did not cause any clinically significant change in plasma profiles of <e10> prednisone </e10> or prednisolone following administration of either oral prednisone or intravenous <e20> prednisolone </e20> .
negative	- did not cause any clinically significant change in plasma profiles of prednisone or <e10> prednisolone </e10> following administration of either oral <e20> prednisone </e20> or intravenous prednisolone .
negative	- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral <e10> prednisone </e10> or intravenous <e20> prednisolone </e20> .
negative	<e10> Phenobarbital </e10> , which induces hepatic metabolism, decreased the AUC of <e20> montelukast </e20> approximately 40% following a single 10-mg dose of montelukast .
negative	<e10> Phenobarbital </e10> , which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e20> montelukast </e20> .
negative	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e10> phenobarbital </e10> or <e20> rifampin </e20> , are co-administered with montelukast .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e10> phenobarbital </e10> or rifampin , are co-administered with <e20> montelukast </e20> .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e10> rifampin </e10> , are co-administered with <e20> montelukast </e20> .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: <e20> theophylline </e20> , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e20> prednisone </e20> , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , <e20> prednisolone </e20> , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral <e22> contraceptives </e22> ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( <e20> norethindrone </e20> # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ <e20> ethinyl_estradiol </e20> # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), <e20> terfenadine </e20> , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , <e20> digoxin </e20> , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of <e10> montelukast </e10> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and <e20> warfarin </e20> .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , <e20> prednisone </e20> , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , prednisone , <e20> prednisolone </e20> , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , prednisone , prednisolone , oral contraceptives ( <e20> norethindrone </e20> # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ <e20> ethinyl_estradiol </e20> # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), <e20> terfenadine </e20> , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , <e20> digoxin </e20> , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e10> theophylline </e10> , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and <e20> warfarin </e20> .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e10> prednisone </e10> , <e20> prednisolone </e20> , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e10> prednisone </e10> , prednisolone , oral contraceptives ( <e20> norethindrone </e20> # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e10> prednisone </e10> , prednisolone , oral contraceptives ( norethindrone # mg/ <e20> ethinyl_estradiol </e20> # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e10> prednisone </e10> , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), <e20> terfenadine </e20> , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e10> prednisone </e10> , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , <e20> digoxin </e20> , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , <e10> prednisone </e10> , prednisolone , oral contraceptives ( norethindrone # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and <e20> warfarin </e20> .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , <e10> prednisolone </e10> , oral contraceptives ( <e20> norethindrone </e20> # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , <e10> prednisolone </e10> , oral contraceptives ( norethindrone # mg/ <e20> ethinyl_estradiol </e20> # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral <e12> contraceptives </e12> ( <e20> norethindrone </e20> # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral <e12> contraceptives </e12> ( norethindrone # mg/ <e20> ethinyl_estradiol </e20> # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( <e10> norethindrone </e10> # mg/ <e20> ethinyl_estradiol </e20> # mcg), terfenadine , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( <e10> norethindrone </e10> # mg/ ethinyl_estradiol # mcg), <e20> terfenadine </e20> , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( <e10> norethindrone </e10> # mg/ ethinyl_estradiol # mcg), terfenadine , <e20> digoxin </e20> , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( <e10> norethindrone </e10> # mg/ ethinyl_estradiol # mcg), terfenadine , digoxin , and <e20> warfarin </e20> .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ <e10> ethinyl_estradiol </e10> # mcg), <e20> terfenadine </e20> , digoxin , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ <e10> ethinyl_estradiol </e10> # mcg), terfenadine , <e20> digoxin </e20> , and warfarin .
negative	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone # mg/ <e10> ethinyl_estradiol </e10> # mcg), terfenadine , digoxin , and <e20> warfarin </e20> .
negative	<e10> Phenobarbital </e10> , which induces hepatic metabolism, decreased the AUC of <e20> montelukast </e20> approximately 40% following a single 10-mg dose of montelukast .
negative	<e10> Phenobarbital </e10> , which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e20> montelukast </e20> .
negative	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e10> phenobarbital </e10> or <e20> rifampin </e20> , are co-administered with montelukast .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e10> phenobarbital </e10> or rifampin , are co-administered with <e20> montelukast </e20> .
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e10> rifampin </e10> , are co-administered with <e20> montelukast </e20> .
effect	Use with Other Central_Nervous_System_Depressants : The depressant effects of <e10> morphine </e10> are potentiated by the presence of other <e22> CNS_depressants </e22> such as alcohol , sedatives , antihistaminics , or psychotropic_drugs .
effect	Use with Other Central_Nervous_System_Depressants : The depressant effects of <e10> morphine </e10> are potentiated by the presence of other CNS_depressants such as <e20> alcohol </e20> , sedatives , antihistaminics , or psychotropic_drugs .
effect	Use with Other Central_Nervous_System_Depressants : The depressant effects of <e10> morphine </e10> are potentiated by the presence of other CNS_depressants such as alcohol , <e22> sedatives </e22> , antihistaminics , or psychotropic_drugs .
effect	Use with Other Central_Nervous_System_Depressants : The depressant effects of <e10> morphine </e10> are potentiated by the presence of other CNS_depressants such as alcohol , sedatives , <e22> antihistaminics </e22> , or psychotropic_drugs .
effect	Use with Other Central_Nervous_System_Depressants : The depressant effects of <e10> morphine </e10> are potentiated by the presence of other CNS_depressants such as alcohol , sedatives , antihistaminics , or <e22> psychotropic_drugs </e22> .
negative	Use with Other Central_Nervous_System_Depressants : The depressant effects of morphine are potentiated by the presence of other <e12> CNS_depressants </e12> such as <e20> alcohol </e20> , sedatives , antihistaminics , or psychotropic_drugs .
negative	Use with Other Central_Nervous_System_Depressants : The depressant effects of morphine are potentiated by the presence of other <e12> CNS_depressants </e12> such as alcohol , <e22> sedatives </e22> , antihistaminics , or psychotropic_drugs .
negative	Use with Other Central_Nervous_System_Depressants : The depressant effects of morphine are potentiated by the presence of other <e12> CNS_depressants </e12> such as alcohol , sedatives , <e22> antihistaminics </e22> , or psychotropic_drugs .
negative	Use with Other Central_Nervous_System_Depressants : The depressant effects of morphine are potentiated by the presence of other <e12> CNS_depressants </e12> such as alcohol , sedatives , antihistaminics , or <e22> psychotropic_drugs </e22> .
effect	Use of <e12> neuroleptics </e12> in conjunction with oral <e20> morphine </e20> may increase the risk of respiratory depression, hypotension and profound sedation or coma.
negative	Interaction with <e12> Mixed_Agonist/Antagonist_Opioid_Analgesics </e12> : Agonist/antagonist_analgesics (i,e,, <e20> pentazocine </e20> , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid_agonist_analgesic .
negative	Interaction with <e12> Mixed_Agonist/Antagonist_Opioid_Analgesics </e12> : Agonist/antagonist_analgesics (i,e,, pentazocine , <e20> nalbuphine </e20> , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid_agonist_analgesic .
negative	Interaction with <e12> Mixed_Agonist/Antagonist_Opioid_Analgesics </e12> : Agonist/antagonist_analgesics (i,e,, pentazocine , nalbuphine , <e20> butorphanol </e20> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid_agonist_analgesic .
negative	Interaction with <e12> Mixed_Agonist/Antagonist_Opioid_Analgesics </e12> : Agonist/antagonist_analgesics (i,e,, pentazocine , nalbuphine , butorphanol , or <e20> buprenorphine </e20> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid_agonist_analgesic .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : <e12> Agonist/antagonist_analgesics </e12> (i,e,, pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, <e10> pentazocine </e10> , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, pentazocine , <e10> nalbuphine </e10> , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, pentazocine , nalbuphine , <e10> butorphanol </e10> , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
advise	Interaction with Mixed_Agonist/Antagonist_Opioid_Analgesics : Agonist/antagonist_analgesics (i,e,, pentazocine , nalbuphine , butorphanol , or <e10> buprenorphine </e10> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e22> opioid_agonist_analgesic </e22> .
negative	<e12> Antacids </e12> : Absorption of a single dose of <e21> Myfortic </e21> was decreased when administered to # stable renal transplant patients also taking magnesium - aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	<e12> Antacids </e12> : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking <e20> magnesium </e20> - aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	<e12> Antacids </e12> : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking magnesium - <e20> aluminum </e20> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	<e12> Antacids </e12> : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking magnesium - aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e21> Myfortic </e21> was administered alone under fasting conditions.
mechanism	Antacids : Absorption of a single dose of <e11> Myfortic </e11> was decreased when administered to # stable renal transplant patients also taking <e20> magnesium </e20> - aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
mechanism	Antacids : Absorption of a single dose of <e11> Myfortic </e11> was decreased when administered to # stable renal transplant patients also taking magnesium - <e20> aluminum </e20> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of <e11> Myfortic </e11> was decreased when administered to # stable renal transplant patients also taking magnesium - aluminum containing <e20> antacids </e20> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking <e10> magnesium </e10> - <e20> aluminum </e20> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking <e10> magnesium </e10> - aluminum containing <e20> antacids </e20> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking <e10> magnesium </e10> - aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e21> Myfortic </e21> was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking magnesium - <e10> aluminum </e10> containing <e20> antacids </e20> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking magnesium - <e10> aluminum </e10> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e21> Myfortic </e21> was administered alone under fasting conditions.
negative	Antacids : Absorption of a single dose of Myfortic was decreased when administered to # stable renal transplant patients also taking magnesium - aluminum containing <e10> antacids </e10> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e21> Myfortic </e21> was administered alone under fasting conditions.
advise	It is recommended that <e11> Myfortic </e11> and <e20> antacids </e20> not be administered simultaneously.
negative	Cyclosporine : When studied in stable renal transplant patients, <e10> cyclosporine </e10> , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e21> Myfortic </e21> .
negative	<e10> Acyclovir </e10> / <e20> Ganciclovir </e20> : may be taken with Myfortic ;
negative	<e10> Acyclovir </e10> / Ganciclovir : may be taken with <e21> Myfortic </e21> ;
negative	Acyclovir / <e10> Ganciclovir </e10> : may be taken with <e21> Myfortic </e21> ;
negative	Both <e10> acyclovir </e10> / ganciclovir and <e23> MPAG </e23> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
negative	Both acyclovir / <e10> ganciclovir </e10> and <e23> MPAG </e23> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
negative	<e10> Azathioprine </e10> / <e20> Mycophenolate_Mofetil </e20> : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	<e10> Azathioprine </e10> / Mycophenolate_Mofetil : Given that azathioprine and <e20> mycophenolate_mofetil </e20> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	<e10> Azathioprine </e10> / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e21> Myfortic </e21> not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	<e10> Azathioprine </e10> / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e20> mycophenolate_mofetil </e20> .
negative	Azathioprine / <e10> Mycophenolate_Mofetil </e10> : Given that <e20> azathioprine </e20> and mycophenolate_mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	Azathioprine / <e10> Mycophenolate_Mofetil </e10> : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e21> Myfortic </e21> not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	Azathioprine / <e10> Mycophenolate_Mofetil </e10> : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e20> azathioprine </e20> or mycophenolate_mofetil .
negative	Azathioprine / Mycophenolate_Mofetil : Given that <e10> azathioprine </e10> and <e20> mycophenolate_mofetil </e20> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	Azathioprine / Mycophenolate_Mofetil : Given that <e10> azathioprine </e10> and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e21> Myfortic </e21> not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	Azathioprine / Mycophenolate_Mofetil : Given that <e10> azathioprine </e10> and mycophenolate_mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e20> mycophenolate_mofetil </e20> .
negative	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and <e10> mycophenolate_mofetil </e10> inhibit purine metabolism, it is recommended that <e21> Myfortic </e21> not be administered concomitantly with azathioprine or mycophenolate_mofetil .
negative	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and <e10> mycophenolate_mofetil </e10> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e20> azathioprine </e20> or mycophenolate_mofetil .
advise	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e11> Myfortic </e11> not be administered concomitantly with <e20> azathioprine </e20> or mycophenolate_mofetil .
advise	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that <e11> Myfortic </e11> not be administered concomitantly with azathioprine or <e20> mycophenolate_mofetil </e20> .
negative	Azathioprine / Mycophenolate_Mofetil : Given that azathioprine and mycophenolate_mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e10> azathioprine </e10> or <e20> mycophenolate_mofetil </e20> .
negative	Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e13> MPA </e13> exposure when coadministered with <e20> mycophenolate_mofetil </e20> .
advise	Therefore, do not administer <e11> Myfortic </e11> with <e20> cholestyramine </e20> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated_charcoal , because of the potential to reduce the efficacy of Myfortic .
advise	Therefore, do not administer <e11> Myfortic </e11> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e20> activated_charcoal </e20> , because of the potential to reduce the efficacy of Myfortic .
negative	Therefore, do not administer Myfortic with <e10> cholestyramine </e10> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e20> activated_charcoal </e20> , because of the potential to reduce the efficacy of Myfortic .
negative	Therefore, do not administer Myfortic with <e10> cholestyramine </e10> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated_charcoal , because of the potential to reduce the efficacy of <e21> Myfortic </e21> .
negative	Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e10> activated_charcoal </e10> , because of the potential to reduce the efficacy of <e21> Myfortic </e21> .
negative	Oral <e12> Contraceptives </e12> : Given the different metabolism of <e21> Myfortic </e21> and oral contraceptives , no drug interaction between these two classes of drug is expected.
negative	Oral Contraceptives : Given the different metabolism of <e11> Myfortic </e11> and oral <e22> contraceptives </e22> , no drug interaction between these two classes of drug is expected.
mechanism	However, in a drug-drug interaction study, mean <e10> levonorgesterol </e10> AUC was decreased by 15% when coadministered with <e20> mycophenolate_mofetil </e20> .
advise	Therefore, it is recommended that oral <e12> contraceptives </e12> are co- administered with <e21> Myfortic </e21> with caution and additional birth control methods be considered.
negative	<e12> Live_Vaccines </e12> : During treatment with <e21> Myfortic </e21> , the use of live_attenuated_vaccines should be avoided and patients should be advised that vaccinations may be less effective.
negative	<e12> Live_Vaccines </e12> : During treatment with Myfortic , the use of <e22> live_attenuated_vaccines </e22> should be avoided and patients should be advised that vaccinations may be less effective.
advise	Live_Vaccines : During treatment with <e11> Myfortic </e11> , the use of <e22> live_attenuated_vaccines </e22> should be avoided and patients should be advised that vaccinations may be less effective.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, <e10> phenytoin </e10> , carbamazepine , and rifampicin ), the clearance of <e20> ondansetron </e20> was significantly increased and ondansetron blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, <e10> phenytoin </e10> , carbamazepine , and rifampicin ), the clearance of ondansetron was significantly increased and <e20> ondansetron </e20> blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , <e10> carbamazepine </e10> , and rifampicin ), the clearance of <e20> ondansetron </e20> was significantly increased and ondansetron blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , <e10> carbamazepine </e10> , and rifampicin ), the clearance of ondansetron was significantly increased and <e20> ondansetron </e20> blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , carbamazepine , and <e10> rifampicin </e10> ), the clearance of <e20> ondansetron </e20> was significantly increased and ondansetron blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , carbamazepine , and <e10> rifampicin </e10> ), the clearance of ondansetron was significantly increased and <e20> ondansetron </e20> blood concentrations were decreased.
negative	However, on the basis of available data, no dosage adjustment for <e10> ondansetron </e10> is recommended for patients on these drugs#,3 <e20> Tramadol </e20> : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from # small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol #,5 Chemotherapy: Tumor response to chemotherapy in the P # mouse leukemia model is not affected by ondansetron .
negative	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs#,3 Tramadol : Although no pharmacokinetic drug interaction between <e10> ondansetron </e10> and <e20> tramadol </e20> has been observed, data from # small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol #,5 Chemotherapy: Tumor response to chemotherapy in the P # mouse leukemia model is not affected by ondansetron .
negative	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs#,3 Tramadol : Although no pharmacokinetic drug interaction between <e10> ondansetron </e10> and tramadol has been observed, data from # small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e20> tramadol </e20> #,5 Chemotherapy: Tumor response to chemotherapy in the P # mouse leukemia model is not affected by ondansetron .
negative	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs#,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and <e10> tramadol </e10> has been observed, data from # small studies indicate that <e20> ondansetron </e20> may be associated with an increase in patient controlled administration of tramadol #,5 Chemotherapy: Tumor response to chemotherapy in the P # mouse leukemia model is not affected by ondansetron .
effect	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs#,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from # small studies indicate that <e10> ondansetron </e10> may be associated with an increase in patient controlled administration of <e20> tramadol </e20> #,5 Chemotherapy: Tumor response to chemotherapy in the P # mouse leukemia model is not affected by ondansetron .
negative	In humans, <e10> carmustine </e10> , etoposide , and cisplatin do not affect the pharmacokinetics of <e20> ondansetron </e20> .
negative	In humans, carmustine , <e10> etoposide </e10> , and cisplatin do not affect the pharmacokinetics of <e20> ondansetron </e20> .
negative	In humans, carmustine , etoposide , and <e10> cisplatin </e10> do not affect the pharmacokinetics of <e20> ondansetron </e20> .
negative	<e10> ondansetron </e10> did not increase blood levels of high-dose <e20> methotrexate </e20> .
advise	Other <e12> beta_adrenergic_aerosol_bronchodilators </e12> should not be used concomitantly with <e21> Alupent </e21> ( metaproterenol_sulfate USP) because they may have additive effects.
advise	Other <e12> beta_adrenergic_aerosol_bronchodilators </e12> should not be used concomitantly with Alupent ( <e20> metaproterenol_sulfate </e20> USP) because they may have additive effects.
advise	<e12> Beta_adrenergic_agonists </e12> should be administered with caution to patients being treated with <e22> monoamine_oxidase_inhibitors </e22> or tricyclic_antidepressants , since the action of beta_adrenergic_agonists on the vascular system may be potentiated.
advise	<e12> Beta_adrenergic_agonists </e12> should be administered with caution to patients being treated with monoamine_oxidase_inhibitors or <e22> tricyclic_antidepressants </e22> , since the action of beta_adrenergic_agonists on the vascular system may be potentiated.
negative	Beta_adrenergic_agonists should be administered with caution to patients being treated with <e12> monoamine_oxidase_inhibitors </e12> or <e22> tricyclic_antidepressants </e22> , since the action of beta_adrenergic_agonists on the vascular system may be potentiated.
negative	Beta_adrenergic_agonists should be administered with caution to patients being treated with <e12> monoamine_oxidase_inhibitors </e12> or tricyclic_antidepressants , since the action of <e22> beta_adrenergic_agonists </e22> on the vascular system may be potentiated.
negative	Beta_adrenergic_agonists should be administered with caution to patients being treated with monoamine_oxidase_inhibitors or <e12> tricyclic_antidepressants </e12> , since the action of <e22> beta_adrenergic_agonists </e22> on the vascular system may be potentiated.
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of <e11> XENICAL </e11> and # grams of <e20> alcohol </e20> (e,g,, approximately # glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of <e11> XENICAL </e11> and # grams of alcohol (e,g,, approximately # glasses of wine) did not result in alteration of <e20> alcohol </e20> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of <e11> XENICAL </e11> and # grams of alcohol (e,g,, approximately # glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e20> orlistat </e20> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of <e11> XENICAL </e11> and # grams of alcohol (e,g,, approximately # glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e20> orlistat </e20> .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of XENICAL and # grams of <e10> alcohol </e10> (e,g,, approximately # glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e20> orlistat </e20> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of XENICAL and # grams of <e10> alcohol </e10> (e,g,, approximately # glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e20> orlistat </e20> .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of XENICAL and # grams of alcohol (e,g,, approximately # glasses of wine) did not result in alteration of <e10> alcohol </e10> pharmacokinetics, <e20> orlistat </e20> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat .
negative	Alcohol : In a multiple-dose study in # normal weight subjects, coadministration of XENICAL and # grams of alcohol (e,g,, approximately # glasses of wine) did not result in alteration of <e10> alcohol </e10> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e20> orlistat </e20> .
negative	Cyclosporine : Preliminary data from a <e11> XENICAL </e11> and <e20> cyclosporine </e20> drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine .
negative	Cyclosporine : Preliminary data from a <e11> XENICAL </e11> and cyclosporine drug interaction study indicate a reduction in <e20> cyclosporine </e20> plasma levels when XENICAL was coadministered with cyclosporine .
negative	Cyclosporine : Preliminary data from a <e11> XENICAL </e11> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with <e20> cyclosporine </e20> .
negative	Cyclosporine : Preliminary data from a XENICAL and <e10> cyclosporine </e10> drug interaction study indicate a reduction in cyclosporine plasma levels when <e21> XENICAL </e21> was coadministered with cyclosporine .
negative	Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in <e10> cyclosporine </e10> plasma levels when <e21> XENICAL </e21> was coadministered with cyclosporine .
mechanism	Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e11> XENICAL </e11> was coadministered with <e20> cyclosporine </e20> .
negative	Digoxin : In # normal-weight subjects receiving <e11> XENICAL </e11> # mg three times a day for # days, XENICAL did not alter the pharmacokinetics of a single dose of <e20> digoxin </e20> .
negative	Digoxin : In # normal-weight subjects receiving XENICAL # mg three times a day for # days, <e11> XENICAL </e11> did not alter the pharmacokinetics of a single dose of <e20> digoxin </e20> .
mechanism	Fat-soluble_Vitamin_Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in <e10> beta-carotene </e10> supplement absorption when concomitantly administered with <e21> XENICAL </e21> .
mechanism	<e11> XENICAL </e11> inhibited absorption of a <e20> vitamin_E_acetate </e20> supplement by approximately 60%.
negative	The effect of <e10> orlistat </e10> on the absorption of supplemental <e22> vitamin_D </e22> , vitamin_A , and nutritionally-derived vitamin_K is not known at this time.
negative	The effect of <e10> orlistat </e10> on the absorption of supplemental vitamin_D , <e22> vitamin_A </e22> , and nutritionally-derived vitamin_K is not known at this time.
negative	The effect of <e10> orlistat </e10> on the absorption of supplemental vitamin_D , vitamin_A , and nutritionally-derived <e22> vitamin_K </e22> is not known at this time.
negative	The effect of orlistat on the absorption of supplemental <e12> vitamin_D </e12> , <e22> vitamin_A </e22> , and nutritionally-derived vitamin_K is not known at this time.
negative	The effect of orlistat on the absorption of supplemental <e12> vitamin_D </e12> , vitamin_A , and nutritionally-derived <e22> vitamin_K </e22> is not known at this time.
negative	The effect of orlistat on the absorption of supplemental vitamin_D , <e12> vitamin_A </e12> , and nutritionally-derived <e22> vitamin_K </e22> is not known at this time.
negative	Glyburide : In # normal-weight subjects receiving <e10> orlistat </e10> # mg three times a day for # days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e20> glyburide </e20> .
negative	Glyburide : In # normal-weight subjects receiving orlistat # mg three times a day for # days, <e10> orlistat </e10> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e20> glyburide </e20> .
negative	Nifedipine (extended-release tablets): In # normal-weight subjects receiving <e11> XENICAL </e11> # mg three times a day for # days, XENICAL did not alter the bioavailability of <e20> nifedipine </e20> (extended-release tablets).
negative	Nifedipine (extended-release tablets): In # normal-weight subjects receiving XENICAL # mg three times a day for # days, <e11> XENICAL </e11> did not alter the bioavailability of <e20> nifedipine </e20> (extended-release tablets).
negative	Oral Contraceptives : In # normal-weight female subjects, the treatment of <e11> XENICAL </e11> # mg three times a day for # days resulted in no changes in the ovulation-suppressing action of oral <e22> contraceptives </e22> .
negative	Phenytoin : In # normal-weight subjects receiving <e11> XENICAL </e11> # mg three times a day for # days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of <e20> phenytoin </e20> .
negative	Phenytoin : In # normal-weight subjects receiving XENICAL # mg three times a day for # days, <e11> XENICAL </e11> did not alter the pharmacokinetics of a single 300-mg dose of <e20> phenytoin </e20> .
negative	Pravastatin : In a 2-way crossover study of # normal-weight, mildly hypercholesterolemic patients receiving <e11> XENICAL </e11> # mg three times a day for # days, XENICAL did not affect the pharmacokinetics of <e20> pravastatin </e20> .
negative	Pravastatin : In a 2-way crossover study of # normal-weight, mildly hypercholesterolemic patients receiving XENICAL # mg three times a day for # days, <e11> XENICAL </e11> did not affect the pharmacokinetics of <e20> pravastatin </e20> .
negative	<e10> Warfarin </e10> : In # normal-weight subjects, administration of <e21> XENICAL </e21> # mg three times a day for # days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
negative	Warfarin : In # normal-weight subjects, administration of <e11> XENICAL </e11> # mg three times a day for # days did not result in any change in either <e20> warfarin </e20> pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
mechanism	Therefore, as <e12> vitamin_K </e12> absorption may be decreased with <e21> XENICAL </e21> , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
negative	Therefore, as <e12> vitamin_K </e12> absorption may be decreased with XENICAL , patients on chronic stable doses of <e20> warfarin </e20> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
negative	Therefore, as <e12> vitamin_K </e12> absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed <e21> XENICAL </e21> should be monitored closely for changes in coagulation parameters.
negative	Therefore, as vitamin_K absorption may be decreased with <e11> XENICAL </e11> , patients on chronic stable doses of <e20> warfarin </e20> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
advise	Therefore, as vitamin_K absorption may be decreased with XENICAL , patients on chronic stable doses of <e10> warfarin </e10> who are prescribed <e21> XENICAL </e21> should be monitored closely for changes in coagulation parameters.
negative	<e12> Tetracycline </e12> , a bacteriostatic <e22> antibiotic </e22> , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
effect	<e12> Tetracycline </e12> , a bacteriostatic antibiotic , may antagonize the bactericidal effect of <e20> penicillin </e20> and concurrent use of these drugs should be avoided.
negative	Tetracycline , a bacteriostatic <e12> antibiotic </e12> , may antagonize the bactericidal effect of <e20> penicillin </e20> and concurrent use of these drugs should be avoided.
negative	No pharmacokinetic interaction between # mg/m2 <e11> ELOXATIN </e11> and infusional <e20> 5-FU </e20> has been observed in patients treated every # weeks.
mechanism	Increases of <e10> 5-FU </e10> plasma concentrations by approximately 20% have been observed with doses of # mg/m2 <e21> ELOXATIN </e21> dosed every # weeks.
negative	<e12> Anticoagulants </e12> <e20> Anabolic_steroids </e20> may increase sensitivity to oral anticoagulants .
effect	Anticoagulants <e10> Anabolic_steroids </e10> may increase sensitivity to oral <e22> anticoagulants </e22> .
mechanism	Warfarin : A multidose study of <e10> oxandrolone </e10> , given as # or # mg BID in # healthy subjects concurrently treated with <e20> warfarin </e20> , resulted in a mean increase in S-warfarin half-life from # to # hours and AUC from # to # ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
negative	Warfarin : A multidose study of <e10> oxandrolone </e10> , given as # or # mg BID in # healthy subjects concurrently treated with warfarin , resulted in a mean increase in <e20> S-warfarin </e20> half-life from # to # hours and AUC from # to # ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
negative	Warfarin : A multidose study of <e10> oxandrolone </e10> , given as # or # mg BID in # healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from # to # hours and AUC from # to # ng*hr/mL: similar increases in <e20> R-warfarin </e20> half-life and AUC were also detected.
negative	Warfarin : A multidose study of oxandrolone , given as # or # mg BID in # healthy subjects concurrently treated with warfarin , resulted in a mean increase in <e10> S-warfarin </e10> half-life from # to # hours and AUC from # to # ng*hr/mL: similar increases in <e20> R-warfarin </e20> half-life and AUC were also detected.
advise	When <e10> oxandrolone </e10> therapy is initiated in a patient already receiving treatment with <e20> warfarin </e20> , the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
negative	When <e10> oxandrolone </e10> therapy is initiated in a patient already receiving treatment with warfarin , the INR or prothrombin time (PT) should be monitored closely and the dose of <e20> warfarin </e20> adjusted as necessary until a stable target INR or PT has been achieved.
advise	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the <e10> warfarin </e10> dosage if indicated are recommended when the <e20> oxandrolone </e20> dose is changed or discontinued.
negative	Oral <e12> hypoglycemic_agents </e12> <e20> Oxandrolone </e20> may inhibit the metabolism of oral hypoglycemic_agents .
mechanism	Oral hypoglycemic_agents <e10> Oxandrolone </e10> may inhibit the metabolism of oral <e22> hypoglycemic_agents </e22> .
negative	<e12> Adrenal_steroids </e12> or <e20> ACTH </e20> In patients with edema, concomitant administration with adrenal_cortical_steroids or ACTH may increase the edema.
negative	<e12> Adrenal_steroids </e12> or ACTH In patients with edema, concomitant administration with <e22> adrenal_cortical_steroids </e22> or ACTH may increase the edema.
negative	<e12> Adrenal_steroids </e12> or ACTH In patients with edema, concomitant administration with adrenal_cortical_steroids or <e20> ACTH </e20> may increase the edema.
negative	Adrenal_steroids or <e10> ACTH </e10> In patients with edema, concomitant administration with <e22> adrenal_cortical_steroids </e22> or ACTH may increase the edema.
negative	Adrenal_steroids or ACTH In patients with edema, concomitant administration with <e12> adrenal_cortical_steroids </e12> or <e20> ACTH </e20> may increase the edema.
effect	The concomitant use of <e10> oxybutynin </e10> with other <e22> anticholinergic_drugs </e22> or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
negative	Mean <e10> oxybutynin_chloride </e10> plasma concentrations were approximately # fold higher when <e21> DITROPAN_XL </e21> was administered with ketoconazole , a potent CYP3A4 inhibitor.
negative	Mean <e10> oxybutynin_chloride </e10> plasma concentrations were approximately # fold higher when DITROPAN_XL was administered with <e20> ketoconazole </e20> , a potent CYP3A4 inhibitor.
mechanism	Mean oxybutynin_chloride plasma concentrations were approximately # fold higher when <e11> DITROPAN_XL </e11> was administered with <e20> ketoconazole </e20> , a potent CYP3A4 inhibitor.
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e12> antimycotic_agents </e12> (e,g,, itraconazole and miconazole ) or <e22> macrolide_antibiotics </e22> (e,g,, erythromycin and clarithromycin ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e12> antimycotic_agents </e12> (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, <e20> erythromycin </e20> and clarithromycin ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e12> antimycotic_agents </e12> (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and <e20> clarithromycin </e20> ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e12> antimycotic_agents </e12> (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, <e10> itraconazole </e10> and miconazole ) or <e22> macrolide_antibiotics </e22> (e,g,, erythromycin and clarithromycin ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, <e10> itraconazole </e10> and miconazole ) or macrolide_antibiotics (e,g,, <e20> erythromycin </e20> and clarithromycin ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, <e10> itraconazole </e10> and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and <e20> clarithromycin </e20> ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, <e10> itraconazole </e10> and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and <e10> miconazole </e10> ) or <e22> macrolide_antibiotics </e22> (e,g,, erythromycin and clarithromycin ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and <e10> miconazole </e10> ) or macrolide_antibiotics (e,g,, <e20> erythromycin </e20> and clarithromycin ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and <e10> miconazole </e10> ) or macrolide_antibiotics (e,g,, erythromycin and <e20> clarithromycin </e20> ), may alter oxybutynin mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and <e10> miconazole </e10> ) or macrolide_antibiotics (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and miconazole ) or <e12> macrolide_antibiotics </e12> (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, <e10> erythromycin </e10> and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and <e10> clarithromycin </e10> ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
negative	Concurrent ingestion of <e12> antacid </e12> (20 mL of antacid containing aluminum_hydroxide , magnesium_hydroxide , and simethicone ) did not significantly affect the exposure of <e20> oxybutynin </e20> or desethyloxybutynin .
negative	Concurrent ingestion of <e12> antacid </e12> (20 mL of antacid containing aluminum_hydroxide , magnesium_hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or <e23> desethyloxybutynin </e23> .
negative	Concurrent ingestion of antacid (20 mL of <e12> antacid </e12> containing aluminum_hydroxide , magnesium_hydroxide , and simethicone ) did not significantly affect the exposure of <e20> oxybutynin </e20> or desethyloxybutynin .
negative	Concurrent ingestion of antacid (20 mL of <e12> antacid </e12> containing aluminum_hydroxide , magnesium_hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or <e23> desethyloxybutynin </e23> .
negative	Concurrent ingestion of antacid (20 mL of antacid containing <e10> aluminum_hydroxide </e10> , magnesium_hydroxide , and simethicone ) did not significantly affect the exposure of <e20> oxybutynin </e20> or desethyloxybutynin .
negative	Concurrent ingestion of antacid (20 mL of antacid containing <e10> aluminum_hydroxide </e10> , magnesium_hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or <e23> desethyloxybutynin </e23> .
negative	Concurrent ingestion of antacid (20 mL of antacid containing aluminum_hydroxide , <e10> magnesium_hydroxide </e10> , and simethicone ) did not significantly affect the exposure of <e20> oxybutynin </e20> or desethyloxybutynin .
negative	Concurrent ingestion of antacid (20 mL of antacid containing aluminum_hydroxide , <e10> magnesium_hydroxide </e10> , and simethicone ) did not significantly affect the exposure of oxybutynin or <e23> desethyloxybutynin </e23> .
negative	Concurrent ingestion of antacid (20 mL of antacid containing aluminum_hydroxide , magnesium_hydroxide , and <e10> simethicone </e10> ) did not significantly affect the exposure of <e20> oxybutynin </e20> or desethyloxybutynin .
negative	Concurrent ingestion of antacid (20 mL of antacid containing aluminum_hydroxide , magnesium_hydroxide , and <e10> simethicone </e10> ) did not significantly affect the exposure of oxybutynin or <e23> desethyloxybutynin </e23> .
effect	The CNS depressant effects of <e10> oxycodone_hydrochloride </e10> may be additive with that of other <e22> CNS_depressants </e22> ,.
negative	The concomitant use of other <e12> CNS_depressants </e12> including <e22> sedatives </e22> , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , <e22> hypnotics </e22> , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , <e22> tranquilizers </e22> , general anesthetics , phenothiazines , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , tranquilizers , general <e22> anesthetics </e22> , phenothiazines , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , tranquilizers , general anesthetics , <e22> phenothiazines </e22> , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other <e22> opioids </e22> , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , <e22> tricyclic_antidepressants </e22> , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic_antidepressants , <e22> monoamine_oxidase_(MAO)_inhibitors </e22> , and alcohol may produce additive CNS depressant effects.
negative	The concomitant use of other <e12> CNS_depressants </e12> including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and <e20> alcohol </e20> may produce additive CNS depressant effects.
negative	The concomitant use of other CNS_depressants including sedatives , <e12> hypnotics </e12> , <e22> tranquilizers </e22> , general anesthetics , phenothiazines , other opioids , tricyclic_antidepressants , monoamine_oxidase_(MAO)_inhibitors , and alcohol may produce additive CNS depressant effects.
effect	<e12> Anticholinergics </e12> or other medications with anticholinergic activity when used concurrently with <e22> opioid_analgesics </e22> may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
effect	It has been reported that the incidence of bradycardia was increased when <e10> oxymorphone </e10> was combined with <e20> propofol </e20> for induction of anesthesia.
effect	In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of <e10> cimetidine </e10> with <e22> opioid_analgesics </e22> ;
negative	Potential for <e11> INVEGA </e11> to Affect Other Drugs <e20> Paliperidone </e20> is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.
negative	Given the primary CNS effects of <e10> paliperidone </e10> , <e21> INVEGA </e21> should be used with caution in combination with other centrally_acting_drugs and alcohol .
advise	Given the primary CNS effects of <e10> paliperidone </e10> , INVEGA should be used with caution in combination with other <e22> centrally_acting_drugs </e22> and alcohol .
advise	Given the primary CNS effects of <e10> paliperidone </e10> , INVEGA should be used with caution in combination with other centrally_acting_drugs and <e20> alcohol </e20> .
advise	Given the primary CNS effects of paliperidone , <e11> INVEGA </e11> should be used with caution in combination with other <e22> centrally_acting_drugs </e22> and alcohol .
advise	Given the primary CNS effects of paliperidone , <e11> INVEGA </e11> should be used with caution in combination with other centrally_acting_drugs and <e20> alcohol </e20> .
negative	Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other <e12> centrally_acting_drugs </e12> and <e20> alcohol </e20> .
effect	<e10> Paliperidone </e10> may antagonize the effect of <e20> levodopa </e20> and other dopamine_agonists .
effect	<e10> Paliperidone </e10> may antagonize the effect of levodopa and other <e22> dopamine_agonists </e22> .
negative	Paliperidone may antagonize the effect of <e10> levodopa </e10> and other <e22> dopamine_agonists </e22> .
negative	Potential for Other Drugs to Affect <e11> INVEGA </e11> <e20> Paliperidone </e20> is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: <e20> theophylline </e20> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e20> cisapride </e20> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e20> antipyrine </e20> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e20> caffeine </e20> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e20> carbamazepine </e20> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e20> diazepam </e20> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e23> desmethyldiazepam </e23> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e20> diclofenac </e20> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e20> naproxen </e20> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e20> piroxicam </e20> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e20> digoxin </e20> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e20> ethanol </e20> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e20> glyburide </e20> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of <e10> pantoprazole </e10> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e10> theophylline </e10> , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , <e10> cisapride </e10> , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , <e10> antipyrine </e10> , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , <e10> caffeine </e10> , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , <e10> carbamazepine </e10> , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , <e10> diazepam </e10> (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, <e13> desmethyldiazepam </e13> ), diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), <e10> diclofenac </e10> , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , <e10> naproxen </e10> , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , <e10> piroxicam </e10> , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , <e10> digoxin </e10> , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , <e10> ethanol </e10> , glyburide , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral <e22> contraceptive </e22> ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( <e20> levonorgestrel </e20> / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / <e20> ethinyl_estradiol </e20> ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), <e20> metoprolol </e20> , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , <e20> nifedipine </e20> , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , <e20> phenytoin </e20> , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , <e20> warfarin </e20> , midazolam , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , <e20> midazolam </e20> , clarithromycin , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , <e20> clarithromycin </e20> , metronidazole , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , <e20> metronidazole </e20> , or amoxicillin .
negative	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam (and its active metabolite, desmethyldiazepam ), diclofenac , naproxen , piroxicam , digoxin , ethanol , <e10> glyburide </e10> , an oral contraceptive ( levonorgestrel / ethinyl_estradiol ), metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or <e20> amoxicillin </e20> .
negative	There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e12> proton_pump_inhibitors </e12> , including <e20> pantoprazole </e20> , and warfarin concomitantly.
effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e12> proton_pump_inhibitors </e12> , including pantoprazole , and <e20> warfarin </e20> concomitantly.
effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton_pump_inhibitors , including <e10> pantoprazole </e10> , and <e20> warfarin </e20> concomitantly.
advise	Patients treated with <e12> proton_pump_inhibitors </e12> and <e20> warfarin </e20> concomitantly should be monitored for increases in INR and prothrombin time.
mechanism	Because of profound and long lasting inhibition of gastric acid secretion, <e10> pantoprazole </e10> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e20> ketoconazole </e20> , ampicillin esters, and iron salts).
mechanism	Because of profound and long lasting inhibition of gastric acid secretion, <e10> pantoprazole </e10> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole , <e20> ampicillin </e20> esters, and iron salts).
mechanism	Because of profound and long lasting inhibition of gastric acid secretion, <e10> pantoprazole </e10> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole , ampicillin esters, and <e20> iron </e20> salts).
negative	Laboratory Tests There have been reports of false-positive urine screening tests for <e10> tetrahydrocannabinol </e10> ( THC ) in patients receiving most <e22> proton_pump_inhibitors </e22> , including pantoprazole .
negative	Laboratory Tests There have been reports of false-positive urine screening tests for <e10> tetrahydrocannabinol </e10> ( THC ) in patients receiving most proton_pump_inhibitors , including <e20> pantoprazole </e20> .
negative	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e10> THC </e10> ) in patients receiving most <e22> proton_pump_inhibitors </e22> , including pantoprazole .
negative	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e10> THC </e10> ) in patients receiving most proton_pump_inhibitors , including <e20> pantoprazole </e20> .
negative	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving most <e12> proton_pump_inhibitors </e12> , including <e20> pantoprazole </e20> .
mechanism	A multiple dose drug-drug interaction study demonstrated that <e10> ketoconazole </e10> approximately doubled <e20> paricalcitol </e20> AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and <e20> ketoconazole </e20> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e20> ketoconazole </e20> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e20> atazanavir </e20> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e20> clarithromycin </e20> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e20> indinavir </e20> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e20> itraconazole </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since <e10> paricalcitol </e10> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e20> voriconazole </e20> .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e20> paricalcitol </e20> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e20> atazanavir </e20> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e20> clarithromycin </e20> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e20> indinavir </e20> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e20> itraconazole </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and <e10> ketoconazole </e10> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e20> voriconazole </e20> .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with <e20> ketoconazole </e20> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including <e20> atazanavir </e20> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , <e20> clarithromycin </e20> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e20> indinavir </e20> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e20> itraconazole </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> or voriconazole .
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e10> paricalcitol </e10> with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e20> voriconazole </e20> .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including <e20> atazanavir </e20> , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , <e20> clarithromycin </e20> , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , <e20> indinavir </e20> , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , <e20> itraconazole </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> or voriconazole .
negative	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e10> ketoconazole </e10> and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or <e20> voriconazole </e20> .
advise	Dose adjustment of <e11> Zemplar </e11> Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as <e20> ketoconazole </e20> .
mechanism	Drugs that impair intestinal absorption of <e12> fat-soluble_vitamins </e12> , such as <e20> cholestyramine </e20> , may interfere with the absorption of Zemplar Capsules.
negative	Drugs that impair intestinal absorption of <e12> fat-soluble_vitamins </e12> , such as cholestyramine , may interfere with the absorption of <e21> Zemplar </e21> Capsules.
mechanism	Drugs that impair intestinal absorption of fat-soluble_vitamins , such as <e10> cholestyramine </e10> , may interfere with the absorption of <e21> Zemplar </e21> Capsules.
advise	patients receiving <e10> lithium </e10> and <e21> Neulasta </e21> should have more frequent monitoring of neutrophil counts.
mechanism	In a pharmacokinetic study of # chronic hepatitis C patients concomitantly receiving <e10> methadone </e10> , treatment with <e21> PEG-Intron </e21> once weekly for # weeks was associated with a mean increase of 16% in methadone AUC;
negative	In a pharmacokinetic study of # chronic hepatitis C patients concomitantly receiving methadone , treatment with <e11> PEG-Intron </e11> once weekly for # weeks was associated with a mean increase of 16% in <e20> methadone </e20> AUC;
negative	Acromegalic patients with diabetes mellitus being treated with <e10> insulin </e10> and/or oral <e22> hypoglycemic </e22> agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT .
advise	Acromegalic patients with diabetes mellitus being treated with <e10> insulin </e10> and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e21> SOMAVERT </e21> .
advise	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral <e12> hypoglycemic </e12> agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e21> SOMAVERT </e21> .
mechanism	In clinical studies, patients on <e12> opioids </e12> often needed higher serum <e20> pegvisomant </e20> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids .
negative	In clinical studies, patients on opioids often needed higher serum <e10> pegvisomant </e10> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving <e22> opioids </e22> .
mechanism	Concomitant administration of substances that are also tubularly secreted (e,g,, <e10> probenecid </e10> ) could potentially result in delayed clearance of <e21> ALIMTA </e21> .
negative	Although <e10> ibuprofen </e10> (400 mg qid) can be administered with <e21> ALIMTA </e21> in patients with normal renal function (creatinine clearance # mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from # to # mL/min).
negative	Although <e10> ibuprofen </e10> (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance # mL/min), caution should be used when administering ibuprofen concurrently with <e21> ALIMTA </e21> to patients with mild to moderate renal insufficiency (creatinine clearance from # to # mL/min).
negative	Although ibuprofen (400 mg qid) can be administered with <e11> ALIMTA </e11> in patients with normal renal function (creatinine clearance # mL/min), caution should be used when administering <e20> ibuprofen </e20> concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from # to # mL/min).
advise	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance # mL/min), caution should be used when administering <e10> ibuprofen </e10> concurrently with <e21> ALIMTA </e21> to patients with mild to moderate renal insufficiency (creatinine clearance from # to # mL/min).
advise	Patients with mild to moderate renal insufficiency should avoid taking <e12> NSAIDs </e12> with short elimination half-lives for a period of # days before, the day of, and # days following administration of <e21> ALIMTA </e21> .
negative	In the absence of data regarding potential interaction between <e11> ALIMTA </e11> and <e22> NSAIDs </e22> with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least # days before, the day of, and # days following ALIMTA administration.
negative	In the absence of data regarding potential interaction between <e11> ALIMTA </e11> and NSAIDs with longer half-lives, all patients taking these <e22> NSAIDs </e22> should interrupt dosing for at least # days before, the day of, and # days following ALIMTA administration.
negative	In the absence of data regarding potential interaction between ALIMTA and <e12> NSAIDs </e12> with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least # days before, the day of, and # days following <e21> ALIMTA </e21> administration.
advise	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these <e12> NSAIDs </e12> should interrupt dosing for at least # days before, the day of, and # days following <e21> ALIMTA </e21> administration.
effect	Decreased seizure threshold has been reported in patients receiving <e11> CYLERT </e11> concomitantly with <e22> antiepileptic_medications </e22> .
effect	Concurrent administration of <e12> bacteriostatic_antibiotics </e12> (e,g,, erythromycin , tetracycline ) may diminish the bactericidal effects of <e22> penicillins </e22> by slowing the rate of bacterial growth.
effect	Concurrent administration of bacteriostatic_antibiotics (e,g,, <e10> erythromycin </e10> , tetracycline ) may diminish the bactericidal effects of <e22> penicillins </e22> by slowing the rate of bacterial growth.
effect	Concurrent administration of bacteriostatic_antibiotics (e,g,, erythromycin , <e10> tetracycline </e10> ) may diminish the bactericidal effects of <e22> penicillins </e22> by slowing the rate of bacterial growth.
mechanism	<e12> Penicillin </e12> blood levels may be prolonged by concurrent administration of <e20> probenecid </e20> which blocks the renal tubular secretion of penicillins .
negative	Penicillin blood levels may be prolonged by concurrent administration of <e10> probenecid </e10> which blocks the renal tubular secretion of <e22> penicillins </e22> .
advise	Usage with Alcohol : Due to the potential for increased CNS depressants effects, <e10> alcohol </e10> should be used with caution in patients who are currently receiving <e20> pentazocine </e20> .
effect	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e11> TRENTAL </e11> with and without <e22> anticoagulants </e22> or platelet_aggregation_inhibitors .
effect	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e11> TRENTAL </e11> with and without anticoagulants or <e22> platelet_aggregation_inhibitors </e22> .
negative	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without <e12> anticoagulants </e12> or <e22> platelet_aggregation_inhibitors </e22> .
mechanism	Concomitant administration of <e11> TRENTAL </e11> and <e20> theophylline </e20> -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
negative	Concomitant administration of <e11> TRENTAL </e11> and theophylline -containing drugs leads to increased <e20> theophylline </e20> levels and theophylline toxicity in some individuals.
negative	Concomitant administration of <e11> TRENTAL </e11> and theophylline -containing drugs leads to increased theophylline levels and <e20> theophylline </e20> toxicity in some individuals.
negative	<e11> TRENTAL </e11> has been used concurrently with <e22> antihypertensive_drugs </e22> , beta_blockers , digitalis , diuretics , antidiabetic_agents , and antiarrhythmics , without observed problems.
negative	<e11> TRENTAL </e11> has been used concurrently with antihypertensive_drugs , <e22> beta_blockers </e22> , digitalis , diuretics , antidiabetic_agents , and antiarrhythmics , without observed problems.
negative	<e11> TRENTAL </e11> has been used concurrently with antihypertensive_drugs , beta_blockers , <e22> digitalis </e22> , diuretics , antidiabetic_agents , and antiarrhythmics , without observed problems.
negative	<e11> TRENTAL </e11> has been used concurrently with antihypertensive_drugs , beta_blockers , digitalis , <e22> diuretics </e22> , antidiabetic_agents , and antiarrhythmics , without observed problems.
negative	<e11> TRENTAL </e11> has been used concurrently with antihypertensive_drugs , beta_blockers , digitalis , diuretics , <e22> antidiabetic_agents </e22> , and antiarrhythmics , without observed problems.
negative	<e11> TRENTAL </e11> has been used concurrently with antihypertensive_drugs , beta_blockers , digitalis , diuretics , antidiabetic_agents , and <e22> antiarrhythmics </e22> , without observed problems.
negative	<e12> Dopamine_antagonists </e12> , such as the <e22> neuroleptics </e22> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
negative	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( <e22> phenothiazines </e22> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
negative	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , <e22> butyrophenones </e22> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
negative	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , <e22> thioxanthines </e22> ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
negative	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e22> metoclopramide </e22> , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
advise	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
negative	<e12> Dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e22> dopamine_agonist </e22> );
negative	Dopamine_antagonists , such as the <e12> neuroleptics </e12> ( phenothiazines , butyrophenones , thioxanthines ) or <e22> metoclopramide </e22> , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
advise	Dopamine_antagonists , such as the <e12> neuroleptics </e12> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
negative	Dopamine_antagonists , such as the <e12> neuroleptics </e12> ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e22> dopamine_agonist </e22> );
negative	Dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthines ) or <e22> metoclopramide </e22> , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
negative	Dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e22> dopamine_agonist </e22> );
negative	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthines ) or <e22> metoclopramide </e22> , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
negative	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e22> dopamine_agonist </e22> );
negative	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthines </e12> ) or <e22> metoclopramide </e22> , ordinarily should not be administered concurrently with Permax (a dopamine_agonist );
advise	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthines </e12> ) or metoclopramide , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
negative	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthines </e12> ) or metoclopramide , ordinarily should not be administered concurrently with Permax (a <e22> dopamine_agonist </e22> );
advise	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e12> metoclopramide </e12> , ordinarily should not be administered concurrently with <e21> Permax </e21> (a dopamine_agonist );
negative	Dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or <e12> metoclopramide </e12> , ordinarily should not be administered concurrently with Permax (a <e22> dopamine_agonist </e22> );
negative	<e12> Diuretics </e12> : Patients on diuretics , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of <e21> ACEON </e21> Tablets therapy.
effect	Diuretics : Patients on <e12> diuretics </e12> , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of <e21> ACEON </e21> Tablets therapy.
effect	The possibility of hypotensive effects can be minimized by either discontinuing the <e12> diuretic </e12> or increasing the salt intake prior to initiation of treatment with <e20> perindopril </e20> .
advise	If <e12> diuretics </e12> cannot be interrupted, close medical supervision should be provided with the first dose of <e21> ACEON </e21> Tablets, for at least two hours and until blood pressure has stabilized for another hour.
negative	The rate and extent of <e10> perindopril </e10> absorption and elimination are not affected by concomitant <e22> diuretics </e22> .
negative	The bioavailability of <e13> perindoprilat </e13> was reduced by <e22> diuretics </e22> , however, and this was associated with a decrease in plasma ACE inhibition.
negative	<e10> Potassium </e10> Supplements and Potassium-Sparing_Diuretics : <e21> ACEON </e21> Tablets may increase serum potassium because of its potential to decrease aldosterone production.
negative	Potassium Supplements and <e12> Potassium-Sparing_Diuretics </e12> : <e21> ACEON </e21> Tablets may increase serum potassium because of its potential to decrease aldosterone production.
negative	Use of <e12> potassium-sparing_diuretics </e12> ( spironolactone , amiloride , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e20> indomethacin </e20> , heparin , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of <e12> potassium-sparing_diuretics </e12> ( spironolactone , amiloride , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e20> heparin </e20> , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of <e12> potassium-sparing_diuretics </e12> ( spironolactone , amiloride , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e20> cyclosporine </e20> and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( <e10> spironolactone </e10> , amiloride , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e20> indomethacin </e20> , heparin , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( <e10> spironolactone </e10> , amiloride , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e20> heparin </e20> , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( <e10> spironolactone </e10> , amiloride , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e20> cyclosporine </e20> and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , <e10> amiloride </e10> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e20> indomethacin </e20> , heparin , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , <e10> amiloride </e10> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e20> heparin </e20> , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , <e10> amiloride </e10> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e20> cyclosporine </e20> and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , amiloride , <e10> triamterene </e10> and others), potassium supplements or other drugs capable of increasing serum potassium ( <e20> indomethacin </e20> , heparin , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , amiloride , <e10> triamterene </e10> and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , <e20> heparin </e20> , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , amiloride , <e10> triamterene </e10> and others), potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e20> cyclosporine </e20> and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , amiloride , triamterene and others), <e10> potassium </e10> supplements or other drugs capable of increasing serum potassium ( <e20> indomethacin </e20> , heparin , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , amiloride , triamterene and others), <e10> potassium </e10> supplements or other drugs capable of increasing serum potassium ( indomethacin , <e20> heparin </e20> , cyclosporine and others) can increase the risk of hyperkalemia.
negative	Use of potassium-sparing_diuretics ( spironolactone , amiloride , triamterene and others), <e10> potassium </e10> supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , <e20> cyclosporine </e20> and others) can increase the risk of hyperkalemia.
negative	Use of a <e12> diuretic </e12> may further increase the risk of <e20> lithium </e20> toxicity.
negative	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma <e10> digoxin </e10> concentrations when coadministered with <e21> ACEON </e21> Tablets, but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded.
negative	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma <e10> digoxin </e10> concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of <e20> perindopril </e20> / perindoprilat has not been excluded.
negative	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma <e10> digoxin </e10> concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of perindopril / <e23> perindoprilat </e23> has not been excluded.
negative	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e11> ACEON </e11> Tablets, but an effect of <e20> digoxin </e20> on the plasma concentration of perindopril / perindoprilat has not been excluded.
negative	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e11> ACEON </e11> Tablets, but an effect of digoxin on the plasma concentration of <e20> perindopril </e20> / perindoprilat has not been excluded.
negative	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e11> ACEON </e11> Tablets, but an effect of digoxin on the plasma concentration of perindopril / <e23> perindoprilat </e23> has not been excluded.
mechanism	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of <e10> digoxin </e10> on the plasma concentration of <e20> perindopril </e20> / perindoprilat has not been excluded.
mechanism	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of <e10> digoxin </e10> on the plasma concentration of perindopril / <e23> perindoprilat </e23> has not been excluded.
int	Gentamicin : Animal data have suggested the possibility of interaction between <e10> perindopril </e10> and <e20> gentamicin </e20> .
negative	Food Interaction: Oral administration of <e11> ACEON </e11> Tablets with food does not significantly lower the rate or extent of <e20> perindopril </e20> absorption relative to the fasted state.
int	Concomitant use of <e10> alcohol </e10> with <e20> phentermine_hydrochloride </e20> may result in an adverse drug interaction.
negative	<e12> Vasopressors </e12> , particularly <e20> metaraminol </e20> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
effect	<e12> Vasopressors </e12> , particularly metaraminol , may cause serious cardiac arrhythmias during <e20> halothane </e20> anesthesia and therefore should be used only with great caution or not at all.
effect	Vasopressors , particularly <e10> metaraminol </e10> , may cause serious cardiac arrhythmias during <e20> halothane </e20> anesthesia and therefore should be used only with great caution or not at all.
effect	MAO_Inhibitors : The pressor effect of <e12> sympathomimetic_pressor_amines </e12> is markedly potentiated in patients receiving <e22> monoamine_oxidase_inhibitors </e22> ( MAOI ).
effect	MAO_Inhibitors : The pressor effect of <e12> sympathomimetic_pressor_amines </e12> is markedly potentiated in patients receiving monoamine_oxidase_inhibitors ( <e22> MAOI </e22> ).
effect	The pressor response of <e12> adrenergic_agents </e12> may also be potentiated by <e22> tricyclic_antidepressants </e22> .
negative	<e12> Vasopressors </e12> , particularly <e20> metaraminol </e20> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
effect	<e12> Vasopressors </e12> , particularly metaraminol , may cause serious cardiac arrhythmias during <e20> halothane </e20> anesthesia and therefore should be used only with great caution or not at all.
effect	Vasopressors , particularly <e10> metaraminol </e10> , may cause serious cardiac arrhythmias during <e20> halothane </e20> anesthesia and therefore should be used only with great caution or not at all.
negative	<e12> MAO_Inhibitors </e12> - The pressor effect of <e22> sympathomimetic_pressor_amines </e22> is markedly potentiated in patients receiving monoamine_oxidase_inhibitors ( MAOI ).
negative	<e12> MAO_Inhibitors </e12> - The pressor effect of sympathomimetic_pressor_amines is markedly potentiated in patients receiving <e22> monoamine_oxidase_inhibitors </e22> ( MAOI ).
negative	<e12> MAO_Inhibitors </e12> - The pressor effect of sympathomimetic_pressor_amines is markedly potentiated in patients receiving monoamine_oxidase_inhibitors ( <e22> MAOI </e22> ).
effect	MAO_Inhibitors - The pressor effect of <e12> sympathomimetic_pressor_amines </e12> is markedly potentiated in patients receiving <e22> monoamine_oxidase_inhibitors </e22> ( MAOI ).
effect	MAO_Inhibitors - The pressor effect of <e12> sympathomimetic_pressor_amines </e12> is markedly potentiated in patients receiving monoamine_oxidase_inhibitors ( <e22> MAOI </e22> ).
effect	The pressor response of <e12> adrenergic_agents </e12> may also be potentiated by <e22> tricyclic_antidepressants </e22> .
advise	<e10> Pilocarpine </e10> should be administered with caution to patients taking <e22> beta_adrenergic_antagonists </e22> because of the possibility of conduction disturbances.
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, <e20> calcium </e20> , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , <e20> hydroxychloroquine_sulfate </e20> , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , <e20> ibuprofen </e20> , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , <e20> levothyroxine_sodium </e20> , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , <e20> medroxyprogesterone_acetate </e20> , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , <e20> methotrexate </e20> , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , <e20> naproxen </e20> , omeprazole , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , <e20> omeprazole </e20> , paracetamol , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , omeprazole , <e20> paracetamol </e20> , and prednisone .
negative	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e10> acetylsalicylic_acid </e10> , artificial tears, calcium , conjugated_estrogens , hydroxychloroquine_sulfate , ibuprofen , levothyroxine_sodium , medroxyprogesterone_acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and <e20> prednisone </e20> .
effect	Catecholamine-depleting drugs (e,g,, <e10> reserpine </e10> ) may have an additive effect when given with <e22> beta-blocking_agents </e22> .
negative	<e10> Pindolol </e10> has been used with a variety of <e22> antihypertensive_agents </e22> , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions.
negative	<e10> Pindolol </e10> has been used with a variety of antihypertensive_agents , including <e20> hydrochlorothiazide </e20> , hydralazine , and guanethidine without unexpected adverse interactions.
negative	<e10> Pindolol </e10> has been used with a variety of antihypertensive_agents , including hydrochlorothiazide , <e20> hydralazine </e20> , and guanethidine without unexpected adverse interactions.
negative	<e10> Pindolol </e10> has been used with a variety of antihypertensive_agents , including hydrochlorothiazide , hydralazine , and <e20> guanethidine </e20> without unexpected adverse interactions.
negative	Pindolol has been used with a variety of <e12> antihypertensive_agents </e12> , including <e20> hydrochlorothiazide </e20> , hydralazine , and guanethidine without unexpected adverse interactions.
negative	Pindolol has been used with a variety of <e12> antihypertensive_agents </e12> , including hydrochlorothiazide , <e20> hydralazine </e20> , and guanethidine without unexpected adverse interactions.
negative	Pindolol has been used with a variety of <e12> antihypertensive_agents </e12> , including hydrochlorothiazide , hydralazine , and <e20> guanethidine </e20> without unexpected adverse interactions.
mechanism	<e10> Pindolol </e10> has been shown to increase serum <e20> thioridazine </e20> levels when both drugs are co-administered.
advise	Other <e12> short-acting_beta_adrenergic_aerosol_bronchodilators </e12> should not be used concomitantly with <e21> MAXAIR_AUTOHALER </e21> because they may have additive effects.
negative	Although this has not occurred in in vitro studies with <e12> coumarin-type_anticoagulants </e12> , interactions with coumarin-type_anticoagulants have been reported with <e21> FELDENE </e21> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type_anticoagulants and other highly protein-bound drugs.
negative	Although this has not occurred in in vitro studies with <e12> coumarin-type_anticoagulants </e12> , interactions with coumarin-type_anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e21> FELDENE </e21> to patients on coumarin-type_anticoagulants and other highly protein-bound drugs.
int	Although this has not occurred in in vitro studies with coumarin-type_anticoagulants , interactions with <e12> coumarin-type_anticoagulants </e12> have been reported with <e21> FELDENE </e21> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type_anticoagulants and other highly protein-bound drugs.
negative	Although this has not occurred in in vitro studies with coumarin-type_anticoagulants , interactions with <e12> coumarin-type_anticoagulants </e12> have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e21> FELDENE </e21> to patients on coumarin-type_anticoagulants and other highly protein-bound drugs.
negative	Although this has not occurred in in vitro studies with coumarin-type_anticoagulants , interactions with coumarin-type_anticoagulants have been reported with <e11> FELDENE </e11> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on <e22> coumarin-type_anticoagulants </e22> and other highly protein-bound drugs.
advise	Although this has not occurred in in vitro studies with coumarin-type_anticoagulants , interactions with coumarin-type_anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e11> FELDENE </e11> to patients on <e22> coumarin-type_anticoagulants </e22> and other highly protein-bound drugs.
negative	Plasma levels of <e10> piroxicam </e10> are depressed to approximately 80% of their normal values when <e21> FELDENE </e21> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of <e10> piroxicam </e10> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e21> aspirin </e21> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of <e10> piroxicam </e10> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e20> antacids </e20> has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of <e10> piroxicam </e10> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , <e22> Nonsteroidal_anti-inflammatory_agents </e22> , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of <e10> piroxicam </e10> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including <e21> FELDENE </e21> , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of <e10> piroxicam </e10> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e11> FELDENE </e11> is administered in conjunction with <e21> aspirin </e21> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e11> FELDENE </e11> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e20> antacids </e20> has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e11> FELDENE </e11> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e20> piroxicam </e20> plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e11> FELDENE </e11> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , <e22> Nonsteroidal_anti-inflammatory_agents </e22> , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e11> FELDENE </e11> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e11> aspirin </e11> (3900 mg/day), but concomitant administration of <e20> antacids </e20> has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e11> aspirin </e11> (3900 mg/day), but concomitant administration of antacids has no effect on <e20> piroxicam </e20> plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e11> aspirin </e11> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , <e22> Nonsteroidal_anti-inflammatory_agents </e22> , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e11> aspirin </e11> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including <e21> FELDENE </e21> , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e11> aspirin </e11> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e10> antacids </e10> has no effect on <e20> piroxicam </e20> plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e10> antacids </e10> has no effect on piroxicam plasma levels , <e22> Nonsteroidal_anti-inflammatory_agents </e22> , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e10> antacids </e10> has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including <e21> FELDENE </e21> , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e10> antacids </e10> has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e10> piroxicam </e10> plasma levels , <e22> Nonsteroidal_anti-inflammatory_agents </e22> , including FELDENE , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e10> piroxicam </e10> plasma levels , Nonsteroidal_anti-inflammatory_agents , including <e21> FELDENE </e21> , have been reported to increase steady state plasma lithium levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e10> piroxicam </e10> plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
negative	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , <e12> Nonsteroidal_anti-inflammatory_agents </e12> , including <e21> FELDENE </e21> , have been reported to increase steady state plasma lithium levels.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , <e12> Nonsteroidal_anti-inflammatory_agents </e12> , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including <e11> FELDENE </e11> , have been reported to increase steady state plasma <e20> lithium </e20> levels.
advise	It is recommended that plasma <e10> lithium </e10> levels be monitored when initiating, adjusting and discontinuing <e21> FELDENE </e21> .
effect	When <e10> atropine </e10> and <e20> pralidoxime </e20> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.
negative	When atropine and <e10> pralidoxime </e10> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when <e20> atropine </e20> is used alone.
negative	This is especially true if the total dose of <e10> atropine </e10> has been large and the administration of <e20> pralidoxime </e20> has been delayed.
negative	2 - # The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of <e10> pralidoxime </e10> : since <e22> barbiturates </e22> are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions;
negative	2 - # The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of <e10> pralidoxime </e10> : since barbiturates are potentiated by the <e22> anticholinesterases </e22> , they should be used cautiously in the treatment of convulsions;
effect	2 - # The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime : since <e12> barbiturates </e12> are potentiated by the <e22> anticholinesterases </e22> , they should be used cautiously in the treatment of convulsions;
negative	<e10> Carbidopa </e10> / <e20> Levodopa </e20> : Carbidopa / Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
negative	Carbidopa / Levodopa : <e10> Carbidopa </e10> / Levodopa does not influence the pharmacokinetics of <e20> pramipexole </e20> in healthy volunteers (N= 10).
negative	Carbidopa / Levodopa : Carbidopa / <e10> Levodopa </e10> does not influence the pharmacokinetics of <e20> pramipexole </e20> in healthy volunteers (N= 10).
negative	<e10> Selegiline </e10> : In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of <e20> pramipexole </e20> .
negative	Selegiline : In healthy volunteers (N= 11), <e10> selegiline </e10> did not influence the pharmacokinetics of <e20> pramipexole </e20> .
negative	Amantadine : Population pharmacokinetic analysis suggests that <e10> amantadine </e10> is unlikely to alter the oral clearance of <e20> pramipexole </e20> (N= 54).
negative	<e10> Cimetidine </e10> : Cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e20> pramipexole </e20> AUC and a 40% increase in half-life (N= 12).
mechanism	Cimetidine : <e10> Cimetidine </e10> , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e20> pramipexole </e20> AUC and a 40% increase in half-life (N= 12).
negative	<e10> Probenecid </e10> : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence <e20> pramipexole </e20> pharmacokinetics (N= 12).
negative	Probenecid : <e10> Probenecid </e10> , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence <e20> pramipexole </e20> pharmacokinetics (N= 12).
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e10> pramipexole </e10> by about 20%, while those secreted by the anionic transport system (e,g,, <e22> cephalosporins </e22> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e10> pramipexole </e10> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e22> penicillins </e22> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e10> pramipexole </e10> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e20> indomethacin </e20> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e10> pramipexole </e10> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e20> hydrochlorothiazide </e20> , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
negative	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e10> pramipexole </e10> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e20> chlorpropamide </e20> ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e12> cephalosporins </e12> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e12> penicillins </e12> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e10> indomethacin </e10> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e10> hydrochlorothiazide </e10> , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e10> chlorpropamide </e10> ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a <e22> dopamine_agonist </e22> , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that <e22> dopamine_antagonists </e22> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that dopamine_antagonists , such as the <e22> neuroleptics </e22> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( <e22> phenothiazines </e22> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e22> butyrophenones </e22> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e22> thioxanthenes </e22> ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since <e10> pramipexole </e10> is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that <e22> dopamine_antagonists </e22> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that dopamine_antagonists , such as the <e22> neuroleptics </e22> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that dopamine_antagonists , such as the neuroleptics ( <e22> phenothiazines </e22> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e22> butyrophenones </e22> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e22> thioxanthenes </e22> ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a <e12> dopamine_agonist </e12> , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the <e22> neuroleptics </e22> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the neuroleptics ( <e22> phenothiazines </e22> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , <e22> butyrophenones </e22> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , <e22> thioxanthenes </e22> ) or metoclopramide , may diminish the effectiveness of MIRAPEX .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
effect	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the <e12> neuroleptics </e12> ( phenothiazines , butyrophenones , thioxanthenes ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
effect	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the <e12> neuroleptics </e12> ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthenes ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
effect	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthenes ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
effect	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
negative	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthenes </e12> ) or <e22> metoclopramide </e22> , may diminish the effectiveness of MIRAPEX .
effect	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthenes </e12> ) or metoclopramide , may diminish the effectiveness of <e21> MIRAPEX </e21> .
effect	Dopamine_antagonists : Since pramipexole is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e12> metoclopramide </e12> , may diminish the effectiveness of <e21> MIRAPEX </e21> .
advise	Due to its effects on gastric emptying, <e11> SYMLIN </e11> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, <e22> anticholinergic_agents </e22> such as atropine ) and agents that slow the intestinal absorption of nutrients (e,g,, alpha_glucosidase_inhibitors ).
advise	Due to its effects on gastric emptying, <e11> SYMLIN </e11> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, anticholinergic_agents such as <e20> atropine </e20> ) and agents that slow the intestinal absorption of nutrients (e,g,, alpha_glucosidase_inhibitors ).
advise	Due to its effects on gastric emptying, <e11> SYMLIN </e11> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, anticholinergic_agents such as atropine ) and agents that slow the intestinal absorption of nutrients (e,g,, <e22> alpha_glucosidase_inhibitors </e22> ).
negative	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, <e12> anticholinergic_agents </e12> such as atropine ) and agents that slow the intestinal absorption of nutrients (e,g,, <e22> alpha_glucosidase_inhibitors </e22> ).
negative	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e,g,, anticholinergic_agents such as <e10> atropine </e10> ) and agents that slow the intestinal absorption of nutrients (e,g,, <e22> alpha_glucosidase_inhibitors </e22> ).
advise	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as <e12> analgesics </e12> ), the agent should be administered at least # hour prior to or # hours after <e21> SYMLIN </e21> injection.
negative	In clinical trials, the concomitant use of <e12> sulfonylureas </e12> or <e22> biguanides </e22> did not alter the adverse event profile of SYMLIN .
negative	In clinical trials, the concomitant use of <e12> sulfonylureas </e12> or biguanides did not alter the adverse event profile of <e21> SYMLIN </e21> .
negative	In clinical trials, the concomitant use of sulfonylureas or <e12> biguanides </e12> did not alter the adverse event profile of <e21> SYMLIN </e21> .
negative	No formal interaction studies have been performed to assess the effect of <e11> SYMLIN </e11> on the kinetics of oral <e22> antidiabetic_agents </e22> .
negative	Mixing <e11> SYMLIN </e11> and <e20> Insulin </e20> The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human_insulin immediately prior to injection.
negative	Mixing <e11> SYMLIN </e11> and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e20> human_insulin </e20> immediately prior to injection.
negative	Mixing SYMLIN and <e10> Insulin </e10> The pharmacokinetic parameters of <e21> SYMLIN </e21> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human_insulin immediately prior to injection.
mechanism	Mixing SYMLIN and Insulin The pharmacokinetic parameters of <e11> SYMLIN </e11> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e20> human_insulin </e20> immediately prior to injection.
negative	Thus, <e11> SYMLIN </e11> and <e20> insulin </e20> should not be mixed and must be administered separately.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin and rifampin may increase the clearance of <e22> corticosteroids </e22> and may require increases in corticosteroid dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in <e22> corticosteroid </e22> dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> and rifampin may increase the clearance of <e22> corticosteroids </e22> and may require increases in corticosteroid dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> and rifampin may increase the clearance of corticosteroids and may require increases in <e22> corticosteroid </e22> dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e10> rifampin </e10> may increase the clearance of <e22> corticosteroids </e22> and may require increases in corticosteroid dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e10> rifampin </e10> may increase the clearance of corticosteroids and may require increases in <e22> corticosteroid </e22> dose to achieve the desired response.
negative	Drugs such as <e10> troleandomycin </e10> and <e20> ketoconazole </e20> may inhibit the metabolism of corticosteroids and thus decrease their clearance.
mechanism	Drugs such as <e10> troleandomycin </e10> and ketoconazole may inhibit the metabolism of <e22> corticosteroids </e22> and thus decrease their clearance.
mechanism	Drugs such as troleandomycin and <e10> ketoconazole </e10> may inhibit the metabolism of <e22> corticosteroids </e22> and thus decrease their clearance.
mechanism	<e12> Corticosteroids </e12> may increase the clearance of chronic high dose <e21> aspirin </e21> .
negative	This could lead to decreased <e12> salicylate </e12> serum levels or increase the risk of salicylate toxicity when <e22> corticosteroid </e22> is withdrawn.
effect	This could lead to decreased salicylate serum levels or increase the risk of <e12> salicylate </e12> toxicity when <e22> corticosteroid </e22> is withdrawn.
advise	<e11> Aspirin </e11> should be used cautiously in conjunction with <e22> corticosteroids </e22> in patients suffering from hypoprothrombinemia.
effect	The effect of <e12> corticosteroids </e12> on oral <e22> anticoagulants </e22> is variable.
effect	There are reports of enhanced as well as diminished effects of <e12> anticoagulants </e12> when given concurrently with <e22> corticosteroids </e22> .
negative	<e12> Anticholinesterases </e12> : Concurrent use of <e20> procaine_hydrochloride </e20> and anticholinesterase_agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine_hydrochloride .
negative	<e12> Anticholinesterases </e12> : Concurrent use of procaine_hydrochloride and <e22> anticholinesterase_agents </e22> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine_hydrochloride .
negative	<e12> Anticholinesterases </e12> : Concurrent use of procaine_hydrochloride and anticholinesterase_agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e20> procaine_hydrochloride </e20> .
effect	Anticholinesterases : Concurrent use of <e10> procaine_hydrochloride </e10> and <e22> anticholinesterase_agents </e22> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine_hydrochloride .
negative	Anticholinesterases : Concurrent use of <e10> procaine_hydrochloride </e10> and anticholinesterase_agents may result in increased systemic toxicity since <e22> anticholinesterases </e22> inhibit the breakdown of procaine_hydrochloride .
negative	Anticholinesterases : Concurrent use of procaine_hydrochloride and <e12> anticholinesterase_agents </e12> may result in increased systemic toxicity since <e22> anticholinesterases </e22> inhibit the breakdown of procaine_hydrochloride .
negative	Anticholinesterases : Concurrent use of procaine_hydrochloride and <e12> anticholinesterase_agents </e12> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e20> procaine_hydrochloride </e20> .
mechanism	Anticholinesterases : Concurrent use of procaine_hydrochloride and anticholinesterase_agents may result in increased systemic toxicity since <e12> anticholinesterases </e12> inhibit the breakdown of <e20> procaine_hydrochloride </e20> .
negative	<e12> CNS_depressant </e12> medications: Concurrent use of <e20> procaine_hydrochloride </e20> and CNS_depressant_medications may result in additive depressant effects.
effect	CNS_depressant medications: Concurrent use of <e10> procaine_hydrochloride </e10> and <e22> CNS_depressant_medications </e22> may result in additive depressant effects.
mechanism	Hyaluronidase : <e10> Hyaluronidase </e10> may increase the diffusion rate of <e20> procaine_hydrochloride </e20> , resulting in a decreased time of onset, but an increase in systemic toxicity.
negative	<e12> Neuromuscular_blocking_agents </e12> (such as suxamethonium_chloride ): Concurrent use of <e20> procaine_hydrochloride </e20> and neuromuscular_blocking_agents may result in prolongation or enhancement of the neuromuscular blockade.
negative	Neuromuscular_blocking_agents (such as <e10> suxamethonium_chloride </e10> ): Concurrent use of <e20> procaine_hydrochloride </e20> and neuromuscular_blocking_agents may result in prolongation or enhancement of the neuromuscular blockade.
negative	Neuromuscular_blocking_agents (such as <e10> suxamethonium_chloride </e10> ): Concurrent use of procaine_hydrochloride and <e22> neuromuscular_blocking_agents </e22> may result in prolongation or enhancement of the neuromuscular blockade.
effect	Neuromuscular_blocking_agents (such as suxamethonium_chloride ): Concurrent use of <e10> procaine_hydrochloride </e10> and <e22> neuromuscular_blocking_agents </e22> may result in prolongation or enhancement of the neuromuscular blockade.
negative	<e12> Sulfonamides </e12> : Concurrent use of <e20> procaine_hydrochloride </e20> and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
effect	Sulfonamides : Concurrent use of <e10> procaine_hydrochloride </e10> and <e22> sulfonamides </e22> may result in a reduction of the antibacterial action of the sulfonamide .
negative	Sulfonamides : Concurrent use of <e10> procaine_hydrochloride </e10> and sulfonamides may result in a reduction of the antibacterial action of the <e22> sulfonamide </e22> .
negative	<e10> Acetazolamide </e10> : Concurrent use of acetazolamide and <e20> procaine_hydrochloride </e20> may extend the plasma half-life of procaine .
negative	<e10> Acetazolamide </e10> : Concurrent use of acetazolamide and procaine_hydrochloride may extend the plasma half-life of <e20> procaine </e20> .
mechanism	Acetazolamide : Concurrent use of <e10> acetazolamide </e10> and <e20> procaine_hydrochloride </e20> may extend the plasma half-life of procaine .
negative	Acetazolamide : Concurrent use of <e10> acetazolamide </e10> and procaine_hydrochloride may extend the plasma half-life of <e20> procaine </e20> .
negative	To minimize CNS depression and possible potentiation, barbiturates , antihistamines , narcotics , <e12> hypotensive_agents </e12> or <e22> phenothiazines </e22> should be used with caution.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, <e22> sympathomimetic_drugs </e22> , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , <e22> tricyclic_antidepressant </e22> drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, <e20> amitriptyline_HCl </e20> , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , <e20> imipramine_HCl </e20> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
advise	Because <e11> Matulane </e11> exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high <e23> tyramine </e23> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, <e12> sympathomimetic_drugs </e12> , <e22> tricyclic_antidepressant </e22> drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, <e12> sympathomimetic_drugs </e12> , tricyclic_antidepressant drugs (e,g,, <e20> amitriptyline_HCl </e20> , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, <e12> sympathomimetic_drugs </e12> , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , <e20> imipramine_HCl </e20> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, <e12> sympathomimetic_drugs </e12> , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high <e23> tyramine </e23> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , <e12> tricyclic_antidepressant </e12> drugs (e,g,, <e20> amitriptyline_HCl </e20> , imipramine_HCl ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , <e12> tricyclic_antidepressant </e12> drugs (e,g,, amitriptyline_HCl , <e20> imipramine_HCl </e20> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , <e12> tricyclic_antidepressant </e12> drugs (e,g,, amitriptyline_HCl , imipramine_HCl ) and other drugs and foods with known high <e23> tyramine </e23> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, <e10> amitriptyline_HCl </e10> , imipramine_HCl ) and other drugs and foods with known high <e23> tyramine </e23> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
negative	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic_drugs , tricyclic_antidepressant drugs (e,g,, amitriptyline_HCl , <e10> imipramine_HCl </e10> ) and other drugs and foods with known high <e23> tyramine </e23> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
effect	<e12> Thiazide_diuretics </e12> may accentuate the orthostatic hypotension that may occur with <e22> phenothiazines </e22> .
effect	Antihypertensive effects of <e10> guanethidine </e10> and related compounds may be counteracted when <e22> phenothiazines </e22> are used concomitantly.
mechanism	Concomitant administration of <e10> propranolol </e10> with <e22> phenothiazines </e22> results in increased plasma levels of both drugs.
effect	The induction dose requirements of <e11> DIPRIVAN </e11> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e22> narcotics </e22> (eg, morphine , meperidine , and fentanyl , etc.
effect	The induction dose requirements of <e11> DIPRIVAN </e11> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e20> morphine </e20> , meperidine , and fentanyl , etc.
effect	The induction dose requirements of <e11> DIPRIVAN </e11> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine , <e20> meperidine </e20> , and fentanyl , etc.
effect	The induction dose requirements of <e11> DIPRIVAN </e11> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine , meperidine , and <e20> fentanyl </e20> , etc.
negative	and combinations of <e12> opioids </e12> and <e22> sedatives </e22> (eg, benzodiazepines , barbiturates , chloral_hydrate , droperidol , etc,).
negative	and combinations of <e12> opioids </e12> and sedatives (eg, <e22> benzodiazepines </e22> , barbiturates , chloral_hydrate , droperidol , etc,).
negative	and combinations of <e12> opioids </e12> and sedatives (eg, benzodiazepines , <e22> barbiturates </e22> , chloral_hydrate , droperidol , etc,).
negative	and combinations of <e12> opioids </e12> and sedatives (eg, benzodiazepines , barbiturates , <e20> chloral_hydrate </e20> , droperidol , etc,).
negative	and combinations of <e12> opioids </e12> and sedatives (eg, benzodiazepines , barbiturates , chloral_hydrate , <e20> droperidol </e20> , etc,).
advise	During maintenance of anesthesia or sedation, the rate of <e11> DIPRIVAN </e11> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e22> analgesic_agents </e22> (eg, nitrous_oxide or opioids ).
advise	During maintenance of anesthesia or sedation, the rate of <e11> DIPRIVAN </e11> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic_agents (eg, <e20> nitrous_oxide </e20> or opioids ).
advise	During maintenance of anesthesia or sedation, the rate of <e11> DIPRIVAN </e11> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic_agents (eg, nitrous_oxide or <e22> opioids </e22> ).
negative	The concurrent administration of potent inhalational agents (eg, <e10> isoflurane </e10> , enflurane , and halothane ) during maintenance with <e21> DIPRIVAN </e21> Injectable Emulsion has not been extensively evaluated.
negative	The concurrent administration of potent inhalational agents (eg, isoflurane , <e10> enflurane </e10> , and halothane ) during maintenance with <e21> DIPRIVAN </e21> Injectable Emulsion has not been extensively evaluated.
negative	The concurrent administration of potent inhalational agents (eg, isoflurane , enflurane , and <e10> halothane </e10> ) during maintenance with <e21> DIPRIVAN </e21> Injectable Emulsion has not been extensively evaluated.
negative	<e11> DIPRIVAN </e11> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e22> neuromuscular_blocking_agents </e22> (eg, succinylcholine and nondepolarizing_muscle_relaxants ).
negative	<e11> DIPRIVAN </e11> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular_blocking_agents (eg, <e20> succinylcholine </e20> and nondepolarizing_muscle_relaxants ).
negative	<e11> DIPRIVAN </e11> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular_blocking_agents (eg, succinylcholine and <e22> nondepolarizing_muscle_relaxants </e22> ).
effect	The CNS-depressant effect of <e10> propoxyphene </e10> is additive with that of other <e22> CNS_depressants </e22> , including alcohol .
effect	The CNS-depressant effect of <e10> propoxyphene </e10> is additive with that of other CNS_depressants , including <e20> alcohol </e20> .
negative	The CNS-depressant effect of propoxyphene is additive with that of other <e12> CNS_depressants </e12> , including <e20> alcohol </e20> .
negative	Such occurrences have been reported when <e10> propoxyphene </e10> was administered to patients on <e22> antidepressants </e22> , anticonvulsants , or warfarin -like drugs.
negative	Such occurrences have been reported when <e10> propoxyphene </e10> was administered to patients on antidepressants , <e22> anticonvulsants </e22> , or warfarin -like drugs.
negative	Such occurrences have been reported when <e10> propoxyphene </e10> was administered to patients on antidepressants , anticonvulsants , or <e20> warfarin </e20> -like drugs.
negative	Such occurrences have been reported when propoxyphene was administered to patients on <e12> antidepressants </e12> , <e22> anticonvulsants </e22> , or warfarin -like drugs.
negative	Such occurrences have been reported when propoxyphene was administered to patients on <e12> antidepressants </e12> , anticonvulsants , or <e20> warfarin </e20> -like drugs.
negative	Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , <e12> anticonvulsants </e12> , or <e20> warfarin </e20> -like drugs.
negative	<e12> MAO_inhibitors </e12> and <e22> beta_adrenergic_blockers </e22> increase the effects of pseudoephedrine .
effect	<e12> MAO_inhibitors </e12> and beta_adrenergic_blockers increase the effects of <e20> pseudoephedrine </e20> .
effect	MAO_inhibitors and <e12> beta_adrenergic_blockers </e12> increase the effects of <e20> pseudoephedrine </e20> .
effect	<e12> Sympathomimetics </e12> may reduce the antihypertensive effects of <e20> methyldopa </e20> , mecamylamine , reserpine and veratrum_alkaloids .
effect	<e12> Sympathomimetics </e12> may reduce the antihypertensive effects of methyldopa , <e20> mecamylamine </e20> , reserpine and veratrum_alkaloids .
effect	<e12> Sympathomimetics </e12> may reduce the antihypertensive effects of methyldopa , mecamylamine , <e20> reserpine </e20> and veratrum_alkaloids .
effect	<e12> Sympathomimetics </e12> may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and <e22> veratrum_alkaloids </e22> .
negative	<e10> Pyrimethamine </e10> may be used with <e22> sulfonamides </e22> , quinine and other antimalarials , and with other antibiotics .
negative	<e10> Pyrimethamine </e10> may be used with sulfonamides , <e20> quinine </e20> and other antimalarials , and with other antibiotics .
negative	<e10> Pyrimethamine </e10> may be used with sulfonamides , quinine and other <e22> antimalarials </e22> , and with other antibiotics .
negative	<e10> Pyrimethamine </e10> may be used with sulfonamides , quinine and other antimalarials , and with other <e22> antibiotics </e22> .
negative	Pyrimethamine may be used with <e12> sulfonamides </e12> , quinine and other antimalarials , and with other <e22> antibiotics </e22> .
negative	Pyrimethamine may be used with sulfonamides , <e10> quinine </e10> and other antimalarials , and with other <e22> antibiotics </e22> .
negative	Pyrimethamine may be used with sulfonamides , quinine and other <e12> antimalarials </e12> , and with other <e22> antibiotics </e22> .
effect	Mild hepatotoxicity has been reported in some patients when <e10> lorazepam </e10> and <e20> pyrimethamine </e20> were administered concomitantly.
negative	<e10> Cholestyramine </e10> : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e20> raloxifene </e20> and should not be coadministered with EVISTA .
negative	<e10> Cholestyramine </e10> : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e21> EVISTA </e21> .
mechanism	Cholestyramine : <e10> Cholestyramine </e10> causes a 60% reduction in the absorption and enterohepatic cycling of <e20> raloxifene </e20> and should not be coadministered with EVISTA .
advise	Cholestyramine : <e10> Cholestyramine </e10> causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e21> EVISTA </e21> .
negative	Cholestyramine : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e10> raloxifene </e10> and should not be coadministered with <e21> EVISTA </e21> .
negative	Warfarin : The coadministration of <e11> EVISTA </e11> and <e20> warfarin </e20> has not been assessed under chronic conditions.
advise	If <e11> EVISTA </e11> is given concurrently with <e20> warfarin </e20> , prothrombin time should be monitored.
negative	In vitro, <e10> raloxifene </e10> did not affect the binding of <e20> warfarin </e20> , phenytoin , or tamoxifen .
negative	In vitro, <e10> raloxifene </e10> did not affect the binding of warfarin , <e20> phenytoin </e20> , or tamoxifen .
negative	In vitro, <e10> raloxifene </e10> did not affect the binding of warfarin , phenytoin , or <e20> tamoxifen </e20> .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as <e20> clofibrate </e20> , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , <e20> indomethacin </e20> , naproxen , ibuprofen , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , <e20> naproxen </e20> , ibuprofen , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , naproxen , <e20> ibuprofen </e20> , diazepam , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , naproxen , ibuprofen , <e20> diazepam </e20> , and diazoxide .
advise	Caution should be used when <e11> EVISTA </e11> is coadministered with other highly protein-bound drugs, such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and <e20> diazoxide </e20> .
mechanism	Coadministration of <e11> TRITEC </e11> with <e20> clarithromycin </e20> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-_hydroxy-_clarithromycin plasma concentrations (31%).
negative	Coadministration of <e11> TRITEC </e11> with clarithromycin resulted in increased plasma <e20> ranitidine </e20> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-_hydroxy-_clarithromycin plasma concentrations (31%).
negative	Coadministration of <e11> TRITEC </e11> with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e23> 14-_hydroxy-_clarithromycin </e23> plasma concentrations (31%).
negative	Coadministration of TRITEC with <e10> clarithromycin </e10> resulted in increased plasma <e20> ranitidine </e20> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-_hydroxy-_clarithromycin plasma concentrations (31%).
negative	Coadministration of TRITEC with clarithromycin resulted in increased plasma <e10> ranitidine </e10> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e23> 14-_hydroxy-_clarithromycin </e23> plasma concentrations (31%).
negative	Coadministration with <e11> aspirin </e11> results in a slight decrease in the rate of <e22> salicylate </e22> absorption that is clinically unimportant.
mechanism	Coadministration with a high dose of <e12> antacid </e12> (170 mEq) results in a 28% decrease in plasma concentrations of <e20> ranitidine </e20> and may decrease plasma concentrations of bismuth from TRITEC .
mechanism	Coadministration with a high dose of <e12> antacid </e12> (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from <e21> TRITEC </e21> .
negative	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of <e10> ranitidine </e10> and may decrease plasma concentrations of bismuth from <e21> TRITEC </e21> .
negative	For information on drug interactions associated with <e10> ranitidine </e10> , refer to the <e21> ZANTAC </e21> package insert.
negative	Co-administration of oral <e10> ketoconazole </e10> # mg twice daily increased <e20> retapamulin </e20> geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.
mechanism	Co-administration of oral <e10> ketoconazole </e10> # mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of <e20> retapamulin </e20> ointment, 1% on the abraded skin of healthy adult males.
negative	Due to low systemic exposure to <e10> retapamulin </e10> following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as <e20> ketoconazole </e20> .
negative	Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for <e10> retapamulin </e10> are unnecessary when co-administered with CYP3A4 inhibitors, such as <e20> ketoconazole </e20> .
negative	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of <e11> ALTABAX </e11> , <e20> retapamulin </e20> is unlikely to affect the metabolism of other P450 substrates.
negative	In addition to bleeding associated with <e10> heparin </e10> and <e22> vitamin_K_antagonists </e22> , drugs that alter platelet function (such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
negative	In addition to bleeding associated with <e10> heparin </e10> and vitamin_K_antagonists , drugs that alter platelet function (such as <e21> aspirin </e21> , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
negative	In addition to bleeding associated with <e10> heparin </e10> and vitamin_K_antagonists , drugs that alter platelet function (such as aspirin , <e20> dipyridamole </e20> , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
negative	In addition to bleeding associated with <e10> heparin </e10> and vitamin_K_antagonists , drugs that alter platelet function (such as aspirin , dipyridamole , and <e20> abciximab </e20> ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
effect	In addition to bleeding associated with <e10> heparin </e10> and vitamin_K_antagonists , drugs that alter platelet function (such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after <e21> Retavase </e21> therapy.
negative	In addition to bleeding associated with heparin and <e12> vitamin_K_antagonists </e12> , drugs that alter platelet function (such as <e21> aspirin </e21> , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
negative	In addition to bleeding associated with heparin and <e12> vitamin_K_antagonists </e12> , drugs that alter platelet function (such as aspirin , <e20> dipyridamole </e20> , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
negative	In addition to bleeding associated with heparin and <e12> vitamin_K_antagonists </e12> , drugs that alter platelet function (such as aspirin , dipyridamole , and <e20> abciximab </e20> ) may increase the risk of bleeding if administered prior to or after Retavase therapy.
effect	In addition to bleeding associated with heparin and <e12> vitamin_K_antagonists </e12> , drugs that alter platelet function (such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after <e21> Retavase </e21> therapy.
effect	In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as <e11> aspirin </e11> , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after <e21> Retavase </e21> therapy.
effect	In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as aspirin , <e10> dipyridamole </e10> , and abciximab ) may increase the risk of bleeding if administered prior to or after <e21> Retavase </e21> therapy.
effect	In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as aspirin , dipyridamole , and <e10> abciximab </e10> ) may increase the risk of bleeding if administered prior to or after <e21> Retavase </e21> therapy.
negative	Interactions for <e10> Vitamin_B2 </e10> ( Riboflavin ): <e20> Alcohol </e20> - impairs the intestinal absorption of riboflavin
negative	Interactions for Vitamin_B2 ( <e10> Riboflavin </e10> ): <e20> Alcohol </e20> - impairs the intestinal absorption of riboflavin
mechanism	Interactions for Vitamin_B2 ( Riboflavin ): <e10> Alcohol </e10> - impairs the intestinal absorption of <e20> riboflavin </e20>
mechanism	<e10> Probenecid </e10> - concurrent use decreases gastrointestinal absorption of <e20> riboflavin </e20> ;
effect	requirements for <e10> riboflavin </e10> may be increased in patients receiving <e20> probenecid </e20> .
negative	Cimetidine : The effects of chronic <e10> cimetidine </e10> use on the metabolism of <e20> rimantadine </e20> are not known.
mechanism	When a single # mg dose of <e10> rimantadine_HCl </e10> was administered one hour after the initiation of <e20> Cimetidine </e20> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ).
negative	When a single # mg dose of <e10> rimantadine_HCl </e10> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e20> cimetidine </e20> ).
negative	When a single # mg dose of rimantadine_HCl was administered one hour after the initiation of <e10> Cimetidine </e10> (300 mg four times a day), the apparent total <e20> rimantadine </e20> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ).
negative	When a single # mg dose of rimantadine_HCl was administered one hour after the initiation of <e10> Cimetidine </e10> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e20> rimantadine </e20> clearance in the same subjects in the absence of cimetidine ).
negative	When a single # mg dose of rimantadine_HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e10> rimantadine </e10> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e20> cimetidine </e20> ).
negative	When a single # mg dose of rimantadine_HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e10> rimantadine </e10> clearance in the same subjects in the absence of <e20> cimetidine </e20> ).
negative	<e10> Acetaminophen </e10> : <e20> Rimantadine_HCl </e20> , # mg, was given twice daily for # days to # healthy volunteers.
mechanism	Coadministration with <e10> acetaminophen </e10> reduced the peak concentration and AUC values for <e20> rimantadine </e20> by approximately 11%.
negative	<e11> Aspirin </e11> : <e20> Rimantadine_HCl </e20> , # mg, was given twice daily fro # days to # healthy volunteers.
mechanism	Peak plasma concentrations and AUC of <e10> rimantadine </e10> were reduced approximately 10% in the presence of <e21> aspirin </e21> .
negative	The elevation of prothrombin time induced by <e10> warfarin </e10> is not affected by administration of <e21> Exelon </e21> .
negative	Single dose pharmacokinetic studies demonstrated that the metabolism of <e10> rivastigmine </e10> is not significantly affected by concurrent administration of <e20> digoxin </e20> , warfarin , diazepam , or fluoxetine .
negative	Single dose pharmacokinetic studies demonstrated that the metabolism of <e10> rivastigmine </e10> is not significantly affected by concurrent administration of digoxin , <e20> warfarin </e20> , diazepam , or fluoxetine .
negative	Single dose pharmacokinetic studies demonstrated that the metabolism of <e10> rivastigmine </e10> is not significantly affected by concurrent administration of digoxin , warfarin , <e20> diazepam </e20> , or fluoxetine .
negative	Single dose pharmacokinetic studies demonstrated that the metabolism of <e10> rivastigmine </e10> is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or <e20> fluoxetine </e20> .
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as <e20> antacids </e20> (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), <e22> antihypertensives </e22> (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e22> calcium_channel_blockers </e22> (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), <e22> antidiabetics </e22> (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), <e22> nonsteroidal_anti-inflammatory_drugs </e22> (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), <e22> estrogens </e22> (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), <e22> salicylate_analgesics </e22> (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), <e22> antianginals </e22> (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of <e10> rivastigmine </e10> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and <e22> antihistamines </e22> (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e10> antacids </e10> (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), <e22> estrogens </e22> (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e10> antacids </e10> (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), <e22> salicylate_analgesics </e22> (n=177), antianginals (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e10> antacids </e10> (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), <e22> antianginals </e22> (n=35), and antihistamines (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e10> antacids </e10> (n=77), antihypertensives (n=72), calcium_channel_blockers (n=75), antidiabetics (n=21), nonsteroidal_anti-inflammatory_drugs (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and <e22> antihistamines </e22> (n=15).
negative	Population PK analysis with a database of # patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e12> calcium_channel_blockers </e12> (n=75), antidiabetics (n=21), <e22> nonsteroidal_anti-inflammatory_drugs </e22> (n=79), estrogens (n=70), salicylate_analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
int	Use with Anticholinergics : Because of their mechanism of action, <e12> cholinesterase_inhibitors </e12> have the potential to interfere with the activity of <e22> anticholinergic_medications </e22> .
negative	Use with <e12> Cholinomimetics </e12> and Other <e22> Cholinesterase_Inhibitors </e22> : A synergistic effect may be expected when cholinesterase_inhibitors are given concurrently with succinylcholine , similar neuromuscular_blocking_agents or cholinergic_agonists such as bethanechol .
effect	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when <e12> cholinesterase_inhibitors </e12> are given concurrently with <e20> succinylcholine </e20> , similar neuromuscular_blocking_agents or cholinergic_agonists such as bethanechol .
effect	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when <e12> cholinesterase_inhibitors </e12> are given concurrently with succinylcholine , similar <e22> neuromuscular_blocking_agents </e22> or cholinergic_agonists such as bethanechol .
effect	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when <e12> cholinesterase_inhibitors </e12> are given concurrently with succinylcholine , similar neuromuscular_blocking_agents or <e22> cholinergic_agonists </e22> such as bethanechol .
effect	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when <e12> cholinesterase_inhibitors </e12> are given concurrently with succinylcholine , similar neuromuscular_blocking_agents or cholinergic_agonists such as <e20> bethanechol </e20> .
negative	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when cholinesterase_inhibitors are given concurrently with <e10> succinylcholine </e10> , similar neuromuscular_blocking_agents or cholinergic_agonists such as <e20> bethanechol </e20> .
negative	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when cholinesterase_inhibitors are given concurrently with succinylcholine , similar <e12> neuromuscular_blocking_agents </e12> or cholinergic_agonists such as <e20> bethanechol </e20> .
negative	Use with Cholinomimetics and Other Cholinesterase_Inhibitors : A synergistic effect may be expected when cholinesterase_inhibitors are given concurrently with succinylcholine , similar neuromuscular_blocking_agents or <e12> cholinergic_agonists </e12> such as <e20> bethanechol </e20> .
negative	Drug Interactions: The use of <e11> ZEMURON </e11> ( rocuronium_bromide ) Injection before <e20> succinylcholine </e20> , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied.
negative	Drug Interactions: The use of <e11> ZEMURON </e11> ( rocuronium_bromide ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of <e20> succinylcholine </e20> , has not been studied.
negative	Drug Interactions: The use of ZEMURON ( <e10> rocuronium_bromide </e10> ) Injection before <e20> succinylcholine </e20> , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied.
negative	Drug Interactions: The use of ZEMURON ( <e10> rocuronium_bromide </e10> ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of <e20> succinylcholine </e20> , has not been studied.
advise	If <e11> ZEMURON </e11> is administered following administration of <e20> succinylcholine </e20> , it should not be given until recovery from succinylcholine has been observed.
negative	If <e11> ZEMURON </e11> is administered following administration of succinylcholine , it should not be given until recovery from <e20> succinylcholine </e20> has been observed.
negative	The median duration of action of <e11> ZEMURON </e11> # mg/kg administered after a # mg/kg dose of <e20> succinylcholine </e20> when T # returned to 75% of control was # minutes (range 14-57, n=12) vs.
negative	There are no controlled studies documenting the use of <e11> ZEMURON </e11> before or after other <e22> nondepolarizing_muscle_relaxants </e22> .
advise	<e10> Ropivacaine </e10> should be used with caution in patients receiving other local <e22> anesthetics </e22> or agents structurally related to amide-type_local_anesthetics , since the toxic effects of these drugs are additive.
negative	<e10> Ropivacaine </e10> should be used with caution in patients receiving other local anesthetics or agents structurally related to <e22> amide-type_local_anesthetics </e22> , since the toxic effects of these drugs are additive.
mechanism	In vivo, the plasma clearance of <e10> ropivacaine </e10> was reduced by 70% during coadministration of <e20> fluvoxamine </e20> (25 mg bid for # days), a selective and potent CYP1A2 inhibitor.
int	Thus strong inhibitors of cytochrome P4501A2, such as <e10> fluvoxamine </e10> , given concomitantly during administration of <e20> Ropivacaine </e20> , can interact with Ropivacaine leading to increased ropivacaine plasma levels.
negative	Thus strong inhibitors of cytochrome P4501A2, such as <e10> fluvoxamine </e10> , given concomitantly during administration of Ropivacaine , can interact with <e20> Ropivacaine </e20> leading to increased ropivacaine plasma levels.
negative	Thus strong inhibitors of cytochrome P4501A2, such as <e10> fluvoxamine </e10> , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased <e20> ropivacaine </e20> plasma levels.
negative	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as <e10> theophylline </e10> and <e20> imipramine </e20> may also occur.
negative	Coadministration of a selective and potent inhibitor of CYP3A4, <e10> ketoconazole </e10> (100 mg bid for # days with <e20> ropivacaine </e20> infusion administered # hour after ketoconazole ) caused a 15% reduction in in-vivo plasma clearance of ropivacaine .
mechanism	Coadministration of a selective and potent inhibitor of CYP3A4, <e10> ketoconazole </e10> (100 mg bid for # days with ropivacaine infusion administered # hour after ketoconazole ) caused a 15% reduction in in-vivo plasma clearance of <e20> ropivacaine </e20> .
negative	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for # days with <e10> ropivacaine </e10> infusion administered # hour after <e20> ketoconazole </e20> ) caused a 15% reduction in in-vivo plasma clearance of ropivacaine .
negative	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for # days with ropivacaine infusion administered # hour after <e10> ketoconazole </e10> ) caused a 15% reduction in in-vivo plasma clearance of <e20> ropivacaine </e20> .
mechanism	An inhibitor of CYP2C8 (such as <e10> gemfibrozil </e10> ) may increase the AUC of <e20> rosiglitazone </e20> and an inducer of CYP2C8 (such as rifampin ) may decrease the AUC of rosiglitazone .
negative	An inhibitor of CYP2C8 (such as <e10> gemfibrozil </e10> ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e20> rifampin </e20> ) may decrease the AUC of rosiglitazone .
negative	An inhibitor of CYP2C8 (such as <e10> gemfibrozil </e10> ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin ) may decrease the AUC of <e20> rosiglitazone </e20> .
negative	An inhibitor of CYP2C8 (such as gemfibrozil ) may increase the AUC of <e10> rosiglitazone </e10> and an inducer of CYP2C8 (such as <e20> rifampin </e20> ) may decrease the AUC of rosiglitazone .
mechanism	An inhibitor of CYP2C8 (such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e10> rifampin </e10> ) may decrease the AUC of <e20> rosiglitazone </e20> .
negative	Concomitant administrations not recommended: - <e10> Terfenadine </e10> and <e20> astemizole </e20> : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
int	Concomitant administrations not recommended: - Terfenadine and astemizole : Certain <e12> macrolides </e12> interact with <e20> terfenadine </e20> and astemizole leading to increased serum concentrations of the latter.
int	Concomitant administrations not recommended: - Terfenadine and astemizole : Certain <e12> macrolides </e12> interact with terfenadine and <e20> astemizole </e20> leading to increased serum concentrations of the latter.
negative	Concomitant administrations not recommended: - Terfenadine and astemizole : Certain macrolides interact with <e10> terfenadine </e10> and <e20> astemizole </e20> leading to increased serum concentrations of the latter.
negative	Although such a reaction has not been demonstrated with <e10> roxithromycin </e10> , concomitant administration of roxithromycin with <e20> terfenadine </e20> or astemizole is not recommended.
negative	Although such a reaction has not been demonstrated with <e10> roxithromycin </e10> , concomitant administration of roxithromycin with terfenadine or <e20> astemizole </e20> is not recommended.
advise	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of <e10> roxithromycin </e10> with <e20> terfenadine </e20> or astemizole is not recommended.
advise	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of <e10> roxithromycin </e10> with terfenadine or <e20> astemizole </e20> is not recommended.
negative	Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with <e10> terfenadine </e10> or <e20> astemizole </e20> is not recommended.
negative	- <e10> Cisapride </e10> , <e20> pimozide </e20> : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide_antibacterials .
negative	- Cisapride , pimozide : Other drugs such as <e10> cisapride </e10> or <e20> pimozide </e20> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide_antibacterials .
mechanism	- Cisapride , pimozide : Other drugs such as <e10> cisapride </e10> or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e22> macrolide_antibacterials </e22> .
negative	- Cisapride , pimozide : Other drugs such as cisapride or <e10> pimozide </e10> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e22> macrolide_antibacterials </e22> .
effect	however, in patients with Paget's Disease prior <e12> diphosphonate </e12> use appears to reduce the anti-resorptive response to <e20> Calcitonin_(salmon) </e20> nasal spray.
negative	<e11> ASPIRIN </e11> AND OTHER <e22> SALICYLATE_DRUGS </e22> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC_ACID TO TOXIC LEVELS.
effect	<e11> ASPIRIN </e11> AND OTHER SALICYLATE_DRUGS WILL BE ADDITIVE TO <e21> DISALCID </e21> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC_ACID TO TOXIC LEVELS.
negative	<e11> ASPIRIN </e11> AND OTHER SALICYLATE_DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e20> SALICYLIC_ACID </e20> TO TOXIC LEVELS.
effect	ASPIRIN AND OTHER <e12> SALICYLATE_DRUGS </e12> WILL BE ADDITIVE TO <e21> DISALCID </e21> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC_ACID TO TOXIC LEVELS.
negative	ASPIRIN AND OTHER <e12> SALICYLATE_DRUGS </e12> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e20> SALICYLIC_ACID </e20> TO TOXIC LEVELS.
negative	ASPIRIN AND OTHER SALICYLATE_DRUGS WILL BE ADDITIVE TO <e11> DISALCID </e11> AND MAY INCREASE PLASMA CONCENTRATIONS OF <e20> SALICYLIC_ACID </e20> TO TOXIC LEVELS.
effect	<e12> Salicylates </e12> given concomitantly with <e22> anticoagulant_drugs </e22> may predispose to systemic bleeding.
effect	<e12> Salicylates </e12> may enhance the hypoglycemic effect of oral <e22> antidiabetic_drugs </e22> of the sulfonylurea class.
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably <e20> penicillin </e20> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , <e20> thiopental </e20> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , <e20> thyroxine </e20> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , <e20> triiodothyronine </e20> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , <e20> phenytoin </e20> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e20> sulfinpyrazone </e20> , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e20> naproxen </e20> , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e20> warfarin </e20> , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e20> methotrexate </e20> , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably <e10> penicillin </e10> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , <e10> thiopental </e10> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , <e10> thyroxine </e10> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , <e10> triiodothyronine </e10> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , <e10> phenytoin </e10> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e10> sulfinpyrazone </e10> , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e10> naproxen </e10> , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e10> warfarin </e10> , methotrexate , and possibly <e22> corticosteroids </e22> .
negative	Salicylate competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e10> methotrexate </e10> , and possibly <e22> corticosteroids </e22> .
effect	Drugs which may potentiate the myeloproliferative effects of <e11> Leukine </e11> , such as <e20> lithium </e20> and corticosteroids , should be used with caution.
effect	Drugs which may potentiate the myeloproliferative effects of <e11> Leukine </e11> , such as lithium and <e22> corticosteroids </e22> , should be used with caution.
negative	Drugs which may potentiate the myeloproliferative effects of Leukine , such as <e10> lithium </e10> and <e22> corticosteroids </e22> , should be used with caution.
advise	<e10> Scopolamine </e10> should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e22> sedatives </e22> , tranquilizers , or alcohol .
advise	<e10> Scopolamine </e10> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , <e22> tranquilizers </e22> , or alcohol .
advise	<e10> Scopolamine </e10> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or <e20> alcohol </e20> .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral <e22> contraceptives </e22> , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain <e22> antibiotics </e22> , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , <e20> quinidine </e20> , theophylline , corticosteroids , anticoagulants , and beta_blockers .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , <e20> theophylline </e20> , corticosteroids , anticoagulants , and beta_blockers .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , <e22> corticosteroids </e22> , anticoagulants , and beta_blockers .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , <e22> anticoagulants </e22> , and beta_blockers .
int	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and <e22> beta_blockers </e22> .
effect	The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of <e10> selegiline </e10> and <e20> meperidine </e20> .
int	This is typical of the interaction of <e10> meperidine </e10> and <e22> MAOIs </e22> .
effect	Severe toxicity has also been reported in patients receiving the combination of <e12> tricyclic_antidepressants </e12> and <e21> ELDEPRYL </e21> and selective_serotonin_reuptake_inhibitors and ELDEPRYL .
negative	Severe toxicity has also been reported in patients receiving the combination of <e12> tricyclic_antidepressants </e12> and ELDEPRYL and <e22> selective_serotonin_reuptake_inhibitors </e22> and ELDEPRYL .
negative	Severe toxicity has also been reported in patients receiving the combination of <e12> tricyclic_antidepressants </e12> and ELDEPRYL and selective_serotonin_reuptake_inhibitors and <e21> ELDEPRYL </e21> .
effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e10> selegiline </e10> and a <e22> sympathomimetic_medication </e22> ( ephedrine ).
effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e10> selegiline </e10> and a sympathomimetic_medication ( <e20> ephedrine </e20> ).
mechanism	Digoxin : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e10> digoxin </e10> with the co-administration of # mg <e20> sitagliptin </e20> for # days.
negative	No dosage adjustment of <e10> digoxin </e10> or <e21> JANUVIA </e21> is recommended.
negative	<e10> norepinephrine </e10> and <e20> dobutamine </e20> are incompatible with sodium_bicarbonate solution.
int	<e10> norepinephrine </e10> and dobutamine are incompatible with <e20> sodium_bicarbonate </e20> solution.
int	norepinephrine and <e10> dobutamine </e10> are incompatible with <e20> sodium_bicarbonate </e20> solution.
negative	The addition of <e10> sodium_bicarbonate </e10> to parenteral solutions containing <e20> calcium </e20> should be avoided, except where compatibility has been previously established.
advise	Do not exceed a # mg daily dose of <e11> VESIcare </e11> when administered with therapeutic doses of <e20> ketoconazole </e20> or other potent CYP3A4 inhibitors.
negative	Patients with Congenital or Acquired QT Prolongation In a study of the effect of <e10> solifenacin </e10> on the QT interval in # healthy women, the QT prolonging effect appeared less with solifenacin # mg than with # mg (three times the maximum recommended dose), and the effect of solifenacin # mg did not appear as large as that of the positive control <e20> moxifloxacin </e20> at its therapeutic dose.
negative	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in # healthy women, the QT prolonging effect appeared less with <e10> solifenacin </e10> # mg than with # mg (three times the maximum recommended dose), and the effect of solifenacin # mg did not appear as large as that of the positive control <e20> moxifloxacin </e20> at its therapeutic dose.
negative	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in # healthy women, the QT prolonging effect appeared less with solifenacin # mg than with # mg (three times the maximum recommended dose), and the effect of <e10> solifenacin </e10> # mg did not appear as large as that of the positive control <e20> moxifloxacin </e20> at its therapeutic dose.
mechanism	Limited published data indicate that <e10> GH </e10> treatment increases cytochrome P450 (CP450) mediated <e20> antipyrine </e20> clearance in man.
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, <e22> corticosteroids </e22> , sex_steroids , anticonvulsants , cyclosporin ).
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, corticosteroids , <e22> sex_steroids </e22> , anticonvulsants , cyclosporin ).
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, corticosteroids , sex_steroids , <e22> anticonvulsants </e22> , cyclosporin ).
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, corticosteroids , sex_steroids , anticonvulsants , <e20> cyclosporin </e20> ).
advise	Caution is recommended when administering <e11> NEXAVAR </e11> with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e,g, <e20> irinotecan </e20> ).
mechanism	Concomitant treatment with <e11> NEXAVAR </e11> resulted in a 21% increase in the AUC of <e20> doxorubicin </e20> .
advise	Caution is recommended when administering <e10> doxorubicin </e10> with <e21> NEXAVAR </e21> .
effect	<e10> Zidovudine </e10> competitively inhibits the intracellular phosphorylation of <e20> stavudine </e20> .
advise	Therefore, use of <e10> zidovudine </e10> in combination with <e21> ZERIT </e21> should be avoided.
effect	In vitro data indicate that the phosphorylation of <e10> stavudine </e10> is also inhibited at relevant concentrations by <e20> doxorubicin </e20> and ribavirin .
effect	In vitro data indicate that the phosphorylation of <e10> stavudine </e10> is also inhibited at relevant concentrations by doxorubicin and <e20> ribavirin </e20> .
negative	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by <e10> doxorubicin </e10> and <e20> ribavirin </e20> .
negative	The interaction of <e11> Streptase </e11> , <e20> Streptokinase </e20> , with other drugs has not been well studied.
negative	Use of <e12> Anticoagulants </e12> and <e22> Antiplatelet_Agents </e22> -- Streptase , Streptokinase , alone or in combination with antiplatelet_agents and anticoagulants , may cause bleeding complications.
negative	Use of <e12> Anticoagulants </e12> and Antiplatelet_Agents -- <e21> Streptase </e21> , Streptokinase , alone or in combination with antiplatelet_agents and anticoagulants , may cause bleeding complications.
negative	Use of <e12> Anticoagulants </e12> and Antiplatelet_Agents -- Streptase , <e20> Streptokinase </e20> , alone or in combination with antiplatelet_agents and anticoagulants , may cause bleeding complications.
negative	Use of <e12> Anticoagulants </e12> and Antiplatelet_Agents -- Streptase , Streptokinase , alone or in combination with <e22> antiplatelet_agents </e22> and anticoagulants , may cause bleeding complications.
negative	Use of Anticoagulants and <e12> Antiplatelet_Agents </e12> -- <e21> Streptase </e21> , Streptokinase , alone or in combination with antiplatelet_agents and anticoagulants , may cause bleeding complications.
negative	Use of Anticoagulants and <e12> Antiplatelet_Agents </e12> -- Streptase , <e20> Streptokinase </e20> , alone or in combination with antiplatelet_agents and anticoagulants , may cause bleeding complications.
negative	Use of Anticoagulants and <e12> Antiplatelet_Agents </e12> -- Streptase , Streptokinase , alone or in combination with antiplatelet_agents and <e22> anticoagulants </e22> , may cause bleeding complications.
negative	Use of Anticoagulants and Antiplatelet_Agents -- <e11> Streptase </e11> , <e20> Streptokinase </e20> , alone or in combination with antiplatelet_agents and anticoagulants , may cause bleeding complications.
effect	Use of Anticoagulants and Antiplatelet_Agents -- <e11> Streptase </e11> , Streptokinase , alone or in combination with <e22> antiplatelet_agents </e22> and anticoagulants , may cause bleeding complications.
effect	Use of Anticoagulants and Antiplatelet_Agents -- <e11> Streptase </e11> , Streptokinase , alone or in combination with antiplatelet_agents and <e22> anticoagulants </e22> , may cause bleeding complications.
effect	Use of Anticoagulants and Antiplatelet_Agents -- Streptase , <e10> Streptokinase </e10> , alone or in combination with <e22> antiplatelet_agents </e22> and anticoagulants , may cause bleeding complications.
effect	Use of Anticoagulants and Antiplatelet_Agents -- Streptase , <e10> Streptokinase </e10> , alone or in combination with antiplatelet_agents and <e22> anticoagulants </e22> , may cause bleeding complications.
negative	Use of Anticoagulants and Antiplatelet_Agents -- Streptase , Streptokinase , alone or in combination with <e12> antiplatelet_agents </e12> and <e22> anticoagulants </e22> , may cause bleeding complications.
negative	In the treatment of acute MI, <e11> aspirin </e11> , when not otherwise contraindicated, should be administered with <e20> Streptokinase </e20> ( see below ).
negative	Anticoagulation and <e12> Antiplatelets </e12> After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of <e21> aspirin </e21> has been shown to reduce the incidence of reinfarction and stroke.
effect	The addition of <e11> aspirin </e11> to <e20> Streptokinase </e20> causes a minimal increase in the risk of minor bleeding (#% vs, #%), but does not appear to increase the incidence of major bleeding (see
mechanism	<e10> Streptozocin </e10> has been reported to prolong the elimination half-life of <e20> doxorubicin </e20> and may lead to severe bone marrow suppression;
advise	a reduction of the <e10> doxorubicin </e10> dosage should be considered in patients receiving <e21> ZANOSAR </e21> concurrently.
effect	The concurrent use of <e10> streptozocin </e10> and <e20> phenytoin </e20> has been reported in one case to result in reduced streptozocin cytotoxicity.
negative	The concurrent use of streptozocin and <e10> phenytoin </e10> has been reported in one case to result in reduced <e20> streptozocin </e20> cytotoxicity.
negative	<e11> CHEMET </e11> is not known to interact with other drugs including <e20> iron </e20> supplements;
advise	Concomitant administration of <e11> CHEMET </e11> with other chelation therapy, such as <e20> CaNa_2_EDTA </e20> is not recommended.
effect	<e10> Sulfamethizole </e10> may increase the effects of <e22> barbiturates </e22> , tolbutamide , and uricosurics .
effect	<e10> Sulfamethizole </e10> may increase the effects of barbiturates , <e20> tolbutamide </e20> , and uricosurics .
effect	<e10> Sulfamethizole </e10> may increase the effects of barbiturates , tolbutamide , and <e22> uricosurics </e22> .
negative	It may also interact with <e12> thiazides </e12> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with <e12> thiazides </e12> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), <e10> cyclosporine </e10> (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), <e10> cyclosporine </e10> (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), <e10> cyclosporine </e10> (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e12> sulfonylurea_agents </e12> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e12> sulfonylurea_agents </e12> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e12> sulfonylurea_agents </e12> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), <e10> warfarin </e10> (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), <e10> warfarin </e10> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), <e10> warfarin </e10> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e10> methotrexate </e10> (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e10> methotrexate </e10> (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e10> methotrexate </e10> ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e10> methotrexate </e10> ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	In elderly patients concurrently receiving certain <e12> diuretics </e12> , primarily <e22> thiazides </e22> , an increased incidence of thrombopenia with purpura has been reported.
negative	It has been reported that <e10> sulfamethoxazole </e10> may prolong the prothrombin time in patients who are receiving the <e22> anticoagulant </e22> warfarin .
effect	It has been reported that <e10> sulfamethoxazole </e10> may prolong the prothrombin time in patients who are receiving the anticoagulant <e20> warfarin </e20> .
negative	It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the <e12> anticoagulant </e12> <e20> warfarin </e20> .
mechanism	<e10> Sulfamethoxazole </e10> may inhibit the hepatic metabolism of <e20> phenytoin </e20> .
mechanism	At a #-g dose, <e10> sulfamethoxazole </e10> produced a slight but significant increase in the half-life of <e20> phenytoin </e20> but did not produce a corresponding decrease in the metabolic clearance rate.
mechanism	<e12> Sulfonamides </e12> can also displace <e20> methotrexate </e20> from plasma protein-binding sites, thus increasing free methotrexate concentrations.
negative	<e12> Sulfonamides </e12> can also displace methotrexate from plasma protein-binding sites, thus increasing free <e20> methotrexate </e20> concentrations.
negative	Reduced absorption of <e10> folic_acid </e10> and <e20> digoxin </e20> have been reported when those agents were administered concomitantly with sulfasalazine .
mechanism	Reduced absorption of <e10> folic_acid </e10> and digoxin have been reported when those agents were administered concomitantly with <e20> sulfasalazine </e20> .
mechanism	Reduced absorption of folic_acid and <e10> digoxin </e10> have been reported when those agents were administered concomitantly with <e20> sulfasalazine </e20> .
negative	When daily doses of <e10> sulfasalazine </e10> # g and weekly doses of <e20> methotrexate </e20> # mg were coadministered to # rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.
negative	Daily doses of <e10> sulfasalazine </e10> # g (maximum # g) and weekly doses of <e20> methotrexate </e20> # mg (maximum # mg) were administered alone or in combination to # rheumatoid arthritis patients in two controlled 52-week clinical studies.
effect	<e10> Sulfoxone </e10> may increase the effects of <e22> barbiturates </e22> , tolbutamide , and uricosurics .
effect	<e10> Sulfoxone </e10> may increase the effects of barbiturates , <e20> tolbutamide </e20> , and uricosurics .
effect	<e10> Sulfoxone </e10> may increase the effects of barbiturates , tolbutamide , and <e22> uricosurics </e22> .
negative	It may also interact with <e12> thiazides </e12> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with <e12> thiazides </e12> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), <e10> cyclosporine </e10> (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), <e10> cyclosporine </e10> (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), <e10> cyclosporine </e10> (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e12> sulfonylurea_agents </e12> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e12> sulfonylurea_agents </e12> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e12> sulfonylurea_agents </e12> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), <e10> warfarin </e10> (increased anticoagulant effect), methotrexate (decreased renal excretion of <e20> methotrexate </e20> ), phenytoin (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), <e10> warfarin </e10> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), <e10> warfarin </e10> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e10> methotrexate </e10> (decreased renal excretion of methotrexate ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e10> methotrexate </e10> (decreased renal excretion of methotrexate ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e10> methotrexate </e10> ), <e20> phenytoin </e20> (decreased hepatic clearance of phenytoin ).
negative	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea_agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e10> methotrexate </e10> ), phenytoin (decreased hepatic clearance of <e20> phenytoin </e20> ).
negative	Because there is a theoretical basis that these effects may be additive, use of <e10> ergotamine </e10> -containing or <e22> ergot-type_medications </e22> (like dihydroergotamine or methysergide ) and sumatriptan within # hours of each other should be avoided.
negative	Because there is a theoretical basis that these effects may be additive, use of <e10> ergotamine </e10> -containing or ergot-type_medications (like dihydroergotamine or <e20> methysergide </e20> ) and sumatriptan within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of <e10> ergotamine </e10> -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or <e12> ergot-type_medications </e12> (like dihydroergotamine or methysergide ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like <e10> dihydroergotamine </e10> or methysergide ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or <e10> methysergide </e10> ) and <e20> sumatriptan </e20> within # hours of each other should be avoided.
mechanism	<e12> MAO-A_inhibitors </e12> reduce <e20> sumatriptan </e20> clearance, significantly increasing systemic exposure.
advise	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving <e22> MAO-A_inhibitors </e22> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving MAO-A_inhibitors is contraindicated , <e22> Selective_serotonin_reuptake_inhibitors </e22> ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( <e22> SSRIs </e22> ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, <e20> fluoxetine </e20> , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , <e20> fluvoxamine </e20> , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , <e20> paroxetine </e20> , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of <e10> sumatriptan_succinate </e10> tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , <e20> sertraline </e20> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , <e22> Selective_serotonin_reuptake_inhibitors </e22> ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , Selective_serotonin_reuptake_inhibitors ( <e22> SSRIs </e22> ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, <e20> fluoxetine </e20> , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , <e20> fluvoxamine </e20> , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , <e20> paroxetine </e20> , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , <e20> sertraline </e20> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan .
negative	Therefore, the use of sumatriptan_succinate tablets in patients receiving <e12> MAO-A_inhibitors </e12> is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
effect	Therefore, the use of sumatriptan_succinate tablets in patients receiving MAO-A_inhibitors is contraindicated , <e12> Selective_serotonin_reuptake_inhibitors </e12> ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
effect	Therefore, the use of sumatriptan_succinate tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( <e12> SSRIs </e12> ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
effect	Therefore, the use of sumatriptan_succinate tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, <e10> fluoxetine </e10> , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
effect	Therefore, the use of sumatriptan_succinate tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , <e10> fluvoxamine </e10> , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
effect	Therefore, the use of sumatriptan_succinate tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , <e10> paroxetine </e10> , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
effect	Therefore, the use of sumatriptan_succinate tablets in patients receiving MAO-A_inhibitors is contraindicated , Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , <e10> sertraline </e10> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e20> sumatriptan </e20> .
advise	If concomitant treatment with <e10> sumatriptan </e10> and an <e22> SSRI </e22> is clinically warranted, appropriate observation of the patient is advised.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, <e20> ketoconazole </e20> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , <e20> itraconazole </e20> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , <e20> clarithromycin </e20> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , <e20> atazanavir </e20> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , <e20> indinavir </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e20> voriconizole </e20> ) may increases sunitinib concentrations.
negative	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, <e10> ketoconazole </e10> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , <e10> itraconazole </e10> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , <e10> clarithromycin </e10> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , <e10> atazanavir </e10> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , <e10> indinavir </e10> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e10> nefazodone </e10> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e10> nelfinavir </e10> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e10> ritonavir </e10> , saquinavir , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e10> saquinavir </e10> , telithromycin , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e10> telithromycin </e10> , voriconizole ) may increases <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e10> voriconizole </e10> ) may increases <e20> sunitinib </e20> concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, <e20> dexamethasone </e20> , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , <e20> phenytoin </e20> , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , <e20> carbamazepine </e20> , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , <e20> rifampin </e20> , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , <e20> rifabutin </e20> , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , <e20> rifapentin </e20> , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , <e20> phenobarbital </e20> , St, Johns Wort) may decrease sunitinib concentrations.
negative	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, <e10> dexamethasone </e10> , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, dexamethasone , <e10> phenytoin </e10> , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , <e10> carbamazepine </e10> , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , <e10> rifampin </e10> , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , <e10> rifabutin </e10> , rifapentin , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , <e10> rifapentin </e10> , phenobarbital , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Co-administration of SUTENT with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , <e10> phenobarbital </e10> , St, Johns Wort) may decrease <e20> sunitinib </e20> concentrations.
negative	Other eye drops or medications such as <e10> acetylcholine_chloride </e10> ( Miochol ) and <e20> carbachol </e20> ( Carboptic , Isopto_Carbachol ) may decrease the effects of suprofen ophthalmic.
negative	Other eye drops or medications such as <e10> acetylcholine_chloride </e10> ( Miochol ) and carbachol ( <e21> Carboptic </e21> , Isopto_Carbachol ) may decrease the effects of suprofen ophthalmic.
negative	Other eye drops or medications such as <e10> acetylcholine_chloride </e10> ( Miochol ) and carbachol ( Carboptic , <e21> Isopto_Carbachol </e21> ) may decrease the effects of suprofen ophthalmic.
effect	Other eye drops or medications such as <e10> acetylcholine_chloride </e10> ( Miochol ) and carbachol ( Carboptic , Isopto_Carbachol ) may decrease the effects of <e20> suprofen </e20> ophthalmic.
negative	Other eye drops or medications such as acetylcholine_chloride ( <e11> Miochol </e11> ) and <e20> carbachol </e20> ( Carboptic , Isopto_Carbachol ) may decrease the effects of suprofen ophthalmic.
negative	Other eye drops or medications such as acetylcholine_chloride ( <e11> Miochol </e11> ) and carbachol ( <e21> Carboptic </e21> , Isopto_Carbachol ) may decrease the effects of suprofen ophthalmic.
negative	Other eye drops or medications such as acetylcholine_chloride ( <e11> Miochol </e11> ) and carbachol ( Carboptic , <e21> Isopto_Carbachol </e21> ) may decrease the effects of suprofen ophthalmic.
effect	Other eye drops or medications such as acetylcholine_chloride ( <e11> Miochol </e11> ) and carbachol ( Carboptic , Isopto_Carbachol ) may decrease the effects of <e20> suprofen </e20> ophthalmic.
effect	Other eye drops or medications such as acetylcholine_chloride ( Miochol ) and <e10> carbachol </e10> ( Carboptic , Isopto_Carbachol ) may decrease the effects of <e20> suprofen </e20> ophthalmic.
effect	Other eye drops or medications such as acetylcholine_chloride ( Miochol ) and carbachol ( <e11> Carboptic </e11> , Isopto_Carbachol ) may decrease the effects of <e20> suprofen </e20> ophthalmic.
effect	Other eye drops or medications such as acetylcholine_chloride ( Miochol ) and carbachol ( Carboptic , <e11> Isopto_Carbachol </e11> ) may decrease the effects of <e20> suprofen </e20> ophthalmic.
negative	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between <e11> FLOMAX </e11> capsules and other <e22> alpha-adrenergic_blocking_agents </e22> have not been determined.
advise	However, interactions may be expected and <e11> FLOMAX </e11> capsules should NOT be used in combination with other <e22> alpha-adrenergic_blocking_agents </e22> .
negative	The pharmacokinetic interaction between <e10> cimetidine </e10> and <e21> FLOMAX </e21> capsules was investigated.
advise	Therefore, <e11> FLOMAX </e11> capsules should be used with caution in combination with <e20> cimetidine </e20> , particularly at doses higher than # mg.
negative	Results from limited in vitro and in vivo drug-drug interaction studies between <e10> tamsulosin_HCI </e10> and <e20> warfarin </e20> are inconclusive.
advise	Therefore, caution should be exercised with concomitant administration of <e10> warfarin </e10> and <e21> FLOMAX </e21> capsules.
mechanism	Administration of <e10> valproic_acid </e10> decreases oral clearance of <e20> temozolomide </e20> by about 5%.
negative	Patients studied in clinical trials of <e11> TNKase </e11> were routinely treated with <e20> heparin </e20> and aspirin .
negative	Patients studied in clinical trials of <e11> TNKase </e11> were routinely treated with heparin and <e21> aspirin </e21> .
negative	Patients studied in clinical trials of TNKase were routinely treated with <e10> heparin </e10> and <e21> aspirin </e21> .
negative	<e12> Anticoagulants </e12> (such as heparin and vitamin_K_antagonists ) and drugs that alter platelet function (such as <e20> acetylsalicylic_acid </e20> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
negative	<e12> Anticoagulants </e12> (such as heparin and vitamin_K_antagonists ) and drugs that alter platelet function (such as acetylsalicylic_acid , <e20> dipyridamole </e20> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
effect	<e12> Anticoagulants </e12> (such as heparin and vitamin_K_antagonists ) and drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e21> TNKase </e21> therapy.
negative	Anticoagulants (such as <e10> heparin </e10> and vitamin_K_antagonists ) and drugs that alter platelet function (such as <e20> acetylsalicylic_acid </e20> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
negative	Anticoagulants (such as <e10> heparin </e10> and vitamin_K_antagonists ) and drugs that alter platelet function (such as acetylsalicylic_acid , <e20> dipyridamole </e20> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
effect	Anticoagulants (such as <e10> heparin </e10> and vitamin_K_antagonists ) and drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e21> TNKase </e21> therapy.
negative	Anticoagulants (such as heparin and <e12> vitamin_K_antagonists </e12> ) and drugs that alter platelet function (such as <e20> acetylsalicylic_acid </e20> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
negative	Anticoagulants (such as heparin and <e12> vitamin_K_antagonists </e12> ) and drugs that alter platelet function (such as acetylsalicylic_acid , <e20> dipyridamole </e20> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
effect	Anticoagulants (such as heparin and <e12> vitamin_K_antagonists </e12> ) and drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e21> TNKase </e21> therapy.
effect	Anticoagulants (such as heparin and vitamin_K_antagonists ) and drugs that alter platelet function (such as <e10> acetylsalicylic_acid </e10> , dipyridamole , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e21> TNKase </e21> therapy.
effect	Anticoagulants (such as heparin and vitamin_K_antagonists ) and drugs that alter platelet function (such as acetylsalicylic_acid , <e10> dipyridamole </e10> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e21> TNKase </e21> therapy.
mechanism	In a study in which # different drugs were tested, therapeutically relevant concentrations of <e10> tolbutamide </e10> , sodium_salicylate and sulfamethizole displaced protein-bound <e20> teniposide </e20> in fresh human serum to a small but significant extent.
mechanism	In a study in which # different drugs were tested, therapeutically relevant concentrations of tolbutamide , <e10> sodium_salicylate </e10> and sulfamethizole displaced protein-bound <e20> teniposide </e20> in fresh human serum to a small but significant extent.
mechanism	In a study in which # different drugs were tested, therapeutically relevant concentrations of tolbutamide , sodium_salicylate and <e10> sulfamethizole </e10> displaced protein-bound <e20> teniposide </e20> in fresh human serum to a small but significant extent.
negative	There was no change in the plasma kinetics of <e10> teniposide </e10> when coadministered with <e20> methotrexate </e20> .
mechanism	An increase in intracellular levels of <e10> methotrexate </e10> was observed in vitro in the presence of <e20> teniposide </e20> .
negative	In vitro studies with human liver microsomes showed that <e10> terbinafine </e10> does not inhibit the metabolism of <e20> tolbutamide </e20> , ethinylestradiol , ethoxycoumarin , and cyclosporine .
negative	In vitro studies with human liver microsomes showed that <e10> terbinafine </e10> does not inhibit the metabolism of tolbutamide , <e20> ethinylestradiol </e20> , ethoxycoumarin , and cyclosporine .
negative	In vitro studies with human liver microsomes showed that <e10> terbinafine </e10> does not inhibit the metabolism of tolbutamide , ethinylestradiol , <e23> ethoxycoumarin </e23> , and cyclosporine .
negative	In vitro studies with human liver microsomes showed that <e10> terbinafine </e10> does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and <e20> cyclosporine </e20> .
negative	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e10> terbinafine </e10> does not affect the clearance of <e20> antipyrine </e20> or digoxin .
negative	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e10> terbinafine </e10> does not affect the clearance of antipyrine or <e20> digoxin </e20> .
negative	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of <e10> antipyrine </e10> or <e20> digoxin </e20> .
mechanism	<e10> Terbinafine </e10> decreases the clearance of <e20> caffeine </e20> by 19%.
mechanism	<e10> Terbinafine </e10> increases the clearance of <e20> cyclosporine </e20> by 15%.
effect	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e10> terbinafine </e10> and <e20> warfarin </e20> , however, a causal relationship between LAMISIL Tablets and these changes has not been established.
negative	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e10> terbinafine </e10> and warfarin , however, a causal relationship between <e21> LAMISIL </e21> Tablets and these changes has not been established.
negative	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and <e10> warfarin </e10> , however, a causal relationship between <e21> LAMISIL </e21> Tablets and these changes has not been established.
mechanism	<e10> Terbinafine </e10> clearance is increased 100% by <e20> rifampin </e20> , a CyP450 enzyme inducer, and decreased 33% by cimetidine , a CyP450 enzyme inhibitor.
mechanism	<e10> Terbinafine </e10> clearance is increased 100% by rifampin , a CyP450 enzyme inducer, and decreased 33% by <e20> cimetidine </e20> , a CyP450 enzyme inhibitor.
negative	Terbinafine clearance is increased 100% by <e10> rifampin </e10> , a CyP450 enzyme inducer, and decreased 33% by <e20> cimetidine </e20> , a CyP450 enzyme inhibitor.
negative	<e10> Terbinafine </e10> clearance is unaffected by <e20> cyclosporine </e20> .
negative	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e12> contraceptives </e12> , hormone replacement therapies, <e22> hypoglycemics </e22> , theophyllines , phenytoins , thiazide_diuretics , beta_blockers , and calcium_channel_blockers .
negative	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e12> contraceptives </e12> , hormone replacement therapies, hypoglycemics , <e20> theophyllines </e20> , phenytoins , thiazide_diuretics , beta_blockers , and calcium_channel_blockers .
negative	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e12> contraceptives </e12> , hormone replacement therapies, hypoglycemics , theophyllines , <e20> phenytoins </e20> , thiazide_diuretics , beta_blockers , and calcium_channel_blockers .
negative	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e12> contraceptives </e12> , hormone replacement therapies, hypoglycemics , theophyllines , phenytoins , <e22> thiazide_diuretics </e22> , beta_blockers , and calcium_channel_blockers .
negative	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e12> contraceptives </e12> , hormone replacement therapies, hypoglycemics , theophyllines , phenytoins , thiazide_diuretics , <e22> beta_blockers </e22> , and calcium_channel_blockers .
negative	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e12> contraceptives </e12> , hormone replacement therapies, hypoglycemics , theophyllines , phenytoins , thiazide_diuretics , beta_blockers , and <e22> calcium_channel_blockers </e22> .
effect	Ketoconazole : Spontaneous adverse reaction reports of patients taking concomitant <e10> ketoconazole </e10> with recommended doses of <e20> terfenadine </e20> demonstrate QT interval prolongation and rare serious cardiac events, e,g.
mechanism	Pharmacokinetic data indicate that <e10> ketoconazole </e10> markedly inhibits the metabolism of <e20> terfenadine </e20> , resulting in elevated plasma terfenadine levels.
negative	Pharmacokinetic data indicate that <e10> ketoconazole </e10> markedly inhibits the metabolism of terfenadine , resulting in elevated plasma <e20> terfenadine </e20> levels.
advise	Concomitant administration of <e10> ketoconazole </e10> and <e20> terfenadine </e20> is contraindicated.
negative	Itraconazole : Torsades de pointes and elevated parent <e10> terfenadine </e10> levels have been reported during concomitant use of terfenadine and <e20> itraconazole </e20> in clinical trials of itraconazole and from foreign post-marketing sources.
negative	Itraconazole : Torsades de pointes and elevated parent <e10> terfenadine </e10> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of <e20> itraconazole </e20> and from foreign post-marketing sources.
mechanism	Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e10> terfenadine </e10> and <e20> itraconazole </e20> in clinical trials of itraconazole and from foreign post-marketing sources.
negative	Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e10> terfenadine </e10> and itraconazole in clinical trials of <e20> itraconazole </e20> and from foreign post-marketing sources.
advise	Concomitant administration of <e10> itraconazole </e10> and <e20> terfenadine </e20> is contraindicated.
negative	Due to the chemical similarity of other <e12> azole-type_antifungal_agents </e12> (including fluconazole , metronidazole , and miconazole ) to <e20> ketoconazole </e20> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other <e12> azole-type_antifungal_agents </e12> (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and <e20> itraconazole </e20> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other <e12> azole-type_antifungal_agents </e12> (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including <e10> fluconazole </e10> , metronidazole , and miconazole ) to <e20> ketoconazole </e20> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including <e10> fluconazole </e10> , metronidazole , and miconazole ) to ketoconazole , and <e20> itraconazole </e20> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other azole-type_antifungal_agents (including <e10> fluconazole </e10> , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , <e10> metronidazole </e10> , and miconazole ) to <e20> ketoconazole </e20> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , <e10> metronidazole </e10> , and miconazole ) to ketoconazole , and <e20> itraconazole </e20> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , <e10> metronidazole </e10> , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and <e10> miconazole </e10> ) to <e20> ketoconazole </e20> , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and <e10> miconazole </e10> ) to ketoconazole , and <e20> itraconazole </e20> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
advise	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and <e10> miconazole </e10> ) to ketoconazole , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and miconazole ) to <e10> ketoconazole </e10> , and <e20> itraconazole </e20> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and miconazole ) to <e10> ketoconazole </e10> , and itraconazole , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
negative	Due to the chemical similarity of other azole-type_antifungal_agents (including fluconazole , metronidazole , and miconazole ) to ketoconazole , and <e10> itraconazole </e10> , concomitant use of these products with <e20> terfenadine </e20> is not recommended pending full examination of potential interactions.
negative	Macrolides : Clinical drug interaction studies indicate that <e10> erythromycin </e10> and <e20> clarithromycin </e20> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent.
mechanism	Macrolides : Clinical drug interaction studies indicate that <e10> erythromycin </e10> and clarithromycin can exert an effect on <e20> terfenadine </e20> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent.
negative	Macrolides : Clinical drug interaction studies indicate that <e10> erythromycin </e10> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e20> ketoconazole </e20> , but to a lesser extent.
mechanism	Macrolides : Clinical drug interaction studies indicate that erythromycin and <e10> clarithromycin </e10> can exert an effect on <e20> terfenadine </e20> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent.
negative	Macrolides : Clinical drug interaction studies indicate that erythromycin and <e10> clarithromycin </e10> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e20> ketoconazole </e20> , but to a lesser extent.
negative	Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e10> terfenadine </e10> metabolism by a mechanism which may be similar to that of <e20> ketoconazole </e20> , but to a lesser extent.
negative	A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving <e10> erythromycin </e10> or <e20> troleandomycin </e20> .
advise	Concomitant administration of <e10> terfenadine </e10> with <e20> clarithromycin </e20> , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide_antibiotics , including azithromycin , is not recommended.
advise	Concomitant administration of <e10> terfenadine </e10> with clarithromycin , <e20> erythromycin </e20> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide_antibiotics , including azithromycin , is not recommended.
advise	Concomitant administration of <e10> terfenadine </e10> with clarithromycin , erythromycin , or <e20> troleandomycin </e20> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide_antibiotics , including azithromycin , is not recommended.
advise	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e10> terfenadine </e10> with other <e22> macrolide_antibiotics </e22> , including azithromycin , is not recommended.
advise	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e10> terfenadine </e10> with other macrolide_antibiotics , including <e20> azithromycin </e20> , is not recommended.
negative	Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e12> macrolide_antibiotics </e12> , including <e20> azithromycin </e20> , is not recommended.
negative	Studies to evaluate potential interactions of <e10> terfenadine </e10> with <e20> azithromycin </e20> are in progress.
effect	When administered concurrently, <e10> testolactone </e10> may increase the effects of oral <e22> anticoagulants </e22> ;
effect	<e10> Thalidomide </e10> has been reported to enhance the sedative activity of <e22> barbiturates </e22> , alcohol , chlorpromazine , and reserpine .
negative	<e10> Thalidomide </e10> has been reported to enhance the sedative activity of barbiturates , <e20> alcohol </e20> , chlorpromazine , and reserpine .
negative	<e10> Thalidomide </e10> has been reported to enhance the sedative activity of barbiturates , alcohol , <e20> chlorpromazine </e20> , and reserpine .
negative	<e10> Thalidomide </e10> has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and <e20> reserpine </e20> .
negative	Oral <e12> Contraceptives </e12> : In # healthy women, the pharmacokinetic profiles of <e20> norethindrone </e20> and ethinyl_estradiol following administration of a single dose containing # mg of norethindrone_acetate and # g of ethinyl_estradiol were studied.
negative	Oral <e12> Contraceptives </e12> : In # healthy women, the pharmacokinetic profiles of norethindrone and <e20> ethinyl_estradiol </e20> following administration of a single dose containing # mg of norethindrone_acetate and # g of ethinyl_estradiol were studied.
negative	Oral <e12> Contraceptives </e12> : In # healthy women, the pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of a single dose containing # mg of <e20> norethindrone_acetate </e20> and # g of ethinyl_estradiol were studied.
negative	Oral <e12> Contraceptives </e12> : In # healthy women, the pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of a single dose containing # mg of norethindrone_acetate and # g of <e20> ethinyl_estradiol </e20> were studied.
negative	Oral Contraceptives : In # healthy women, the pharmacokinetic profiles of <e10> norethindrone </e10> and <e20> ethinyl_estradiol </e20> following administration of a single dose containing # mg of norethindrone_acetate and # g of ethinyl_estradiol were studied.
negative	Oral Contraceptives : In # healthy women, the pharmacokinetic profiles of <e10> norethindrone </e10> and ethinyl_estradiol following administration of a single dose containing # mg of norethindrone_acetate and # g of <e20> ethinyl_estradiol </e20> were studied.
negative	Oral Contraceptives : In # healthy women, the pharmacokinetic profiles of norethindrone and <e10> ethinyl_estradiol </e10> following administration of a single dose containing # mg of <e20> norethindrone_acetate </e20> and # g of ethinyl_estradiol were studied.
negative	Oral Contraceptives : In # healthy women, the pharmacokinetic profiles of norethindrone and ethinyl_estradiol following administration of a single dose containing # mg of <e10> norethindrone_acetate </e10> and # g of <e20> ethinyl_estradiol </e20> were studied.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with <e22> Hormonal_Contraceptives </e22> : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of <e22> HIV-protease_inhibitors </e22> , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , <e20> griseofulvin </e20> , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , griseofulvin , <e20> modafinil </e20> , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , <e22> penicillins </e22> , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , <e20> rifampin </e20> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , <e20> rifabutin </e20> , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , <e20> phenytoin </e20> , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- <e10> Thalidomide </e10> Drug Interactions Drugs That Interfere with Hormonal_Contraceptives : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , <e20> carbamazepine </e20> , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of <e22> HIV-protease_inhibitors </e22> , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , <e20> griseofulvin </e20> , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , griseofulvin , <e20> modafinil </e20> , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , <e22> penicillins </e22> , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , <e20> rifampin </e20> , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , <e20> rifabutin </e20> , phenytoin , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , <e20> phenytoin </e20> , carbamazepine , or certain herbal supplements such as St.
negative	Important Non- Thalidomide Drug Interactions Drugs That Interfere with <e12> Hormonal_Contraceptives </e12> : Concomitant use of HIV-protease_inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , <e20> carbamazepine </e20> , or certain herbal supplements such as St.
effect	<e13> John's_Wort </e13> with <e22> hormonal_contraceptive_agents </e22> may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.
mechanism	<e10> Thiabendazole </e10> may compete with other drugs, such as <e20> theophylline </e20> , for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
advise	Therefore, when concomitant use of <e10> thiabendazole </e10> and <e22> xanthine_derivatives </e22> is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
int	Interactions for <e10> Vitamin_B1 </e10> ( Thiamine ): <e22> Loop_Diuretics </e22> , Oral Contraceptives , Stavudine , Tricyclic_Antidepressants
int	Interactions for <e10> Vitamin_B1 </e10> ( Thiamine ): Loop_Diuretics , Oral <e22> Contraceptives </e22> , Stavudine , Tricyclic_Antidepressants
int	Interactions for <e10> Vitamin_B1 </e10> ( Thiamine ): Loop_Diuretics , Oral Contraceptives , <e20> Stavudine </e20> , Tricyclic_Antidepressants
int	Interactions for <e10> Vitamin_B1 </e10> ( Thiamine ): Loop_Diuretics , Oral Contraceptives , Stavudine , <e22> Tricyclic_Antidepressants </e22>
int	Interactions for Vitamin_B1 ( <e10> Thiamine </e10> ): <e22> Loop_Diuretics </e22> , Oral Contraceptives , Stavudine , Tricyclic_Antidepressants
int	Interactions for Vitamin_B1 ( <e10> Thiamine </e10> ): Loop_Diuretics , Oral <e22> Contraceptives </e22> , Stavudine , Tricyclic_Antidepressants
int	Interactions for Vitamin_B1 ( <e10> Thiamine </e10> ): Loop_Diuretics , Oral Contraceptives , <e20> Stavudine </e20> , Tricyclic_Antidepressants
int	Interactions for Vitamin_B1 ( <e10> Thiamine </e10> ): Loop_Diuretics , Oral Contraceptives , Stavudine , <e22> Tricyclic_Antidepressants </e22>
negative	Interactions for Vitamin_B1 ( Thiamine ): <e12> Loop_Diuretics </e12> , Oral <e22> Contraceptives </e22> , Stavudine , Tricyclic_Antidepressants
negative	Interactions for Vitamin_B1 ( Thiamine ): <e12> Loop_Diuretics </e12> , Oral Contraceptives , <e20> Stavudine </e20> , Tricyclic_Antidepressants
negative	Interactions for Vitamin_B1 ( Thiamine ): <e12> Loop_Diuretics </e12> , Oral Contraceptives , Stavudine , <e22> Tricyclic_Antidepressants </e22>
negative	Interactions for Vitamin_B1 ( Thiamine ): Loop_Diuretics , Oral <e12> Contraceptives </e12> , <e20> Stavudine </e20> , Tricyclic_Antidepressants
negative	Interactions for Vitamin_B1 ( Thiamine ): Loop_Diuretics , Oral <e12> Contraceptives </e12> , Stavudine , <e22> Tricyclic_Antidepressants </e22>
negative	Interactions for Vitamin_B1 ( Thiamine ): Loop_Diuretics , Oral Contraceptives , <e10> Stavudine </e10> , <e22> Tricyclic_Antidepressants </e22>
effect	<e12> Phenothiazines </e12> are capable of potentiating <e22> CNS_depressants </e22> (e,g,, barbiturates , anesthetics , opiates , alcohol , etc.
effect	<e12> Phenothiazines </e12> are capable of potentiating CNS_depressants (e,g,, <e22> barbiturates </e22> , anesthetics , opiates , alcohol , etc.
effect	<e12> Phenothiazines </e12> are capable of potentiating CNS_depressants (e,g,, barbiturates , <e22> anesthetics </e22> , opiates , alcohol , etc.
effect	<e12> Phenothiazines </e12> are capable of potentiating CNS_depressants (e,g,, barbiturates , anesthetics , <e22> opiates </e22> , alcohol , etc.
effect	<e12> Phenothiazines </e12> are capable of potentiating CNS_depressants (e,g,, barbiturates , anesthetics , opiates , <e20> alcohol </e20> , etc.
negative	as well as <e10> atropine </e10> and <e23> phosphorous_insecticides </e23> .
effect	There is usually complete cross-resistance between <e11> PURINETHOL </e11> ( mercaptopurine ) and <e21> TABLOID </e21> brand Thioguanine .
effect	There is usually complete cross-resistance between <e11> PURINETHOL </e11> ( mercaptopurine ) and TABLOID brand <e20> Thioguanine </e20> .
effect	There is usually complete cross-resistance between PURINETHOL ( <e10> mercaptopurine </e10> ) and <e21> TABLOID </e21> brand Thioguanine .
effect	There is usually complete cross-resistance between PURINETHOL ( <e10> mercaptopurine </e10> ) and TABLOID brand <e20> Thioguanine </e20> .
negative	There is usually complete cross-resistance between PURINETHOL ( mercaptopurine ) and <e11> TABLOID </e11> brand <e20> Thioguanine </e20> .
mechanism	As there is in vitro evidence that <e12> aminosalicylate_derivatives </e12> (e,g,, olsalazine , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	As there is in vitro evidence that aminosalicylate_derivatives (e,g,, <e10> olsalazine </e10> , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	As there is in vitro evidence that aminosalicylate_derivatives (e,g,, olsalazine , <e10> mesalazine </e10> , or sulphasalazine ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	As there is in vitro evidence that aminosalicylate_derivatives (e,g,, olsalazine , mesalazine , or <e10> sulphasalazine </e10> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
advise	Caution should be exercised when administering <e11> ZADAXIN </e11> therapy in combination with other <e22> immunomodulating_drugs </e22> .
advise	Prothrombin time or other suitable anticoagulation test should be monitored if <e10> tigecycline </e10> is administered with <e20> warfarin </e20> .
effect	Concurrent use of <e12> antibacterial_drugs </e12> with oral <e22> contraceptives </e22> may render oral contraceptives less effective.
negative	Concurrent use of <e12> antibacterial_drugs </e12> with oral contraceptives may render oral <e22> contraceptives </e22> less effective.
mechanism	The bioavailability of <e11> SKELID </e11> is decreased 80% by <e20> calcium </e20> , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of <e11> SKELID </e11> is decreased 80% by calcium , when <e20> calcium </e20> and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of <e11> SKELID </e11> is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some <e20> aluminum </e20> - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of <e11> SKELID </e11> is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or <e20> magnesium </e20> -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of <e11> SKELID </e11> is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing <e20> antacids </e20> , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by <e10> calcium </e10> , when calcium and <e21> SKELID </e21> are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by <e10> calcium </e10> , when calcium and SKELID are administered at the same time, and 60% by some <e20> aluminum </e20> - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by <e10> calcium </e10> , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or <e20> magnesium </e20> -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by <e10> calcium </e10> , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing <e20> antacids </e20> , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by <e10> calcium </e10> , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before <e21> SKELID </e21> .
negative	The bioavailability of SKELID is decreased 80% by calcium , when <e10> calcium </e10> and <e21> SKELID </e21> are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when <e10> calcium </e10> and SKELID are administered at the same time, and 60% by some <e20> aluminum </e20> - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when <e10> calcium </e10> and SKELID are administered at the same time, and 60% by some aluminum - or <e20> magnesium </e20> -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when <e10> calcium </e10> and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing <e20> antacids </e20> , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when <e10> calcium </e10> and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before <e21> SKELID </e21> .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and <e11> SKELID </e11> are administered at the same time, and 60% by some <e20> aluminum </e20> - or magnesium -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and <e11> SKELID </e11> are administered at the same time, and 60% by some aluminum - or <e20> magnesium </e20> -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and <e11> SKELID </e11> are administered at the same time, and 60% by some aluminum - or magnesium -containing <e20> antacids </e20> , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some <e10> aluminum </e10> - or <e20> magnesium </e20> -containing antacids , when administered # hour before SKELID .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some <e10> aluminum </e10> - or magnesium -containing <e20> antacids </e20> , when administered # hour before SKELID .
mechanism	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some <e10> aluminum </e10> - or magnesium -containing antacids , when administered # hour before <e21> SKELID </e21> .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or <e10> magnesium </e10> -containing <e20> antacids </e20> , when administered # hour before SKELID .
mechanism	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or <e10> magnesium </e10> -containing antacids , when administered # hour before <e21> SKELID </e21> .
negative	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing <e10> antacids </e10> , when administered # hour before <e21> SKELID </e21> .
mechanism	<e11> Aspirin </e11> may decrease bioavailability of <e21> SKELID </e21> by up to 50% when taken # hours after SKELID .
negative	<e11> Aspirin </e11> may decrease bioavailability of SKELID by up to 50% when taken # hours after <e21> SKELID </e21> .
mechanism	The bioavailability of <e11> SKELID </e11> is increased 2-4 fold by <e20> indomethacin </e20> but is not significantly altered by coadministration of diclofenac .
negative	The bioavailability of <e11> SKELID </e11> is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of <e20> diclofenac </e20> .
negative	The bioavailability of SKELID is increased 2-4 fold by <e10> indomethacin </e10> but is not significantly altered by coadministration of <e20> diclofenac </e20> .
negative	The pharmacokinetic parameters of <e10> digoxin </e10> are not significantly modified by <e21> SKELID </e21> coadministration.
negative	In vitro studies show that <e10> tiludronate </e10> does not displace <e20> warfarin </e20> from its binding site on protein.
negative	These include <e12> sympathomimetic_bronchodilators </e12> , methylxanthines , and oral and inhaled <e22> steroids </e22> .
negative	These include sympathomimetic_bronchodilators , <e12> methylxanthines </e12> , and oral and inhaled <e22> steroids </e22> .
advise	However, the co administration of <e11> SPIRIVA </e11> with other <e22> anticholinergic </e22> containing drugs (e,g,, ipratropium ) has not been studied and is therefore not recommended.
advise	However, the co administration of <e11> SPIRIVA </e11> with other anticholinergic containing drugs (e,g,, <e20> ipratropium </e20> ) has not been studied and is therefore not recommended.
negative	However, the co administration of SPIRIVA with other <e12> anticholinergic </e12> containing drugs (e,g,, <e20> ipratropium </e20> ) has not been studied and is therefore not recommended.
negative	<e11> AGGRASTAT </e11> has been studied on a background of <e21> aspirin </e21> and heparin .
negative	<e11> AGGRASTAT </e11> has been studied on a background of aspirin and <e20> heparin </e20> .
negative	AGGRASTAT has been studied on a background of <e11> aspirin </e11> and <e20> heparin </e20> .
effect	The use of <e11> AGGRASTAT </e11> , in combination with <e20> heparin </e20> and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone (see
effect	The use of <e11> AGGRASTAT </e11> , in combination with heparin and <e21> aspirin </e21> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see
negative	The use of <e11> AGGRASTAT </e11> , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to <e20> heparin </e20> and aspirin alone (see
negative	The use of <e11> AGGRASTAT </e11> , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and <e21> aspirin </e21> alone (see
negative	The use of AGGRASTAT , in combination with <e10> heparin </e10> and <e21> aspirin </e21> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see
negative	The use of AGGRASTAT , in combination with <e10> heparin </e10> and aspirin , has been associated with an increase in bleeding compared to heparin and <e21> aspirin </e21> alone (see
negative	The use of AGGRASTAT , in combination with heparin and <e11> aspirin </e11> , has been associated with an increase in bleeding compared to <e20> heparin </e20> and aspirin alone (see
negative	The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to <e10> heparin </e10> and <e21> aspirin </e21> alone (see
negative	In clinical studies of <e11> TOBI </e11> , patients taking TOBI concomitantly with <e20> dornase_alfa </e20> ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of <e11> TOBI </e11> , patients taking TOBI concomitantly with dornase_alfa ( <e21> PULMOZYME </e21> , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of <e11> TOBI </e11> , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), <e22> (beta)-agonists </e22> , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of <e11> TOBI </e11> , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled <e22> corticosteroids </e22> , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of <e11> TOBI </e11> , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other <e22> anti-pseudomonal_antibiotics </e22> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of <e11> TOBI </e11> , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
effect	In clinical studies of TOBI , patients taking <e11> TOBI </e11> concomitantly with <e20> dornase_alfa </e20> ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
effect	In clinical studies of TOBI , patients taking <e11> TOBI </e11> concomitantly with dornase_alfa ( <e21> PULMOZYME </e21> , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
effect	In clinical studies of TOBI , patients taking <e11> TOBI </e11> concomitantly with dornase_alfa ( PULMOZYME , Genentech), <e22> (beta)-agonists </e22> , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
effect	In clinical studies of TOBI , patients taking <e11> TOBI </e11> concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled <e22> corticosteroids </e22> , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
effect	In clinical studies of TOBI , patients taking <e11> TOBI </e11> concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other <e22> anti-pseudomonal_antibiotics </e22> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
effect	In clinical studies of TOBI , patients taking <e11> TOBI </e11> concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with <e10> dornase_alfa </e10> ( PULMOZYME , Genentech), <e22> (beta)-agonists </e22> , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with <e10> dornase_alfa </e10> ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( <e11> PULMOZYME </e11> , Genentech), <e22> (beta)-agonists </e22> , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( <e11> PULMOZYME </e11> , Genentech), (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), <e12> (beta)-agonists </e12> , inhaled <e22> corticosteroids </e22> , other anti-pseudomonal_antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), <e12> (beta)-agonists </e12> , inhaled corticosteroids , other <e22> anti-pseudomonal_antibiotics </e22> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), <e12> (beta)-agonists </e12> , inhaled corticosteroids , other anti-pseudomonal_antibiotics , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled <e12> corticosteroids </e12> , other anti-pseudomonal_antibiotics , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
negative	In clinical studies of TOBI , patients taking TOBI concomitantly with dornase_alfa ( PULMOZYME , Genentech), (beta)-agonists , inhaled corticosteroids , other <e12> anti-pseudomonal_antibiotics </e12> , or parenteral <e22> aminoglycosides </e22> demonstrated adverse experience profiles similar to the study population as a whole.
effect	Some <e12> diuretics </e12> can enhance <e22> aminoglycoside </e22> toxicity by altering antibiotic concentrations in serum and tissue.
negative	Some <e12> diuretics </e12> can enhance aminoglycoside toxicity by altering <e22> antibiotic </e22> concentrations in serum and tissue.
negative	Some diuretics can enhance <e12> aminoglycoside </e12> toxicity by altering <e22> antibiotic </e22> concentrations in serum and tissue.
advise	<e11> TOBI </e11> should not be administered concomitantly with <e20> ethacrynic_acid </e20> , furosemide , urea , or mannitol .
advise	<e11> TOBI </e11> should not be administered concomitantly with ethacrynic_acid , <e20> furosemide </e20> , urea , or mannitol .
advise	<e11> TOBI </e11> should not be administered concomitantly with ethacrynic_acid , furosemide , <e20> urea </e20> , or mannitol .
advise	<e11> TOBI </e11> should not be administered concomitantly with ethacrynic_acid , furosemide , urea , or <e20> mannitol </e20> .
negative	The in vitro binding of <e10> warfarin </e10> to human plasma proteins is unaffected by <e20> tolmetin </e20> , and tolmetin does not alter the prothrombin time of normal volunteers.
negative	The in vitro binding of <e10> warfarin </e10> to human plasma proteins is unaffected by tolmetin , and <e20> tolmetin </e20> does not alter the prothrombin time of normal volunteers.
effect	However, increased prothrombin time and bleeding have been reported in patients on concomitant <e11> TOLECTIN </e11> and <e20> warfarin </e20> therapy.
advise	Therefore, caution should be exercised when administering <e11> TOLECTIN </e11> to patients on <e22> anticoagulants </e22> .
negative	In adult diabetic patients under treatment with either <e12> sulfonylureas </e12> or <e20> insulin </e20> there is no change in the clinical effects of either TOLECTIN or the hypoglycemic_agents .
negative	In adult diabetic patients under treatment with either <e12> sulfonylureas </e12> or insulin there is no change in the clinical effects of either <e21> TOLECTIN </e21> or the hypoglycemic_agents .
negative	In adult diabetic patients under treatment with either <e12> sulfonylureas </e12> or insulin there is no change in the clinical effects of either TOLECTIN or the <e22> hypoglycemic_agents </e22> .
negative	In adult diabetic patients under treatment with either sulfonylureas or <e10> insulin </e10> there is no change in the clinical effects of either <e21> TOLECTIN </e21> or the hypoglycemic_agents .
negative	In adult diabetic patients under treatment with either sulfonylureas or <e10> insulin </e10> there is no change in the clinical effects of either TOLECTIN or the <e22> hypoglycemic_agents </e22> .
negative	In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either <e11> TOLECTIN </e11> or the <e22> hypoglycemic_agents </e22> .
advise	Caution should be used if <e11> TOLECTIN </e11> is administered concomitantly with <e20> methotrexate </e20> .
negative	<e11> TOLECTIN </e11> and other <e22> nonsteroidal_anti-inflammatory_drugs </e22> have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate .
mechanism	<e11> TOLECTIN </e11> and other nonsteroidal_anti-inflammatory_drugs have been reported to reduce the tubular secretion of <e20> methotrexate </e20> in an animal model, possibly enhancing the toxicity of methotrexate .
negative	<e11> TOLECTIN </e11> and other nonsteroidal_anti-inflammatory_drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of <e20> methotrexate </e20> .
mechanism	TOLECTIN and other <e12> nonsteroidal_anti-inflammatory_drugs </e12> have been reported to reduce the tubular secretion of <e20> methotrexate </e20> in an animal model, possibly enhancing the toxicity of methotrexate .
negative	TOLECTIN and other <e12> nonsteroidal_anti-inflammatory_drugs </e12> have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of <e20> methotrexate </e20> .
mechanism	CYP3A4 Inhibitors: <e10> Ketoconazole </e10> , an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of <e20> tolterodine </e20> when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other <e22> azole_antifungals </e22> (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, <e20> itraconazole </e20> , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , <e20> miconazole </e20> ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or <e22> macrolide_antibiotics </e22> (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, <e20> erythromycin </e20> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , <e20> clarithromycin </e20> ) or cyclosporine or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or <e20> cyclosporine </e20> or vinblastine , the recommended dose of DETROL_LA is # mg daily.
negative	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or <e20> vinblastine </e20> , the recommended dose of DETROL_LA is # mg daily.
advise	For patients receiving <e10> ketoconazole </e10> or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e12> azole_antifungals </e12> (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, <e10> itraconazole </e10> , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , <e10> miconazole </e10> ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or <e12> macrolide_antibiotics </e12> (eg, erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, <e10> erythromycin </e10> , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , <e10> clarithromycin </e10> ) or cyclosporine or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
negative	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or <e10> cyclosporine </e10> or <e20> vinblastine </e20> , the recommended dose of DETROL_LA is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or <e10> cyclosporine </e10> or vinblastine , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole_antifungals (eg, itraconazole , miconazole ) or macrolide_antibiotics (eg, erythromycin , clarithromycin ) or cyclosporine or <e10> vinblastine </e10> , the recommended dose of <e21> DETROL_LA </e21> is # mg daily.
mechanism	Administration of <e10> paclitaxel </e10> in combination with <e21> HERCEPTIN </e21> resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a #-fold increase in HERCEPTIN serum levels in clinical studies.
negative	Administration of <e10> paclitaxel </e10> in combination with HERCEPTIN resulted in a two-fold decrease in <e21> HERCEPTIN </e21> clearance in a non-human primate study and in a #-fold increase in HERCEPTIN serum levels in clinical studies.
negative	Administration of <e10> paclitaxel </e10> in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a #-fold increase in <e21> HERCEPTIN </e21> serum levels in clinical studies.
int	<e10> Trilostane </e10> may interact with <e20> aminoglutethimide </e20> or mitotane (causing too great a decrease in adrenal function).
int	<e10> Trilostane </e10> may interact with aminoglutethimide or <e20> mitotane </e20> (causing too great a decrease in adrenal function).
negative	Trilostane may interact with <e10> aminoglutethimide </e10> or <e20> mitotane </e20> (causing too great a decrease in adrenal function).
mechanism	<e10> Trimethoprim </e10> may inhibit the hepatic metabolism of <e20> phenytoin </e20> .
mechanism	<e10> Trimethoprim </e10> , given at a common clinical dosage, increased the <e20> phenytoin </e20> half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
mechanism	<e10> Trimethoprim </e10> , given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the <e20> phenytoin </e20> metabolic clearance rate by 30%.
effect	Agents that might be coadministered with <e10> trimetrexate </e10> in AIDS patients for other indications that could elicit this activity include <e20> erythromycin </e20> , rifampin , rifabutin , ketoconazole , and fluconazole .
effect	Agents that might be coadministered with <e10> trimetrexate </e10> in AIDS patients for other indications that could elicit this activity include erythromycin , <e20> rifampin </e20> , rifabutin , ketoconazole , and fluconazole .
effect	Agents that might be coadministered with <e10> trimetrexate </e10> in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , <e20> rifabutin </e20> , ketoconazole , and fluconazole .
effect	Agents that might be coadministered with <e10> trimetrexate </e10> in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , <e20> ketoconazole </e20> , and fluconazole .
effect	Agents that might be coadministered with <e10> trimetrexate </e10> in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and <e20> fluconazole </e20> .
mechanism	In vitro perfusion of isolated rat liver has shown that <e10> cimetidine </e10> caused a significant reduction in <e20> trimetrexate </e20> metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
negative	In vitro perfusion of isolated rat liver has shown that <e10> cimetidine </e10> caused a significant reduction in trimetrexate metabolism and that <e20> acetaminophen </e20> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
negative	In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in <e10> trimetrexate </e10> metabolism and that <e20> acetaminophen </e20> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
mechanism	Based on an in vitro rat liver model, nitrogen substituted <e12> imidazole_drugs </e12> ( clotrimazole , ketoconazole , miconazole ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole_drugs ( <e10> clotrimazole </e10> , ketoconazole , miconazole ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole_drugs ( clotrimazole , <e10> ketoconazole </e10> , miconazole ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole_drugs ( clotrimazole , ketoconazole , <e10> miconazole </e10> ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
effect	<e10> Triprolidine </e10> may enhance the sedative effects of <e22> central_nervous_system_depressants </e22> including alcohol , barbiturates , hypnotics , narcotic_analgesics , sedatives , and tranquillisers .
effect	<e10> Triprolidine </e10> may enhance the sedative effects of central_nervous_system_depressants including <e20> alcohol </e20> , barbiturates , hypnotics , narcotic_analgesics , sedatives , and tranquillisers .
effect	<e10> Triprolidine </e10> may enhance the sedative effects of central_nervous_system_depressants including alcohol , <e22> barbiturates </e22> , hypnotics , narcotic_analgesics , sedatives , and tranquillisers .
effect	<e10> Triprolidine </e10> may enhance the sedative effects of central_nervous_system_depressants including alcohol , barbiturates , <e22> hypnotics </e22> , narcotic_analgesics , sedatives , and tranquillisers .
effect	<e10> Triprolidine </e10> may enhance the sedative effects of central_nervous_system_depressants including alcohol , barbiturates , hypnotics , <e22> narcotic_analgesics </e22> , sedatives , and tranquillisers .
effect	<e10> Triprolidine </e10> may enhance the sedative effects of central_nervous_system_depressants including alcohol , barbiturates , hypnotics , narcotic_analgesics , <e22> sedatives </e22> , and tranquillisers .
effect	<e10> Triprolidine </e10> may enhance the sedative effects of central_nervous_system_depressants including alcohol , barbiturates , hypnotics , narcotic_analgesics , sedatives , and <e22> tranquillisers </e22> .
negative	Triprolidine may enhance the sedative effects of <e12> central_nervous_system_depressants </e12> including <e20> alcohol </e20> , barbiturates , hypnotics , narcotic_analgesics , sedatives , and tranquillisers .
negative	Triprolidine may enhance the sedative effects of <e12> central_nervous_system_depressants </e12> including alcohol , <e22> barbiturates </e22> , hypnotics , narcotic_analgesics , sedatives , and tranquillisers .
negative	Triprolidine may enhance the sedative effects of <e12> central_nervous_system_depressants </e12> including alcohol , barbiturates , <e22> hypnotics </e22> , narcotic_analgesics , sedatives , and tranquillisers .
negative	Triprolidine may enhance the sedative effects of <e12> central_nervous_system_depressants </e12> including alcohol , barbiturates , hypnotics , <e22> narcotic_analgesics </e22> , sedatives , and tranquillisers .
negative	Triprolidine may enhance the sedative effects of <e12> central_nervous_system_depressants </e12> including alcohol , barbiturates , hypnotics , narcotic_analgesics , <e22> sedatives </e22> , and tranquillisers .
negative	Triprolidine may enhance the sedative effects of <e12> central_nervous_system_depressants </e12> including alcohol , barbiturates , hypnotics , narcotic_analgesics , sedatives , and <e22> tranquillisers </e22> .
negative	The effects of <e12> anticholinergic_drugs </e12> , such as <e20> atropine </e20> and tricyclic_antidepressants may be enhanced by the concomitant administration of triprolidine .
negative	The effects of <e12> anticholinergic_drugs </e12> , such as atropine and <e22> tricyclic_antidepressants </e22> may be enhanced by the concomitant administration of triprolidine .
effect	The effects of <e12> anticholinergic_drugs </e12> , such as atropine and tricyclic_antidepressants may be enhanced by the concomitant administration of <e20> triprolidine </e20> .
negative	The effects of anticholinergic_drugs , such as <e10> atropine </e10> and <e22> tricyclic_antidepressants </e22> may be enhanced by the concomitant administration of triprolidine .
effect	The effects of anticholinergic_drugs , such as <e10> atropine </e10> and tricyclic_antidepressants may be enhanced by the concomitant administration of <e20> triprolidine </e20> .
effect	The effects of anticholinergic_drugs , such as atropine and <e12> tricyclic_antidepressants </e12> may be enhanced by the concomitant administration of <e20> triprolidine </e20> .
effect	The concomitant use of <e11> Sanctura </e11> with other <e22> anticholinergic_agents </e22> that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, <e20> digoxin </e20> , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ).
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , <e20> procainamide </e20> , pancuronium , morphine , vancomycin , metformin and tenofovir ).
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , <e20> pancuronium </e20> , morphine , vancomycin , metformin and tenofovir ).
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , <e20> morphine </e20> , vancomycin , metformin and tenofovir ).
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , <e20> vancomycin </e20> , metformin and tenofovir ).
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , vancomycin , <e20> metformin </e20> and tenofovir ).
negative	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e11> Sanctura </e11> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and <e20> tenofovir </e20> ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, <e20> digoxin </e20> , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , <e20> procainamide </e20> , pancuronium , morphine , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , <e20> pancuronium </e20> , morphine , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , <e20> morphine </e20> , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , <e20> vancomycin </e20> , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , vancomycin , <e20> metformin </e20> and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and <e20> tenofovir </e20> ).
effect	Concomitant administration of <e10> vancomycin </e10> and <e22> anesthetic_agents </e22> has been associated with erythema and histamine-like flushing and anaphylactoid reactions.
mechanism	A study published in # found that <e10> vigabatrin </e10> causes a statistically significant increase in plasma clearance of <e20> carbamazepine </e20> .
mechanism	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e10> vigabatrin </e10> with <e20> phenytoin </e20> lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
negative	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e10> vigabatrin </e10> with phenytoin lowered the serum <e20> phenytoin </e20> concentration in patients with treatment-resistant epilepsy.
mechanism	Drug Interactions: Women on oral <e12> contraceptives </e12> have shown a significant increase in plasma <e22> vitamin_A </e22> levels.
mechanism	Limited evidence suggests that <e10> ascorbic_acid </e10> may influence the intensity and duration of action of <e20> bishydroxycoumarin </e20> .
negative	<e12> Coumarin-Derivative_Anticoagulants </e12> : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e21> ZOLINZA </e21> concomitantly with coumarin-derivative_anticoagulants .
effect	Coumarin-Derivative_Anticoagulants : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e11> ZOLINZA </e11> concomitantly with <e22> coumarin-derivative_anticoagulants </e22> .
advise	Physicians should carefully monitor PT and INR in patients concurrently administered <e11> ZOLINZA </e11> and <e22> coumarin_derivatives </e22> .
negative	Other <e12> HDAC_Inhibitors </e12> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e21> ZOLINZA </e21> and other HDAC_inhibitors (e,g,, valproic_acid ).
negative	Other <e12> HDAC_Inhibitors </e12> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC_inhibitors (e,g,, <e20> valproic_acid </e20> ).
effect	Other HDAC_Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e11> ZOLINZA </e11> and other <e22> HDAC_inhibitors </e22> (e,g,, valproic_acid ).
effect	Other HDAC_Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e11> ZOLINZA </e11> and other HDAC_inhibitors (e,g,, <e20> valproic_acid </e20> ).
